Surface modified cubosomes for drug delivery across the blood-brain barrier by Azhari, Hanisah
 
Surface modified cubosomes 









A thesis submitted for the degree of 
Doctor of Philosophy 












The bottleneck in delivering drugs to the brain for treatment of diseases related 
to central nervous system (CNS), lies behind the presence of blood-brain barrier (BBB). 
This barrier prevents most of the large and a number of small molecules from entering 
the brain, thus posing a considerable challenge in administration of drugs. The present 
treatment for CNS diseases involves oral drug delivery that seems to result in limited 
efficacy of drug therapy and undesired peripheral side effects. While invasive strategies 
have been proved to increase drug loading into the brain, the procedures can be risky 
with debilitating side effects, thus unsuitable for long-term treatment. Nevertheless, the 
use of particulate drug carriers, such as nanoparticles, can be a promising non-invasive 
strategy to increase drug loading into the brain by masking drug properties, to ascertain 
higher encapsulation efficacy and to enhance the stability of the drugs. One type of lipid-
based nanoparticles, cubosomes, had been investigated in this study to determine its 
suitability as a drug carrier. By decorating and modifying the surface of cubosomes with 
specific moieties, several pathways can serve as targets at the BBB. With that, this thesis 
looked into intraveneous formulation of cubosomes as a drug carrier to cross the BBB, 
primarily due to several advantages it has to offer. The overarching aim of this thesis, 
hence, is to assess the hypothesis that the surface of cubosomes can be modified with 
specific moieties so as to serve as effective drug carriers to enter the brain.  
In order to target low-density lipoprotein (LDL) receptors at the BBB, Chapter 
3 presents the investigation of phytantriol cubosomes stabilised with BBB-targeting 
moieties; Tween 80 and Poloxamer 188. These stabilisers serve as cubosome stabilisers 
and also to target the BBB. Optimum concentrations of Tween 80 and Poloxamer 188 
had been determined at 15% w/w (of phytantriol), where the cubosomes formed Im3m 
and Pn3m internal structures, respectively. The homogeneous cubosomes were formed 
iv 
 
and no vesicles had been observed with cubosomes stabilised using Tween 80. 
Nevertheless, in vitro cellular uptake displayed lack of uptake proposed to be from lack 
of ApoE in the cell culture media, which appeared to prevent the interaction of the 
cubosomes with LDL-receptors. This indicates the significance of ApoE in the plasma 
which initially binds to the cubosomes surface decorated with Tween 80 and Poloxamer 
188, followed by the interaction with LDL-receptor and internalisation into the brain 
endothelial cells.  
In Chapter 4, cationic cubosomes were investigated as an alternative potential 
drug carrier to enter the brain. In order to investigate the effects of using single and double 
chain cationic lipids; cetyltrimethylammonium bromide, CTAB (single chain), 1,2-
Dioleoyl-3-trimethylammonium-propane, DOTAP and 1,2-di-O-octadecenyl-3-
trimethylammonium propane, DOTMA (double chain) were added into the standard 
cubosome formulation which were stabilised by Pluronic F127. The concentration of 
cationic lipids in the cubosome formulation was optimised to avoid instability and to 
hinder any changes from occurring in the internal structure. The addition of 1.4 mol% 
cationic lipids maintained the internal structure as Pn3m structure and formed 
homogenous dispersion. In addition, observation under electron microscopy displayed 
the presence of vesicles which is believed to be the precursors to cubosome formation. 
Despite of the associated cellular toxicity risks of using cationic lipids, in vitro study 
exhibited that the addition of cationic lipids was not toxic at the studied concentration. 
Incorporation of cationic lipids increased the cellular uptake of the cubosomes, which 
was due to the electrostatic interaction with the cell membrane, followed by uptake via 
adsorptive endocytosis pathway.  
In order to further determine the potential of using surface modified cubosomes 
to target the BBB, all the formulations were administered intraveneously into zebrafish 
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larvae in vivo in Chapter 5, where the uptake and the toxicity of cubosomes in the 
midbrain region had been assessed. There was a significant two-fold uptake of 
cubosomes from larvae treated with Tween 80 and CTAB cubosomes, while lack of 
uptake observed in other formulations. The uptake of CTAB cubosomes into the 
midbrain could be related to the local toxicity effect, as visualised in toxicity studies. 
Other formulations, nonetheless, did not cause toxicity to the brain and no significant 
uptake. The uptake of Tween 80 cubosomes was not related to local toxicity and 
observation under electron microscopy revealed that gold-labelled Tween 80 cubosomes 
ended up in the brain parenchyma of the larvae. This observation highlights the potential 
of Tween 80 cubosomes as a drug carrier to target the brain.  
In summary, this thesis supported the hypothesis that cubosomes can act as a drug 
carrier and be surface modified to cross the blood-brain barrier through selected 
pathways. Despite the lack of uptake in other cubosome formulations, Tween 80 
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1 General introduction 
1.1 Problem statement 
In the past few decades, there has been a steady increase in the incidence of central 
nervous system (CNS) diseases worldwide such as Alzheimer’s disease, Parkinson’s 
disease, epilepsy, brain tumour, migraine and spectrum disorders 1. The projection of 
patients diagnosed with Alzheimer’s disease is expected to be 13.2 million people in the 
United States by the year 2050 2, with Parkinson’s disease showing a similar trend. In 
2005, about 4.6 million people in Western Europe were diagnosed with Parkinson’s 
disease and this number is expected to rise up to 9.3 million in 2030 3. CNS disorders not 
only impact the aging population, but also extend to the younger population 4. The 
increase in the incidence of spectrum disorders like autism has also sparked a worldwide 
concern and the need for better therapies, adding a significant pressure to the health 
authorities 5. CNS diseases not only contribute to the economic burden of a country, but 
also affect people’s quality of lives 4. There is a need to develop better treatment options 
to stop or slow down the disease progression of these aforementioned debilitating CNS 
diseases. 
Even though there are a large number of CNS drugs being used clinically, 
achieving therapeutic levels of drug in the brain, particularly for new therapeutic 
compounds remains a significant challenge due to the presence of physical and chemical 
barriers at the brain that limits the type and amount of CNS drugs to enter the brain 6-8. 
One of the major barriers to achieve therapeutic levels of drug in the brain to treat CNS 
disorders lies behind the presence of the blood-brain barrier (BBB) that selectively 
prevents drug molecules from entering the brain parenchyma 9. Large molecules such as 
monoclonal antibodies, antisense drugs and recombinant proteins show potential benefits 
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in treating CNS diseases, however, due to the size and the physical properties of these 
molecules, their uptake is limited 10-13. Furthermore, small or water-soluble drug 
molecules with therapeutic CNS effects are also prohibited from entering the brain 
because of the selectivity at the BBB. If these selectivity issues at the BBB can be 
resolved by masking the properties of the drug molecules, there is a high chance that a 
variety of drugs can be utilised to treat CNS diseases, reach therapeutic levels in the brain 
and at the same time reduce any peripheral side effects 14. 
Nanoparticles can be used as drug carriers to improve drug delivery to the brain. 
Various nanoparticles synthesised from polymers and lipid such as polymeric 
nanoparticles and liposomes have been developed to increase delivery of drugs into the 
brain. Surface decorations or modification on the surface of the nanoparticles have been 
developed to target specific pathways at the BBB and to allow uptake of drug molecules 
into the brain 7, 15-21.  
Lipid-based nanoparticles have been investigated as drug carriers, including 
liposomes and solid lipid nanoparticles 22, 23. For example, liposomes were surface 
modified with the addition of transferrin to target the transferrin receptor at the BBB 22, 
24, 25 where docetaxel encapsulated in the transferrin conjugated liposomes was delivered 
into the brain (rats) as compared to non-targeted liposomes 25. A number of studies on 
transferrin-conjugated liposomes were studied and reviewed 22 to show that transferrin 
conjugated liposomes can be a potential carrier to target the BBB. Meanwhile, solid lipid 
nanoparticles are also widely studied as drug carriers to target the brain. The studies on 
solid lipid nanoparticles were compiled and reviewed previously 23, 26. To target the BBB, 
the surface of solid lipid nanoparticles was coated with apolipoprotein E and Tween 80 
27 for uptake through LDL-receptors, while melanotransferrin antibody was conjugated 
on the surface to utilise the transferrin receptors 28. Even though these studies were 
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showing the potential of liposomes and solid lipid nanoparticles as drug carrier to target 
the brain, this thesis will explore a different type of a more versatile platform of drug 
carriers with ease of preparation and a higher drug loading potential to maximise the 
uptake of drugs into the brain.   
The use of lipid-based nanoparticles, cubosomes as drug carrier to the brain is yet 
to be discovered. This thesis will explore a novel lipid-based delivery system, cubosomes 
to target different endogenous molecular trafficking pathways at the BBB with the aim 
of increasing drug delivery to the brain. Suitable in vitro and in vivo models will be used 
to investigate the potential of cubosomes for cellular uptake and toxicity at the BBB.  
 
1.2 The role of blood-brain barrier (BBB) in drug delivery to the brain  
The anatomy and the transport systems at the BBB play an important role in 
developing a suitable strategy for delivering drugs into the brain.  
 
1.2.1 Anatomy of the BBB 
The discovery of the BBB was documented back in the 1880s where Paul Ehrlich 
showed that when an aniline dye was administered intravenously into a rat, all the organs 
were stained except for the brain and the spinal cord (reviewed by 29-31). This observation 
formed the basis of the presence of a barrier at the brain, which selectively allows 
molecules to pass. The biological reason for this barrier is now well established and is to 
protect the brain from toxins and cells of the immune system by regulating the entry of 
compounds into and out of the brain, while only allowing the entry of molecules that are 
crucial for brain homeostasis 32-34. The BBB is made of the cellular complex known as 
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the neurovascular unit (NVU), which collectively forms the physical, transport and 
metabolic barrier at the BBB 35, 36.  
The NVU consists of endothelial cells, astrocytes, pericytes, neurons and 
surrounded by basal lamina (Figure 1.1). The network of constant “communication” 
within the NVU forms a functional BBB and maintains the integrity of the barrier. The 
presence of NVU limits the uptake of drug molecules into the brain as the cells are 
“cemented” together by the presence of tight junctions (TJ) and adherens junctions (AJ) 
37. TJ are the predominant barrier for paracellular diffusion of molecules across BBB. 
They appear as a parallel series of interconnected strands or fibrils and are comprised of 
integral membrane proteins; occludin, claudin and junctional adhesion molecules 36, 38-40. 
Signalling and regulatory proteins like ZO-1-associated nucleic acid binding protein, 
multi-PDZ-protein 1, afadin (AF6) and membrane-associated guanylate kinase tightly 
regulate the paracellular pathway, hindering the free diffusion of polar solutes and drugs 
across the BBB. 
 




Astrocytes and pericytes are located in close proximity within the NVU and 
together they modulate the maturation of brain endothelial cells. Pericytes are often found 
in between endothelial cells whilst astrocytes are located at the capillary basement 
membrane. Pericytes are involved in the angiogenesis of micro-capillaries at the BBB 
and provide structural integrity to the blood vessels through their close contact with 
endothelial cells 29, 30, 38, 41-43. Astrocytes are involved in phenotypic changes of the 
endothelial cells at BBB and contribute to the BBB development 38, 44-46. Soluble factors 
secreted by astrocytes (for example zonular occludin, ZO) have been shown to promote 
the TJ formation by increasing the length, width and number of TJ 47, 48.  
 
1.2.2 The transport of drug molecules across the BBB 
In contrast to peripheral capillaries, brain endothelial cells lack fenestrations, 
have lower pinocytic activity, higher mitochondrial content and presence of tight 
junctions 30. As a result, the transport of molecules across the brain endothelial cells is 




Figure 1.2 Schematic diagrams of (a) the BBB which shows the tight junction that limits 
the permeability of molecules through paracellular route. Peripheral blood capillaries (b) 
have loose tight junctions, presence of fenestrae and high pinocytic activities that allow 
more molecules to pass through. 
 
Despite the strict regulation at BBB, selected drug molecules are still able to enter 
the brain through similar pathways to that used by endogenous molecules such as 
glucose, hormones, proteins and ions, to maintain homeostasis 49, 50. Small hydrophilic 
molecules can enter the brain through the paracellular pathway whilst lipid molecules 
enter predominantly through the transcellular pathway as shown in Figure 1.3. Large 
molecules utilise carrier-mediated, receptor-mediated and adsorptive endocytosis 
transport pathways. Molecules that are substrates to efflux pumps are pumped out of the 
cells by active efflux transporters 37, 51, 52. In addition, molecules are also subjected to 
metabolism by intracellular and extracellular enzymes such as monoamine oxidase, 
peptidases, nucleotidases and cytochrome P450 enzymes 53. The transport pathways at 










1.2.2.1 Passive transport system 
Passive transport of molecules across the BBB can be through the paracellular 
pathway (Figure 1.3a) where the transport is often restricted to small polar molecules 
and ions of less than 500 Da due to the presence of TJs 54-56. The transient opening of TJs 
has been explored as a mean to allow drug molecules to pass through the paracellular 
pathway 57-59. Administration of bradykinin and its analogues in patients with malignant 
glioma has been shown to transiently increase the permeability of drugs such as the 
chemotherapeutic carboplatin across BBB through paracellular transport in pre-clinical 
studies 60. These molecules initially bind to the B2 bradykinin receptor and trigger an 
increase in intracellular Ca2+ that causes contraction of brain endothelial cells and 
malformation of TJs and an increase in drug permeability at the BBB 61-63. This technique 
was tested on small polar molecule, inulin (400 Da) where the opening of TJs by Cereport 
(bradykinin agonist) allowed the diffusion of inulin across the HBMEC cell 62. However, 
the permeability across the TJs from Cereport administration was restricted to small polar 
molecules only. 
Several peptides have also been investigated as potential TJ modulators. PN-159 
(permeabilising peptide) was found to increase the uptake of larger polar molecules such 
as albumin (65 kDa) across the tight junction. The exact mechanism of action of the 
peptide remains to be fully elucidated, but “leakiness” of the TJs due to the inhibition of 
ZO-1 cytoplasmic TJ linker protein, which decreases the tightness in between endothelial 
cells has been proposed as a potential mechanism of action 64. Other peptides such as 7-
mer and AT-1002 have also been shown to induce transient TJ opening at the BBB 65-68. 
However, chronic administration of TJ modulators have not been fully explored and there 
are concerns that it may lead to the damage at BBB and disrupt its protective role 59, 65. 
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Another passive pathway at the BBB is through transcellular pathway, where 
small lipophilic and amphiphilic molecules (< 700 Da) have been reported to passively 
diffuse across the endothelial plasma membrane 9, 69, 70. Transcellular transport of small 
molecules and drugs with high lipophilicity is favoured across the BBB, as the cell 
membrane is made of lipid bilayers which impart a large surface area to the cell 
membrane and allows high rates of diffusion into cells 71. However, the amount of 
cholesterol in endothelial cells increases lipid-packing density in the endothelial cell 
membrane, and limits the movement of large lipid molecules across the cell 72, 73. The 
permeability of the BBB to lipophilic drugs can be predicted from the octanol/water 
partition coefficient at pH 7.4 (log P) for non-ionised and ionised molecules. In general, 
drug molecules with -1  log P  4 show increased permeability across the BBB 74. 
Increasing lipophilicity of drugs has been used as a strategy to increase their permeability 
across BBB, however this does not always improve transcellular diffusion. Increasing 
lipophilicity of drugs favours binding to efflux transporters, thus prohibiting their entry 
into the brain 75.   
Active efflux transporters (Figure 1.3d) are important in regulating brain 
homeostasis by preventing certain xenobiotic, hydrophilic and hydrophobic molecules 
from entering the brain, thus protecting the brain from potential damage 43, 76. The 
adenosine triphosphate-binding cassette (ABC) transporters, which include the P-
glycoprotein (P-gp) transporter, multidrug-resistance protein family (MRP) and breast 
cancer resistance protein (BCRP) are the main efflux transporters at the BBB.  
P-gp is an efficient gatekeeper, as it actively transports molecules out of the brain 
with high efficiency and it is highly expressed at the BBB 77. A large number of lipophilic 
drugs are pumped out by P-gp 75. For example, cyclosporine A, which is lipid soluble, 
does not show high therapeutic accumulation as expected due to the presence of efflux 
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transporters 37. The drug molecules are actively being pumped out of the cells by the 
efflux transporters. Co-administration of cyclosporine A with a P-gp inhibitor was shown 
to increase its uptake 78. In addition, successful seizure treatment has been reported with 
co-administration of phenytoin drug (P-gp substrate) with verapamil, a P-gp inhibitor 79, 
80.  
Regadenoson®, an A2 adenosine receptor agonist is a coronary vasodilator 
commonly used in cardio stress test and known to inhibit the efflux transporter P-gp. In 
a clinical trial, co-administration of Regadenoson® with temozolamide in patients with 
malignant glioma and resectable brain tumours showed a positive impact on the survival 
of the patient (life expectancy). Increased uptake of temozolamide into the brain was 
observed and associated with the inhibition of P-gp transport by Regadenoson® 81-85. 
Moreover, the short half-life of Regadenoson® (2 to 3 min) can induce transient increase 
in the permeability of the BBB to allow higher drug accumulation in the brain 86. 
However, chronic administration of efflux pumps inhibitors can lead to neurotoxicity 87, 
88. Defects in efflux transporter have been implicated in neurological conditions such as 





1.2.2.3 Carrier-mediated transporters  
To maintain brain homeostasis, important nutrients such as glucose, amino acids, 
nucleosides and organic ions move from the blood into the brain (influx transport 
system), while to prevent the accumulation of toxins, neurotoxic compounds and 
metabolites are transported out (efflux transport system). Selected polar macromolecules 
enter the brain through carrier-mediated transporters (Figure 1.3c), which are located at 
the luminal or abluminal side of the cells, making this a form of molecular transport 
unidirectional. The type of transporter determines the direction of molecular transport; 
either into or out of the brain 89. Sodium-independent neutral amino acid transporter 
(system L) transports L-tyrosine, L-tryptophan and L-histidine into the brain as 
neurotransmitter precursors 90, 91. Other amino acids including L-leucine, L-isoleucine, 
L-methionine, L-phenylalanine, L-valine and L-threonine are transported through system 
L and involved in protein synthesis in the brain.  
In order to use the carrier-mediated pathway for drug delivery, the drug molecules 
need to mimic the structure of endogeneous substrates. Only two transporters will be 
discussed here as examples of carrier-mediated transporters used for drug delivery; LAT1 
and GLUT1. System L has LAT1 (SLC7A6), to transport amino acid-mimetic drugs such 
as L-Dopa into the brain. L-Dopa is converted into dopamine and used as a treatment for 
schizophrenia and Parkinson’s disease 92-95.  
GLUT1 is located at luminal and abluminal sites of the BBB but allows only 
unidirectional transport of D-glucose from the blood into cell and into the brain 
parenchyma. Initially D-glucose enters the endothelial cells through GLUT1 at the 
luminal site and then transported out of the cell into the brain parenchyma using GLUT1 
on the abluminal site. GLUT1 is also able to transport L-dehydroascorbic acid into the 
brain which is converted to L-ascorbic acid. L-ascorbic acid is not a substrate of GLUT1 
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which means that it will retain in the brain without being transported out and leads to a 
higher concentration of L-ascorbic acid in the brain 96, 97. Based on the knowledge of D-
glucose transport, drug molecules have been conjugated with glucose molecule to 
improve their delivery into the brain. For example, glucose conjugated to chlorambucil 
was shown to bind to the GLUT1 receptor and inhibit the binding of other glucose 
molecules from the blood. The binding of glucose conjugated chlorambucil to GLUT1 
was in a concentration dependent manner which shows that the transport of chlorambucil 
into the cells can be increased from the conjugation with glucose 98.  
Nanoparticles have also been coated with glucose to target the GLUT-1 glucose 
transporters at the BBB. For example, intranasal administration of exosomes which are a 
type of nanoparticle, coated with glucose led to increased uptake and localisation of the 
exosomes at the lesion site in the mouse model of brain ischaemia within 24 hours after 
intranasal administration. As compared to intravenous administration of glucose coated 
exosomes, the exosomes retained in the brain after intranasal administration. This showed 
that while both routes demonstrate significant uptake of exosomes in the brain, but the 
administration through IV route was subjected to rapid clearance from the brain. 
However, in both routes, from the receptor inhibition study using cytochalasin B (glucose 
transport inhibitor) and receptor saturation using D-glucose, the uptake of glucose coated 
exosomes into the cell were proposed to be via GLUT-1 transporters at BBB. In addition, 
dual labelling with fluorescence molecule allows the tracking of nanoparticle’s fate after 
the administration 99. A detailed review on developing nanoparticles conjugated to 
glucose transporter substrates in order to utilise GLUT receptors at the BBB was 
previously published 100. In addition, there are other carrier-mediated transporters such 
as nucleoside transport system, organic anion transport system and neurotransmitter 
transport system available which will not be discussed in any further detail in this thesis.  
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Despite the potential, there are some major drawbacks in developing drug 
molecules to target carrier-mediated transporters. The drug molecule has to be designed 
to structurally mimic the endogenous substrates or conjugated to the substrates for 
successful binding and uptake by the transporters. This can lead to competitive binding 
with endogenous substrates. Furthermore, chronic administration of the drug molecules 
can lead to receptor saturation and disrupt normal homeostasis at the BBB 101. 
Nevertheless, this pathway is promising, and drug molecules are being developed to 
utilise the transporters to deliver drug to the brain.  
15 
 
1.2.2.4 Receptor-mediated transcytosis  
Macromolecules like peptide and proteins bind to specific receptors on the surface 
of the endothelial cells and are endocytosed (Figure 1.3e) 102. The uptake process starts 
with ligand binding to a receptor, which triggers a cascade of reactions. Firstly, the 
receptor-ligand complex is internalised by clathrin-coated pits into the cell, and forms an 
early endosome 103. Then the contents of the endosome are released into the cell upon the 
enzymatic activity by the lysosome, and the receptors are recycled back to the plasma 
membrane. The content will either stay in the cytosol or is translocated to the cell 
basement membrane and enters the brain parenchyma 104. This process is energy 
dependent 105.  
Certain receptor-mediated pathways are currently being explored as potential 
target to design “Trojan horse” molecules which are endocytosed by the endothelial cells 
106, 107. For example, the transferrin receptor (TfR) expressed at the luminal and abluminal 
side of endothelial cells allows bidirectional transport of transferrin molecules 107. TfR is 
expressed at the luminal and abluminal side of endothelial cell to allow the transport of 
TfR substrate in both ways 108, 109, 110. Chitosan nanoparticles functionalised with 
transferrin molecules and loaded with fibroblast growth factor had increased uptake into 
the brain as compared to non-functionalised chitosan nanoparticles. The inhibition of 
uptake by imatinib suggested that the uptake of transferrin functionalised chitosan 
nanoparticles was from the binding with TfR at the BBB 111. Insulin receptors and low 
density lipoprotein (LDL) receptors are also expressed on endothelial cells at relatively 
high levels 112-114 and have been explored for drug and nanoparticle delivery into the brain 
37. This pathway will be explored in this thesis by developing cubosomes nanoparticles 
surface decorated with specific moiety to target the LDL-receptor at the brain. Further 
discussion will be outlined in detail in Chapter 3. 
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1.2.2.5 Adsorptive endocytosis  
Macromolecules such as albumin can enter the brain through adsorptive 
endocytosis pathway (Figure 1.3f). Uptake of molecules via this pathway depends on the 
electrostatic interactions between positively charged molecules or ligands and the 
negatively charged cell membrane (endothelial glycocalyx) 37. An endocytic cascade 
follows, and the molecules are translocated from the blood to the brain. The whole 
process is energy and temperature dependent 37, 115-118. The uptake is low affinity, high 
capacity and less specific than receptor-mediated transcytosis, as electrostatic 
interactions can occur on cells from other tissues in the body 119. Ebiratide, a drug used 
for treating Alzheimer’s disease has a positive charge and in in vitro studies with primary 
cultured bovine brain capillary endothelial cells showed that the uptake of Ebiratide into 
the cells was via adsorptive endocytosis 120, 121. This pathway will be explored by 
developing cationic cubosomes to target the negatively charged membrane of the brain 
endothelial cells for further uptake by the brain. A more detailed discussion on this 






1.3 Strategies for drug delivery to the brain 
1.3.1 Invasive strategies 
Although advanced drug development has led to various drug formulations and 
techniques to improve drug delivery to the brain, several potent drug molecules are still 
not able to cross the BBB and reach the desired therapeutic level. One strategy to 
overcome this problem is to use invasive methods often involving surgery to breach the 
BBB and directly deliver the drug into the brain parenchyma. These approaches are 
discussed in more detail below.   
 
1.3.1.1 Intracerebroventricular injection 
Intracerebroventricular injection involves the direct delivery of drug molecules 
that have limited permeability across the BBB, by administering into specific sites within 
the brain parenchyma 122-124. This pathway is preferred when a high dose of drug loading 
in the brain is desired. It has been studied for treating Alzheimer’s disease, autism, seizure 
and in cerebral ischemia-reperfusion injury 125-127. It provides a faster effect as compared 
to intravenous and oral administration. For example, intracerebroventricular injection of 
fibroblast growth factor reached a higher concentration in the brain as compared to 
intravenous injection 128, 129. However, due to the invasive technique involved in this 
method, it is not suitable for chronic administration 130-132. 
 
1.3.1.2 Intracerebral administration 
Intracerebral administration involves administration of drugs directly into the 
brain parenchyma. In convection enhanced delivery, a catheter is implanted directly in 
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the brain and the application of hydrostatic pressure allows the drugs to diffuse directly 
for further penetration into the brain. Another way is to implant degradable or non-
degradable polymers directly into the brain to release the drug slowly over time. In phase 
I/II clinical trial, the cancer drug, D2C7-IT was studied as immunotoxin for glioblastoma 
treatment and delivered through intracerebral convection-enhanced delivery using 
osmotic pumps. D2C7-IT was shown to have strong anti-tumour effect by inhibiting the 
protein synthesis and kills the epidermal growth factor receptors expressed on the 
glioblastoma cells 133. The continuous release of drugs from this method can reduce the 
frequency of drug administration and costs. The result from this study is promising and 
the study is on its way for Phase I/II clinical trials for adults with recurrent malignant 
glioma.  
Gliadel® wafer which contains carmustine (alkylating agent) was released into 
the market to treat high-grade glioma. This wafer is implanted at the tumour site, during 
tumour removal surgery in the brain. The degradation of the wafers leads to the release 
of carmustine and kills the tumour tissues. Even though the prognosis after using 
Gliadel® is still poor (increased survival by 2 months), this treatment still offers an 
improvement in survival for glioma patients 134.  
Another CNS drug, vigabatrin, an epilepsy drug that is commonly administered 
orally; was delivered via intracerebral administration in rat models with refractory 
epilepsy and showed that there was a small increase (p<0.05) in seizure threshold, which 
comes from the increase in local GABA concentration 135. It is used as an adjuvant 
treatment for epilepsy and seizure. This drug is commonly used orally; however, 
delivering this drug through intracerebral administration has shown potential in treating 
refractory epilepsy. Unfortunately, chronic intracerebral administration of vigabatrin in 
the brain was associated with encephalopathy and extrapyramidal symptoms 136.  
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Despite the advantages offered from intracerebral administration of drugs, the 
other  limitations behind this technique are (1) the risk of developing astrogliosis 
(abnormal increase of astrocytes due to trauma) because of the hydrostatic pressure from 
the infusion, and (2) the need to replace the implant in the brain which necessitates 
expensive and invasive procedures 35, 137. 
 
1.3.1.3 Osmotic disruption 
Reversible osmotic disruption at the BBB can temporarily open the cerebral 
vessel TJs to deliver drug molecules into the brain. To induce disruption, a hypertonic 
solution such as mannitol (around 1.4 M) is administered via carotid artery as a short 
(often 30 min) infusion. The changes in osmolarity lead to a transient increase in 
intracellular Ca2+ concentrations and alter intracellular signal transduction. The change 
in Ca2+ concentration leads to calcium-mediated oxidative stress and causes the opening 
of TJs between the endothelial cells 138, 139. During this period, BBB becomes “leaky” 
and significantly more administered drugs can cross the BBB 140, 141. However, after 
removal of the mannitol, the BBB does not fully recover as the osmotic disruption causes 
damage to the cells. Repeated application of this procedure can lead to a long-term 
damage to BBB and compromising the BBB integrity. Risks of stroke and epileptic 
seizures are associated with this method of drug delivery 142. However, it can be used in 
later stage of neurological disease when aggressive drug loading is desired to reduce the 
severity of the disease, improve prognosis and the risk of death outweigh the risk of 




1.3.1.4 Focused ultrasound 
Ultrasound energy has been studied as a less invasive method to deliver drug 
molecules to targeted areas within the brain. Focused ultrasound allows transcranial 
delivery of drug into a specific area in the brain with higher drug penetration and longer 
drug retention at the target site 147. Microbubbles are used in focused ultrasound therapy 
where they function as a catalyst to amplify the local cavitation in the capillary of the 
brain. Conventional microbubbles are made of perflutren (Definity® and Optison™) or 
sulphur hexafluoride (Sonovue) 148. Initially, microbubbles are injected intravenously as 
a contrast agent followed by administration of the drug molecule, or the drug can be 
incorporated into the core shell of the microbubble and the ultrasound is applied (0.1 to 
1.5 MHz) to the brain region of interest. Ultrasound causes an oscillation in the blood 
vessel and increases permeability of the endothelial cells by opening the TJs 149. The 
permeability at the BBB can last anywhere from six to eight hours after the procedure 
150-152. The core shell is stabilised using phospholipids, proteins or polymers 153, 154. 
Adding ligands on the surface of microbubbles can further promote specific tissue 
targeting for localised drug delivery 155. Polyethylene glycol (PEG)ylated liposomes 
containing glial cell line-derived neurotrophic factor and nuclear receptor-related factor 
1 was conjugated to microbubbles and was found to increase dopaminergic neurons in 
the rat model of Parkinson’s disease 156. The opening of endothelial cells at the BBB by 






Figure 1.4 Schematic illustration of the effects from microbubbles during ultrasound 
application. Ultrasound causes microbubbles to oscillate (stable cavitation) or implode 
(inertial cavitation). In stable cavitation, the tight junctions on the endothelial cells can 
temporarily open from push-pull mechanisms while microstream is a fluid-flow that 
occurs from the rapid expansion and contraction of microbubbles which affect the 
integrity of the endothelial lining. In addition, acoustic radiation force occurs due to the 
pressure gradients that lead to a reduction in vascular permeability. Meanwhile, in 
“inertial cavitation”, the fragmentation of microbubbles causes an increase in temperature 
and pressure, which lead to formation of “shock waves” and “micro jet”. These effects 
will increase vascular permeability. Lastly, “free radical” can also be formed and 
permeabilise the endothelial cells. Drug molecules in the blood or in the microbubbles 
core shell can cross the BBB from one of the mechanism shown (Reproduced with 
permission from 157). 
 
The degree of permeability from BBB disruption can be controlled by the 
concentration and size of the microbubbles 158-160. The leakiness at the BBB allows the 
movement of small and large molecules into the brain. Doxorubicin (580 Da), paclitaxel 
(854 Da), and herceptin (148 kDa) were shown to have increased permeability into the 
brain using the focused ultrasound method 6, 161. Temozolamide delivery using ultrasound 
is in clinical trials for the treatment of glioblastoma 162. Moreover, a leaky BBB was 
shown to contribute to the clearance of amyloid from the brain in Alzheimer’s patient. 
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This technology is still in the pre-clinical stage but shows great promise in treating 
Alzheimer’s disease 163. The limitation in using focused ultrasound comes from the 
unpredictable disturbance in the brain from the ultrasound with unknown long-term 
damage from the repeated opening of the BBB. More studies are underway in utilising 
magnetic resonance imaging as a guide to target ultrasound precisely and to evaluate any 
damage at BBB from the ultrasound 164. 
 
1.3.2 Non-invasive strategies 
Even though invasive strategies can provide a higher drug loading in the brain 
parenchyma, risks associated with the techniques can be high with expensive costs and 
require specialist expertise 165-167. Invasive strategies are also not often suitable for 
chronic drug administration. Hence, non-invasive strategies are more favourable for 
long-term treatment of neurological diseases. Non-invasive strategies currently being 
investigated include chemical modification of drug molecules, intranasal drug delivery 
and formulation approaches to manipulate the BBB pathways 70, 168-170. These are 
discussed in more detail below. 
 
1.3.2.1 Chemical modification of drug molecules 
Since the majority of drug molecules lack properties for entry into endothelial 
cells (such as being lipophilic and having a molecular weight <400 Da), the development 
of prodrugs has been investigated 171, 172. Prodrugs are inactive molecules that require a 
chemical or enzymatic reaction to convert them into active drug molecule such as L-dopa 
as discussed in Section 1.2.2.3. 
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Recently, paliperidone prodrug dimer (Pal-8SSme) was synthesised where the 
original drug, paliperidone (anti-psychotic) is a substrate to P-gp and ABC transporters 
at the BBB. Two molecules of paliperidone were attached via dimerisation and this leads 
to inhibition of P-gp and ABC transporters at the BBB. After the uptake and inhibition at 
the BBB cells, the dimers then converted to paliperidone monomer and delivered into the 
brain parenchyma. The synthesis allows the entry of paliperidone into the brain without 
being pumped out by P-gp and ABC transporters 173.  
Sobetirome ethanolamide prodrug was developed to stimulate myelin repair in 
multiple sclerosis. Sobetirome is a thyroid hormone which has limited permeability 
across the BBB. The synthesis of ester prodrugs of sobetirome will increase the uptake 
through active (amino acid, glucose and choline transporters) and passive pathways at 
the endothelial cells, and within the cells, non-specific esterases will cleave the prodrug 
ester and leaving behind active sobetirome in the brain 174. The addition of ester molecule 
on CNS drugs provides a useful strategy to utilise the esterases available in the 
endothelial cells to convert the prodrug into active drug molecules within the brain 
parenchyma.  
 
1.3.2.2 Intranasal drug delivery 
Intranasal drug delivery has been shown to bypass the BBB and deliver drugs into 
the brain. The drug needs to be administered into the olfactory region of the nasal cavity 
(Figure 1.5), from where it is believed that the drug traverses the olfactory epithelium 
and enters the olfactory bulb. The drug is then thought to travel through the olfactory and 





Figure 1.5 Intranasal drug delivery provides drug access of to the brain through olfactory 
pathway and trigeminal pathway. Reproduced with permission 176. 
 
Intranasal administration of insulin has been investigated for treating Alzheimer’s 
disease 177-179. The use of intranasal insulin was found to support memory function and 
improve cognitive impairment in patients with Alzheimer’s disease 180. CPEX 
Pharmaceuticals has developed their intranasal insulin product (Nasulin®) to deliver the 
insulin for diabetic management 181, 182. However, at the same time, the use of nasal 
insulin was found to support memory function and improve cognitive impairment in 
patients with Alzheimer’s disease 180. Other studies reported improvements of cognitive 
function corresponding to a decline in amyloid protein, Aβ42 level in cerebrospinal fluid 
after intranasal insulin administration 168, 183. In another study, chloramphenicol 
acetyltransferase, a bacterial enzyme that catalyses chloramphenicol antibiotic, was 
successfully delivered into the brain region of rats through intranasal administration 
within 15 minutes of application 184.  
Even though these studies suggest that intranasal administration can be a potential 
non-invasive therapy for delivering drugs to the brain, there are still challenges in using 
the intranasal pathways  The limitations in using nasal pathway includes the limited 
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volume for administration, mucociliary clearance, potential enzymatic degradation and 
small anterior anatomy of the nasal cavity 185-189. 
 
1.3.2.3 Nanoparticles as drug carriers 
Nanoparticles are potential drug carriers that have been widely studied for the 
delivery of drugs into the brain across the BBB 190, 191. Nanoparticles are 1 to 1000 nm 
particles in diameter, and can be produced from biodegradable polymers, lipids or a 
combination of both as shown in Table 1 and are able to bind or encapsulate drug 
molecules 192. The size allows the particles to be endocytosed into the cell via the different 
pathways discussed in Section 1.2.2. The encapsulation of drugs inside the nanoparticles 
provides protection to drugs from degradation and importantly, can mask undesirable 
properties of the drug that may prevent uptake into the brain 193. Nanoparticles can also 
be modified to provide controlled release properties 194-197 and the surface can be 
decorated with ligands for site-specific drug targeting, or the charge on the surface can 
be controlled 198-202.  
Poly(lactic-co-glycolic acid (PLGA) and polybutylcyanoacrylate (PBCA) 
polymers have been used extensively to prepare nanoparticles which can target the BBB. 
These polymeric nanoparticles have also been surface decorated with surfactants such as 
Tween 80 and poloxamers, such as Poloxamer 188, to target receptors present on the 
endothelial cells. PLGA nanoparticles decorated with Poloxamer 188 or alginate 
hydrogel were able to increase the uptake of doxorubicin, dexamethasone, loperamide, 
quercetin and cerebrolysin 203-205. PBCA nanoparticles surface modified with Tween 80 
were shown to increase the uptake of dalargin, gemcitabine, kyotorphine, loperamide and 
gemcitabine into the brain in all groups studied 152, 206-210. Modifications of other types of 
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nanoparticles including micelles, liposomes, microcapsules, dendrimers, solid lipid 
nanoparticle and cerium oxide are shown in Table 1.1 below. However, despite the 
extensive studies, the uptake was not being replicated in humans. The scalability and 
manufacturing issues can be the limitation in producing the formulation at a larger scale. 
In addition, stability is another concern where in lab setting, the nanoparticles are freshly 





Table 1.1 Nanoparticles developed as drug carriers to target the BBB 





 Polymer   PLGA Poloxamer 188 Doxorubicin 212 
      Loperamide 213 
     Alginate 
hydrogel 
Dexamethasone 203 
     None Quercetin 204 
     None Cerebrolysin 205 
    PBCA Tween 80 Dalargin 206 
      Gemcitabine 214 
    Kyotorphin 207 
   Loperamide 210 
   Rivastigmine 209, 215 
Dendrimers None No drug used 216, 217 
 Lipid  Micelles None Bevacizumab 208 
 Liposomes PC:Chol:DSPG 
 
AmBisome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Amphotericin B 218 
219 
220
 Solid lipid Cationic bovine 
serum albumin 
Doxorubicin 221 
     None Atazanavir 222 
     Transferrin Quinine 223 
Others   Cerium oxide None Lenalidomide 224 
  Microcapsules Sodium alginate Human endostatin 225 




Varying degrees of brain uptake have been reported from nanoparticle uptake 
studies. Uptake of nanoparticles into the brain are usually observed under fluorescent or 
electron microscope by fluorescent labelling or with electron dense molecule. Electron 
dense molecules such as gold, silver or platinum also allow observation and localisation 
of the nanoparticles in the brain at a cellular level with the aid of electron microscopy. 
Fluorescently labelled PBCA nanoparticles coated with Tween 80 were observed in 
mouse brain sections under a fluorescence microscope and confirmed the uptake into the 
brain of a mouse 226.  
The use of fluorescence and electron microscopy can be a challenge in measuring 
the successful uptake of nanoparticle into the brain. For example, in electron microscopy, 
the animal needs to be sacrificed and the brain sample needs to go through various 
preservation and fixation steps. The administration of PEG-amine/galactose coated with 
gold nanoparticles in rat model was observed primarily in the cytosol of microvascular 
endothelium in the brain. 227, 228.  Even though the authors concluded that the observation 
was due to the uptake into the brain, however, there is a concern that the observation of 
the particle was an artefact from the processing of the tissue sectioning and preservation 
methods used for electron microscopy techniques. Osmium tetroxide and glutaraldehyde 
have been found to produce artefacts that look like dense particles in tissue sections 229-
231. Therefore, ideally the uptake of nanoparticles into the brain is best done using live 






1.4 Cubosomes as drug carrier to the brain 
Despite various studies conducted on various type of nanoparticles to carry drugs 
to target the brain, this thesis is interested with the use of lipid-based nanoparticles. 
Certain amphiphilic lipids that can self-assembled in water to form highly ordered 
structures can be dispersed in aqueous environment to form lyotropic liquid crystals 232. 
There are various types of self-assembled lipid carriers which include liposomes, 
cubosomes and hexosomes. In the next few sections, the dispersions of lyotropic liquid 
crystals will be discussed and the advantage of using cubosomes as the drug carrier of 
option to target the BBB will be reviewed.  
 
1.4.1 Lyotropic liquid crystals  
Lyotropic liquid crystals (LLC) are an interesting field to explore in developing 
lipid-based nanoparticles to target the BBB. Molecules that commonly form LLC phases 
are amphiphilic with a hydrophilic head and a lipophilic tail that can self-assemble in 
aqueous environments to form highly ordered structures (mesophases), which have 
properties in between solid crystals and isotropic liquids 233-235. Furthermore, these large-
scale structures can be dispersed into nanosized particles. LLCs are sensitive to changes 
in the concentration of amphiphiles or water, where the molecules can change from a less 
ordered state (micelles) to more ordered state (inverse cubic phase) or vice versa 236. The 
flexibility provided by fine-tuning the concentration of amphiphiles and water provides 
an advantage of using LLCs as self-assembling lipid nanoparticles over polymer-based 
nanoparticles 237-239. In the following sections, the lipid self-assembly of LLCs will be 
discussed, as will the advantages of using cubosomes as a drug carrier to target the brain.  
30 
 
1.4.2 Lipid self-assembly 
Amphiphilic molecules such as polar lipids that form LLC can self-assemble and 
spontaneously form different ordered structures in aqueous environment such as the 
lamellar, hexagonal and cubic mesophases. Amphiphilic molecules consist of 
hydrophobic tail and hydrophilic head, which orientate to form lipid bilayers in an 
aqueous environment. The specific structure or mesophase formed is greatly influenced 
by the molecular structure of the amphiphiles and can be predicted using the critical 
packing parameter (CPP). The CPP is a geometrical value that compares the ratio 
between the volume of hydrophobic liquid tail (v), the cross-sectional lipid head area (a) 
and the lipid chain length (l) as shown in Equation 1 below. The CPP can be used to 
predict the curvature (shape) and the geometry of the whole molecule at the lipid-water 
interface. 
 





The curvature of lipid monolayers is affected by the amphiphilic lipid structure 
as shown in Figure 1.6. Lipids with CPP value of 1 (Type 0) usually self-assemble into 
planar or bilayer structures with zero mean curvature. When the value of the CPP is less 
than one, the polar heads of the lipids form a convex interface and “normal oil in water” 
morphologies with positive curvature form (Type I). In contrast, when the CPP is more 
than one, the curvature is towards the aqueous environment, resulting in negative 





Figure 1.6 Schematic drawings of the curvature of lipid monolayers. Type 0 displays zero 
curvature with planar structure; Type I shows a monolayer with positive curvature and 
Type II represents a lipid monolayer with negative curvature. 
 
 
Figure 1.7 illustrates the formation of different bilayer structures, which are 
affected by the molecular packing parameter. As the value of the packing parameter (P) 




Figure 1.7 Schematic illustration of the structure formation from self-assembly of 
amphiphilic molecules. The molecular packing parameter (P) formed different curvatures 
and lead to different structures. P: packing parameter, v: molecular volume, l: length of 
molecule and a: cross-sectional area of head group (Adapted from 240 with permission). 
 
In addition to lipid molecular structure, changes in temperature, pressure, aqueous 
environment and additives can also influence phase transition 241. The mesophase 
structure can also be affected by the concentration of amphiphiles. At very low 
amphiphile concentration, the molecules have no specific arrangement and are randomly 
dispersed throughout the aqueous phase. Increasing the concentration of amphiphile 
leads to spontaneous assembly into simple vesicles or micelles. The hydrophobic tails 
from the amphiphiles are repelled by the aqueous phase while the hydrophilic head form 
the outer surface of the micelles, favouring the aqueous phase. The lamellar phase is often 
formed after the hexagonal phase and is composed of a layer of amphiphiles arranged in 
an ordered manner, separated by a layer of aqueous phase. The bicontinuous cubic phase 
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is formed upon the addition of higher concentrations of amphiphiles to the system 242, 243. 
The CPP concept provides a guide in amphiphilic arrangement, but not all amphiphilic 
lipids will follow the CPP. For example, in GMO, increasing the concentration of GMO 
leads to the formation of inverse micellar phase followed by lamellar phase 244, 245. 
Another example is the lipid phytantriol used in this thesis, where increasing its 
concentration leads to a more ordered state where the molecules start to form a 
discontinuous cubic phase and hexagonal phase 246.  
 
1.4.3 Lamellar phase  
Lamellar phase, the most commonly studied LLC, is a one-dimensional stack of 
bilayers that are separated by layers of water 247. The hydrophobic tails are shielded from 
the aqueous environment in the bilayers. The fluidity and arrangement of the tails further 
characterise this phase. In the crystalline lamellar (Lc) phase, the lipid molecules are 
ordered and changes in external environment, such as in temperature increase, the fluidity 
of the lipid tails changes. Subsequent heating causes a transition from Lc to a lamellar gel 
(Lβ) phase and continuous heating leads to the formation of the fluid lamellar phase (Lα). 
At elevated temperatures, the fluid isotropic phase (L2), which consists of reverse 
micelles is preferred, while in most phospholipid systems, the hexagonal phase appears 
before the L2 phase upon heating 
248. The Lα phase is the most common phase adopted by 
biological membranes.  
In nanoparticle technology for drug delivery, liposomes are the most widely 
studied lamellar phase. Liposomes are particles made of phospholipids that orientate to 
form lipid bilayer 249-252. The lipid arrangement allows the incorporation of hydrophilic 
drugs in the liposome core and hydrophobic drugs in the lipid bilayer. Liposomes can be 
surface decorated to increase the delivery to targeted cells (Figure 1.8). The addition of 
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charged lipids, polyethylene glycol and ligands will improve the targeting effect of 
liposome and reduce the toxicity of the encapsulated drugs 253.  
 
Figure 1.8 Surface modified liposome for drug delivery. Hydrophilic drugs are 
encapsulated in the aqueous core while hydrophobic drugs in the lipid bilayer. In 
conventional liposome (A), the lipid bilayer can be made of charged or neutral lipids and 
cholesterol. Polyethylene glycol (PEG) is added to form PEGylated liposome (B) to 
provide stability to liposome while ligands such as antibodies, protein and peptides can 
be added to form ligand-targeted liposome (C) to target selected receptors. Theranostic 
liposome (D) consists of both targeting ligand and imaging molecule to allow localisation 
of the liposome after administration. (Reproduced with permission 253). 
 
Currently, there are several liposomal formulations in the market. Intravenous 
formulation of liposomes such as Ambisome, Abelcet and Amphotec encapsulate 
amphotericin B, used to treat severe fungal infection. Several liposomal formulations 
with doxorubicin are marketed under the brand names Myocet, Caelyx and Doxil, and 
are used intravenously as chemotherapeutic agents to treat Kaposi’s sarcoma, ovarian and 
breast cancers. In targeting the brain, Depocyt, a cytarabine-encapsulated liposome is 
used for treating neoplastic and lymphomatous meningitis. The difference in all the 
liposome formulations lies behind the composition of the lipid bilayers. The surface 
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decoration of liposomes allows targeting to specific tissues in the body and reduces 
toxicity of the drug by masking the drugs inside the liposome 253. Apart from being a 
drug carrier, liposomes have also been extensively studied for vaccine delivery 254-256. 
The advantages of using liposomes as drug carriers and the challenges in translating 
liposome research to marketed products are widely studied and reviewed by Narang et. 
al 257, 257.  
 
1.4.4 Hexagonal phase  
The hexagonal phase consists of a series of cylindrical micelles arranged into a 
two-dimensional hexagonal lattice, where back-to-back lipid layers separate the 
cylinders. It can present as the normal hexagonal (HI) or inverse hexagonal phase (HII). 
The HII phase occurs at a high temperature as a result of increased chain disorder, where 
the cylindrical arrangement is entropically more favourable 248. The dispersions of 
hexagonal phase in aqueous solution lead to the formation of hexagonal particles called 
hexosomes 258. Glycerate based surfactants such as phytanyl glycerate and oleyl glycerate 
form hexosomes and have shown to have potential in drug delivery 237, 259. Irinotecan, a 
highly lipophilic cancer drug molecule was successfully incorporated into hexosomes for 
cancer therapy 237. There have been a small number of studies reported on the potential 
use of hexosomes as a drug carrier to the brain. The addition of cationic lipids in 
hexosomes dispersions was able to encapsulate plasmid DNA, through electrostatic 
interaction between the negatively charged DNA, for brain delivery 260, 261.  
1.4.5  Bicontinuous cubic phase  
The bicontinuous cubic phase is a unique structure and consists of a continuous 
single lipid bilayer (thickness about 3.5 nm), separating two non-intersecting aqueous 
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channels with an interfacial area of about 400 m2/g 258, 262, 263. The lipid bilayers are 
organised in a honeycombed structure with two internal aqueous channels that has shown 
the potential to accommodate various types of drug molecules 264. The bulk cubic phase 
is viscous and solid-like, does not display any optical properties under cross-polarised 
light and categorised as isotropic 235, 265. The amphiphiles that make up the cubic phase 
can absorb water, which leads to the formation of a gel-like structure in the bulk phase 
with a cubic structure. The internal structure and high surface area of the cubic phase 
allows a high loading of amphiphilic, hydrophobic and hydrophilic drug molecules 266-
268.  
A few studies have investigated the potential of the cubic phase and cubosomes 
as drug carriers via different routes of administration (Table 1.3). The high viscosity and 
gel-like structure of the bulk phase provides a suitable structure with adhesive properties 
for topical and buccal drug delivery of Leu5 enkephalin, cyclosporin A and 
sulforhodamine drugs 269-271. The bulk phase can provide slow release properties as the 






Table 1.2 Examples of studies on cubosomes carrying drug molecules through oral, 
buccal, topical and intravenous administration 





Buccal Leu5 enkephalin 269 




Intravenous Camptothecin 274 
 
Unfortunately, due to the high viscosity of the bulk gel, it is not suitable for 
intravenous drug preparation. However, due to its ability to maintain the cubic internal 
structure in excess water, it can be dispersed to form colloidal dispersions, called 
cubosomes 275. There are three common types of cubosomes that have been identified 
from X-ray crystallographic studies; primitive (Im3m), diamond (Pn3m) and gyroid 
(Ia3d) in order of increasing curvature as illustrated in Figure 1.9 276. The water content 
in the system influences the transition of cubosomes from one type to another. In 
addition, temperature, type of additives and amphiphiles used also play a role in the 
transition 264. The inverse cubic phase of phytantriol lipid is reported to be stable in the 
presence of excess water and this provides various advantages in formulating cubosomes 
as a drug carrier for intravenous formulation to the brain 246, 277. The significance of this 





Figure 1.9 Schematic representations of the inverse bicontinuous cubic phases with 
increasing curvature: Im3m (primitive), Pn3m (diamond) and Ia3d (gyroid). Individual 
lipids are shown as ball-stick figures, whilst the regions filled with green and red colour 
represent water channels 278. 
 
1.4.6 The advantages of using cubosomes as drug carrier  
Cubosomes have the potential to offer various advantages as drug carriers to cross 
the BBB. The ability of cubosomes to be stably dispersed in excess water allows the 
delivery of drugs through intravenous administration 274. The amphiphilic lipids 
commonly used in preparing cubosomes formulation have low toxicity 279, 280 and the 
amphiphilic lipids assembly mimics the lipid orientation in the lipid bilayer within cell 
membrane 281, 282. The internal tortuous structures of cubosomes allow a higher drug 
loading as compared to other lipid nanoparticles such as liposomes 283. Hydrophobic and 
hydrophilic drugs can be encapsulated in the lipid bilayer and aqueous core respectively 
284-286. In addition, cubosomes formulation can be modified to produce various 
encapsulation and release properties of drug molecules. Figure 1.10 illustrates how the 
surface of cubosomes may potentially be modified by molecules into the lipid bilayer. 
To have a desired effect such as to target the encapsulated drug to specific tissues or 





Figure 1.10 Schematic illustration of the internal structure of cubosomes which allow 
surface modifications with surfactant, charged lipid and the addition of ligands. The 
tortuous structure of the lipid bilayers and the aqueous pores allow encapsulation of a 
higher amount of hydrophobic and hydrophilic drug due to the high surface area (Adapted 
and modified from 287 with permission). 
  
Whilst early studies in cubosome research proposed that due to the nature of its 
structure, cubosomes may be able to modulate the release of encapsulated drug molecules 
264, 288, 289. However, in 2013, Boyd et al. showed that cubosomes produce a burst instead 
of sustained release of drug in vitro 290. The authors also went on to suggest that the 
degradation of cubosomes in the body would cause immediate release of the drug 
molecules. However, this has not been demonstrated to date. Cubosomes still offer 
various benefits as a drug carrier. The encapsulation of drug within the complex structure 
of cubosomes has been shown to offer protection against chemical of physical 
degradation of protein bioactives 291.   
The drug release properties of cubosomes are influenced by the structure and 
changes in the environment. Hydrophilic drugs are encapsulated within the aqueous 
channels and the release is affected by the size of the channels and the molecular weight 
of the drugs 237. Adding specific additives such as octyl glucoside detergent into 
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cubosome formulation can increase the size of the channel, thus increasing the rate of 
release 292. The molecular size of the drugs will also determine whether the drug can be 
released faster or slower. Meanwhile, lipophilic drug molecules will be trapped within 
the tortuous lipid bilayer of the cubosomes and the release is affected by the partitioning 
between the lipid bilayers and the aqueous site 286. The release rate and properties are 
affected by various factors such as the type of lipids that make up the cubosomes, the 
type of drugs, pH, temperature changes, size of aqueous channels and the addition of 
additives 292-294. A number of drugs were encapsulated in the cubosomes and shown to 
have sustained release properties in vitro, and were reviewed by Drummond, C 
previously 258. Given the contradiction in the literature, 290 more robust methods need to 
be developed to evaluate the release of drugs from these complex lipid structures.  
 
1.5 Characterisation of lyotropic liquid crystalline dispersions.  
There are a number of different techniques which can be used to characterise the 
physicochemical properties of lyotropic liquid crystalline dispersions. These techniques 
are discussed in detail below as they will be used in this thesis for formulation of BBB-
targeted cubosomes.     
 
1.5.1.1 Dynamic light scattering  
Dynamic light scattering has been frequently used in studying colloidal systems. 
It is a simple and convenient method to study the size, heterogeneity and stability of 
different types of colloidal dispersions. In this technique, a small solution containing 
colloidal particles (cubosomes) is placed in the path of a focused laser. The random 
Brownian motion in the scattered laser causes the intensity to fluctuate (at the detector) 
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which generates the diffusion coefficients or particle size. The measurement relies on 
partice concentration, size of particle core and type of ions in the dispersions 295.  
 
1.5.1.2 Small angle X-ray scattering  
Scattering techniques provide information on shape, size and nanostructure of 
bulk and dispersed liquid crystalline systems. The common radiation sources used in 
scattering are light, X-ray and neutron. In small angle X-ray diffraction (SAXS), a 
radiation of wavelength λ (usually ~1 Å) is passed through the sample. This is either 
absorbed or scattered and an X-ray detector measures the intensity of scattering as a 
function of the scattering angle relative to the incident beam. The scattered intensity from 
the sample is normalised to non-sample-related scattering (background). The intensity of 
the scattering (q) is defined as: 
 





Where λ is the wavelength of radiation, and 2𝜃 is the scattering angle. The 
intensity versus scattering angle is plotted (q vs. 2θ) and Bragg peaks are identified. 
Bragg peaks are specific for a given liquid crystalline phase (Table 1.3). However, more 
than one type of Bragg peaks pattern can occur, and these indicate the presence of a 
multiple phase system. At least three peaks are needed to differentiate the symmetry 





Table 1.3 Lyotropic liquid crystalline mesophases; the ratio of spacing between Bragg 
reflections 235 
Mesophase Descriptor Peak ratio 
Lamellar Lα, Lβ 1 : 2 :    1 : 2 : 3 : 4 … etc. 
Bicontinuous cubic P (Im3m) 
D (Pn3m) 
G (Ia3d) 
√2 : √4 : √6 : √8 : √10… etc. 
√2 : √3 : √4 : √6 : √8… etc. 
√6 : √8 : √14 : √16 : √18 : √20…etc. 
Hexagonal HI, HII √3 : √4 : √7 : √12…etc. 
P: Primitive, D: Diamond, G: Gyroid 
 
1.5.1.3 Electron microscopy 
Electron microscopy (EM) allows direct visualisation of both bulk and dispersed 
mesophases. Scanning (SEM) and transmission (TEM) techniques are most commonly 
used depending on the information required.  
SEM generates a low-resolution image (10 to 100 nm) but does allow mapping 
of surface morphological features and characterisation. Cryogenic field emission 
scanning electron microscopy (cryo-FESEM) has been shown to have better resolution 
as compared to standard SEM and therefore it is possible to characterise microstructure. 
It has been successfully used to visualise the structure of dispersed cubosomes and 
hexosomes particles 296-298. In cryo-FESEM, samples are snap frozen at very low 
temperatures in liquid nitrogen or propane and then viewed under the microscope. The 
main limitation of cryo-FESEM is ice crystal formation during sample preparation 299 
which can distort the original structure of the sample. To avoid the ice crystal formation, 
high pressure freezing technique and metal cryo coating can be applied. However, these 
techniques can affect the physical condition of the samples and disrupt the structure of 
particles 300. 
TEM is not commonly used to observe cubosomes structure, because of the need 
to chemically fix the liquid sample. If the sample is subjected to harsh conditions during 
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fixation, it may change the structure of the original particles. An alternative to this 
problem is to do physical fixation on the sample by utilising cryo-TEM technique. The 
sample is subjected to fast cooling and increase in vapour-pressure up to cryogenic 
temperature, which leads to a vitrified and not a typical frozen sample. The vitrification 
process leads to formation of a high viscosity, low-vapour-pressure sample 299. This 
technology preserves the size, shape and the nature state of the sample at studied 
concentration and temperature 262. The image of the original nanostructure is preserved 
and captured. However, the sample viscosity is a limitation, as very viscous samples are 
not suitable for cryo-TEM preparation. The sample might not be able to freeze properly 
to form a thin layer of vitrified sample 299.  
 
1.5.1.4 Cryogenic-electron tomography 
Cryogenic electron tomography (cryo-ET) is another method used to image 
particles in its native state. The samples are processed in a similar manner to cryo-TEM 
samples as described in Section 1.5.3. The vitrified sample (on the grid) undergo minimal 
chemical and physical changes and the cryogenic processing allows the sample 
preservation in the native state. During TEM imaging, under cryogenic conditions, the 
sample is tilted at different angles and the images were collected. To avoid radiation 
damage due to continuous imaging, a low dose of electron is used (around 50 e-1 Å-2) and 
the contrast is increased by defocusing the sample 301. By applying sub-tomogram 
averaging to all the tilt series, the information from each image can be combined and 
averaged to form the 3D structure. Since a large number of images are captured, any 
specific image at certain tilt angle with poor resolution can be deleted and excluded, 
without losing any detail information of the structure. Images with high resolution and 
good signal-to-noise ratio are usually collected at low tilt. Whilst at high tilts, the images 
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have lower resolution with the risk of structural damage to the sample due to the beam 
exposure 302. 
The advantage of using cryo-ET is that the preservation of the sample is in its 
original state. This is useful for biological samples such as lipid-based nanoparticles that 
can be easily damaged by chemical fixation. This technique can offer a better 
preservation method to allow detailed observation of cubosome particles in the 
dispersion, without any changes in the structure. The 3D reconstruction from the tilt 
series will allow the detailed internal and surface structure to be observed instead of 2D 
form from normal cryo-TEM imaging 303. It offers a detailed examination of biological 
particles including virus and bacteria 304. Cryo-ET technique is important in this thesis as 
it can showcase the 3D image of the detailed cubosomes structure and cryo fixation 
provides a better preservation technique as compared to chemical fixation.  
 
1.6 In vitro model of the BBB 
Various studies have been conducted to develop in vitro cell culture models that 
can mimic in vivo properties of the human BBB 305. The use of immortalised cells allows 
a larger number of studies to be conducted in a large scale, including nanoparticle uptake 
studies. Any in vitro BBB model should be easy to grow with preservation of transporters 
and receptors. Cerebral microvessel endothelial cells (CMEC) from bovine origin were 
isolated in the 1980s to provide a BBB in vitro model 306. Even though these primary 
brain endothelial cells expressed functional receptors, tight junctions and other key BBB 
markers, the challenges in getting fresh brain tissues prohibited larger studies.  
Recently, an immortalised human BBB cell line, the hCMEC/D3 was developed 
by a group of scientists in France. Since the development of hCMEC/D3 cells in 2005, 
more than 100 studies have been published in various areas of neurological research, 
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using this cell line 305, 307. The cell line was developed from human temporal lobe 
microvessels isolated from excised tissue from the brain of an epileptic patient. The cells 
were enriched and immortalised by lentiviral vector transduction using SV40 large T 
antigen and the catalytic subunit of human telomerase (hTERT). Specific colony was 
selected by limited dilution cloning and characterised, which then named as hCMEC/D3 
cells. These endothelial cells showed similar morphology to primary brain endothelial 
cells such as elongated cells and contact inhibition when grown on collagen. This 
phenotype was maintained and the endothelial markers were retained up until passage 33 
305, 307, 308. 
To confirm the suitability of hCMEC/D3 cell as an in vitro BBB model, the 
expression of membrane receptors and transporters were tested using various techniques 
including quantitative proteomic analysis, immunochemical analysis and RT-PCR 
analysis 305. MRP, BCRP and P-gp were found on hCMEC/D3 after an assessment by 
quantitative proteomic analysis 309-311. The level of expression was found to be similar to 
isolated human brain microvessels 309. P-gp was shown to be expressed up to passage 38 
and localised at the apical side of hCMEC/D3 cells. Even though P-gp expression was 
found to be lower than primary human brain capillary endothelial cell (HBCE), the 
expression was comparable and inhibited by P-gp inhibitors such as taquidar and 
vinblastine 311, 312. High levels of transferrin and Glut-1 receptors were expressed by 
hCMEC/D3 with similar density to human brain microvessels 309. Other influx 
transporters present at hCMEC/D3 cells are LDL-receptors, amino acid transporters, 
organic ion transporters (OATP) and all members of solute carrier family (SLC) 
transporters 305. In order to use hCMEC/D3 cell line to study cubosomes uptake via 
receptor mediated endocytosis, the presence of these transporters especially LDL-
receptors are important.  
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hCMEC/D3 cell line can offer various advantages in conducting high throughput 
in vitro studies. The cost involved is lower than primary cell culture, and it also retains 
phenotype, receptors and transporters similar to primary human brain endothelial cell, 
which makes it a suitable BBB in vitro model to be conducted in this thesis for cubosomes 
toxicity and uptake studies.  
The introduction section has outlined the challenges and opportunities in 
delivering drug to the brain to treat neurological diseases. Given the possibilities for 
encapsulation and release of drugs of varying properties, together with the ability to 
modify the surface chemistry using BBB targeting moieties on the surface, cubosomes 
emerge as a suitable platform as a drug carrier system to improve drug delivery into the 
brain. 
 
1.7 Thesis hypotheses 
A number of hypotheses were developed and tested in this thesis in order to 
examine the potential of cubosomes as drug carriers to the brain. These were: 
1. That cubosomes can be surface decorated with different stabilisers to target 
receptor-mediated transcytosis at BBB.  
2. That cubosomes co-formulated with cationic lipids can target the adsorptive 
endocytosis pathway at BBB. 
3. That cubosomes surface decorated with different stabilisers and cationic 




In order to investigate the above hypotheses, the aims of this thesis are: 
i) To formulate and characterise cubosomes surface decorated with non-ionic 
stabilisers and charged lipids to understand: 
a) the effect of using non-ionic stabilisers at different concentration on the 
stability of cubosomes and the internal structure. 
b) the influence of lipid chain length (from charged lipids) on the formation 
of cubosomes. 
c) the monolayer interactions of charged lipids with the cubic phase forming 
lipid phytantriol. 
 
ii) To investigate the interaction of surface decorated cubosomes in vitro with a 
human brain endothelial cell line. 
a) by evaluating the toxicity of cubosomes stabilised from non-ionic 
stabilisers and the addition of charged lipids 
b) by determining the cell uptake of surface decorated cubosomes 
 
iii) To investigate the uptake and toxicity of surface decorated cubosomes into the 
brain in vivo using a zebrafish model by: 
a) evaluating the toxicity effect of surface decorated cubosomes in zebrafish 
brain 

















2  General materials and methods 
2.1 Materials 
Chloroform (HPLC grade), dichloromethane and 1,2-propandiol (propylene 
glycol) were purchased from Merck (Darmstadt, Germany). Phytantriol (3,7,11,15-
tetramethyl-1,2,3-hexadecanetriol, ≥95% purity) was purchased from A & E Connock 
(Hampshire, England).  Lutrol® or Poloxamer 407 (Pluronic F127) was obtained from 
BASF (Ludwigshafen, Germany). Kolliphor® (Poloxamer 188), 
cetyltrimethylammonium bromide (CTAB) and Tween 80 (Polysorbate 80) were 
purchased from Sigma-Aldrich (New Zealand). 1,2-Dioleoyl-3-trimethylammonium-
propane (DOTAP), 1,2-dimyristoyl-sn-glycero-3-phospho 1’-rac glycerol (DMPG) and 
1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) were purchased from 
Avanti Polar Lipids. Inc (Alabama, USA). Octanethiol functionalized 3 nm gold 
nanoparticle was from Nanoprobes (New York, USA). 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (LR) and 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD) were 
purchased from Avanti Polar Lipids Inc (Alabama, USA). All chemicals were used as 
received. Milli-Q water (ion exchanged, distilled and purified by Millipore, Bedford, 





2.2.1 Preparation and characterisation of cubosome dispersions  
2.2.1.1 Preparation of cubosome dispersions 
Phytantriol (20 mg/mL), stabilisers (5 to 20% w/w of Pluronic F127, Tween 80 
or Poloxamer 188 to phytantriol), and propylene glycol (co-solvent, 54 mg/mL) and 
where appropriate, CTAB, DOTAP, DOTMA or DMPG (1.4 to 5.3 mol % to phytantriol) 
were weighed into a glass vial and dissolved completely in sufficient chloroform 
(typically 5 mL). For preparing tagged cubosomes, NBD (37.3 µM), LR (205.6 mM) or 
octanethiol functionalized 3 nm gold nanoparticle (0.01 mM) was added to the mixture 
at this stage. Chloroform was subsequently evaporated under vacuum at 45 °C leaving 
behind a lipid mixture (liquid precursor). Water (1 mL) was added to the liquid precursor 
and the mixture was vortex mixed for 10 min to form cubosome dispersion 313. 
 
2.2.1.2  Size, polydispersity and ζ -potential 
The particles size distribution and ζ-potential were determined using dynamic 
light scattering (DLS) (Malvern Zetasizer 3000, Malvern, UK). Measurements were 
performed at 25 °C and the results presented are the mean of three successive 
measurements of 100 s of at least three independent experiments, using a refractive index 
of 1.467 for phytantriol. Samples were diluted with water to adjust the signal level. The 
average particle size (Z-average), polydispersity index (PDI) and ζ-potential (based on 




2.2.1.3 Small angle X-ray scattering (SAXS) 
Measurements were conducted on the SAXS/WAXS beamline at the Australian 
Synchrotron (Clayton, VIC) to identify phase structures using previously described 
methods315. Samples were added to 96 well microplate and mounted vertically in the 
beam path. The 2D SAXS patterns were collected using a Pilatus 1 M (170 mm × 170 
mm) detector which was located 960 mm from the sample position, with 2 s exposure 
and X-ray wavelength of 1.0322 Å. The diffraction patterns were integrated using the 
Scatterbrain software operating on the beam line and plotted as intensity versus scattering 
vectors (q) to identify peak ratios as described in order to determine the liquid crystalline 
structure 265. The relative positions of the Bragg peaks were used to define the cubic-
phase space groups and mean lattice parameter, as discussed in 316. 
 
2.2.1.4 Cryo-transmission electron microscopy (cryo-TEM) 
Cubosome dispersions (3 µL) were added to 300 mesh R2/2 Quantifoil grids 
(Quantifoil GmbH, Germany) that were glow-discharged for 10 s. Excess dispersion was 
removed by blotting with filter paper (Whatman Nr. 1). Grids were rapidly plunged into 
liquid ethane and kept near its freezing temperature (-120 °C) in a Reichert KF80 freezing 
device (C. Reichert Optische Werke, Austria). The samples were stored in liquid nitrogen 
before loading into a Gatan 914 cryo holder (Gatan Inc, California, U.S.A) and viewed 
in a JEOL 2200FS transmission electron microscope (JEOL Ltd, Japan) fitted with a 




2.2.1.5 Cryo-electron tomography (Cryo-ET) 
Selected samples from Section 2.2.1.4 were subjected for Cryo-ET. Automated 
tilt series images from the grid were acquired using SerialEM software (University of 
Colorado, Boulder, U.S.A). Tilt angle increments of 1.5 or 2 degrees with the tilt range 
of -60 to +60 degrees was used 317. Tomograms were reconstructed and analysed using 
IMOD software (University of Colorado, Boulder, U.S.A) 318. Nonlinear anisotropic 
diffusion was carried out using ETOMO to de-noise the merged tomogram and 3D 
images were visualised using Chimera 1.10.2 (University of California) 319. 
 
2.2.2 Langmuir monolayer studies  
To study the effect of charged lipids (CTAB, DOTAP, DOTMA and DMPG) on 
phytantriol lipid monolayer, the interfacial behaviour was investigated at ambient 
temperature (25 ± 1 °C) using the Langmuir-Blodgett trough (NIMA, Coventry, UK). A 
surface area of 100 cm2 and a volume of 50 mL were used. Prior to conducting each 
experiment, the Teflon trough and barriers were cleaned with dichloromethane and Milli-
Q water. After the subphase was added (Milli-Q water), a Wilhelmy paper plate 
(Whatman’s No.1 Chromatography paper, Australia) was connected to the pressure 
sensor to measure the surface pressure (π). 
Single and mixed components of phytantriol and charged lipid were dissolved in 
chloroform. The concentration of phytantriol was constant (0.5 mg/mL) while the 
concentration of added component varied. A 20 uL aliquot of the single or mixed 
component mixture was spread on the subphase using a Hamilton syringe and left for 10 
min for the chloroform to evaporate. Compression was applied at a speed of 5 cm2/min 
and the π-A isotherms were recorded by the instrument software (Nima 516, KSV Nima, 
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Finland). Experiments were conducted at room temperature with three replicates. 
Collapse pressure and limiting area per molecule for each single and mixed component 
mixture was calculated. 
 
2.2.2.1 Analysis of π-A isotherms 
The compression of the monolayer will lead to a stage where the monolayer will 
collapse. This is known as the collapse pressure where a sudden change in the pressure 
occurs, the isotherms deviate from the straight line and a plateau of maximum pressure 
was observed (Figure 2.6) 320. To obtain the experimental limiting molecular area, the 
rising linear part of the isotherm was extrapolated to zero pressure as shown in Figure 
2.6 and to get the ideal limiting molecular area (Ai) was calculated using additivity rule 
as Equation 3 321, 322. 
 
Equation 3            𝑨𝒊 = 𝑿𝒑𝒉𝒚𝒕𝑨𝒑𝒉𝒚𝒕 + 𝑿𝒄𝒉𝒂𝒓𝒈𝒆𝒅 𝒍𝒊𝒑𝒊𝒅𝑨𝒄𝒉𝒂𝒓𝒈𝒆𝒅 𝒍𝒊𝒑𝒊𝒅 
 
Where Xphyt is the mole fraction of phytantriol, Xcharged lipid  is the mole fraction of 
charged lipid while Aphyt and Acharged lipid  are the experimental limiting molecular area for 
pure phytantriol and pure charged lipid monolayers respectively. The deviation between 
the calculated ideal limiting molecular areas to the experimental values were compared 
to evaluate the miscibility and interaction between the phytantriol and charged lipids in 






Figure 2.1 Schematic diagram of π-A isotherm showing the extrapolation for the collapse 
pressure and limiting molecular area. 
 
2.2.3 Cell maintenance 
Immortalised human brain capillary endothelial cells (hCMEC/D3) were 
purchased from Cedarlane, Canada and passage 23 to 34 were used in all experiments. 
Cells were grown in flask pre-coated collagen type 1 (Falcon™) and grown in EBM-2 
medium (Lonza, Basel, Switzerland) supplemented with 5% fetal bovine serum (Life 
Technologies, NZ), 1% penicillin-streptomycin (Life Technologies, NZ), 1.4 µM 
hydrocortisone (Sigma-Aldrich), 5 µg/mL ascorbic acid (Sigma-Aldrich), 0.001% 
chemically defined lipid concentrate (Life Technologies, NZ), 10 mM HEPES (Life 
Technologies, NZ) and 1 ng/mL human Basic Fibroblast Growth Factor (Sigma-Aldrich). 
Cells were grown at 37 °C with 5% CO2 and saturated humidity. Cell culture medium 
was replaced every 2 to 3 days and studies were conducted when the cells reached 70 to 
80% confluency, 3 to 4 days after seeding.    
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2.2.3.1  Cell viability and uptake studies 
For functional assays, cells were seeded on type 1 collagen pre-coated 24 well 
plates (FalconTM) with the density of 50,000 cells/well. Cells were washed three times 
with Dubelco’s phosphate buffered saline (Invitrogen Corporation) and incubated with 
fluorescently-labelled cubosomes at various concentrations for 2 h at 37 °C. After that, 
the media was removed, and cells were washed with FACS buffer to remove any 
remaining formulation (see Appendix 1 for FACS buffer recipe). Tryple (Gibco, 
Denmark) was added to each well and left for 10 min at 37 °C to allow the cells to detach.  
The cells were re-suspended with FACS buffer and centrifuged for 10 min at 1000 rpm. 
Supernatants were discarded and the cells were re-suspended in 100 µL of FACS buffer 
containing 1 µg/mL propidium iodide (PI) for staining the dead cells. Cells were then 
analysed using flow cytometry to determine the cell viability for toxicity studies and 
cubosome uptake. 
 
2.2.3.2 Evaluating cell uptake for cubosome surface coated with cationic lipids  
To further study the uptake of cubosome modified with charged lipid was through 
adsorptive endocytosis, the uptake study was repeated. Adsorptive endocytosis is an 
active process and requires energy. To test the hypothesis that the uptake of cubosome 
surface modified with cationic lipids is through adsorptive endocytosis, the cells were 
incubated with cubosome formulation for 2 h at 37 °C and 4 °C. After 2 h of incubation, 
the uptake at both temperature was analysed using flow cytometer. 
To further elucidate that there was an electrostatic interaction between positively 
charged cationic cubosome, in a separate study, the cells were pre-incubated with poly-
L-lysine (931 nM) for 1 h. Then poly-L-lysine was removed, and the cells were washed 
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with PBS to remove any remaining poly-L-lysine. The cells were then incubated with 
cubosome formulation at 37 °C for 2 h. The uptake was analysed. 
 
2.2.3.3 Analysis of cubosome toxicity and uptake by flow cytometry 
Cell viability and uptake of surface modified cubosomes after 2 h incubation was 
measured using flow cytometer. The measurement was carried out using FACSCantoTM 
II flow cytometer (BD Biosciences, California, USA) and data acquired using 
CellQuestPro software (BD Biosciences). Data analysis was conducted using FlowJo® 
7.6 software (Tree Star, Oregon, USA). Typical gating strategy used in data analysis is 
shown in Figure 2.2A-C. Cell viability was defined as the percentage of PI-negative cells 
out of single cells as PI was used to stain the dead cells. Uptake by the cells was analysed 
by comparing NBD positive population of live cells treated by cubosome to that of 
control where the cells were incubated with NBD suspension (without cubosome) at the 
same concentration of NBD in cubosome formulation. Auto fluorescence of the cells was 
taken into account by deducting the positive signal from the untreated cells. Figure 2.2D 
shows the signal from auto fluorescence of untreated cells (negative population) while 





Figure 2.2 Gating strategy for FACS analysis of live cells and NBD positive cells for 
viability and uptake studies. The cells debris was excluded (A) and doublets removed 
(B). The gating at (C) is to set the population of live cells (PI-negative) with NBD positive 
cells, which is located at Q3. The histograms were used to illustrate the untreated cells 
population (red) under FITC channel (D) and the shift in the signal for NBD positive 
cells (E) (in blue). 
 
 
2.2.3.4 Observation of cubosome uptake under fluorescence microscopy 
To observe the cellular uptake of cubosome (NBD-labelled) under fluorescence 
microscope, after 2 hr of incubation with cubosome formulation, the cells were washed 
with PBS to remove any remaining cubosome in the incubation media. 0.5 mL PBS was 
added into each well as a buffer and Hoechst 3342 (Thermo Fisher Scientific, US) with 
concentration of 8.1 µM was prepared with PBS and added into each well. The cells were 
incubated for 10 min. Then each well was washed three times with PBS to remove the 
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staining and then incubated with CellMask™ Deep Red Plasma membrane stain (Thermo 
Fisher Scientific, USA) at 1:1000 dilution for 10 min to stain the plasma membrane.  The 
cells were then washed with PBS to remove the staining. Media was added into each well 
and cubosomes uptake was observed under fluorescence microscope (Nikon Corp., 
Japan) fitted with TxRed, DAPI and FITC filter. The images were analysed using ND2 
software (Nikon Corp., Japan). 
 
2.2.4 Statistical analysis 
The results are expressed as mean ± standard deviation (SD). One-way analysis 
of variance (ANOVA) with Tukey’s multiple comparison’s test using Prism 6 (GraphPad 
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3 Formulation and characterisation of cubosomes that target receptor-mediated 
endocytosis at BBB. 
3.1 Introduction 
Nanoparticles decorated with ligands to target BBB have been proposed as a 
potential method to carry CNS drug molecules into the brain. As discussed in Chapter 
1, this thesis will focus on the utilisation of cubosome as a drug carrier to target specific 
pathways at the BBB. This will be achieved by formulating cubosomes which contain 
molecules that have previously been shown to target the BBB to improve delivery of 
drugs to the brain. In particular, this chapter focus on targeting cubosomes towards the 
BBB via receptor-mediated endocytosis. Various receptors present on the endothelial 
surface to shuttle different endogenous molecules into the brain. The shuttling of 
molecules through this pathway was discussed in Section 1.2.3.4 previously. Low 
density lipoprotein receptor is the receptor of interest in this chapter where cubosomes 
were formulated specifically to target this receptor at the BBB.  
 
3.1.1 Low density lipoprotein receptors as potential BBB target 
Low density lipoprotein (LDL) receptors allow lipoprotein transport from the 
blood circulation into the cells throughout the body. Lipoproteins are essential carriers of 
lipid molecules such as cholesterol from the blood circulation into the cells in the form 
of fatty acyl esters 324. The cholesteryl esters are hydrolysed into sterols which are 
important in the construction of cellular membranes, production of steroid hormone and 
synthesis of bile acid 325, 326. Lipoproteins require binding with apolipoproteins (Apo) in 
plasma, which mediate its interaction with LDL-receptors. ApoA to E are present in the 
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blood stream bind to lipoproteins and facilitate their interaction with the LDL-receptor 
327, 328.  
To improve the drug delivery to the brain, nanoparticles have been designed to 
mimic the uptake of lipoproteins across the BBB 329, 330. In particular, decorating the 
surface of nanoparticles with ApoE has been shown to facilitate their binding to LDL-
receptors and their subsequent transport across the BBB 331-333. For example, rosmarinic 
acid, an antioxidant and an anti-inflammatory agent currently being investigated for the 
treatment of Alzheimer’s disease, has limited permeability across the BBB. To overcome 
poor permeability issues, in one study, rosmarinic acid was conjugated to 
polyacrylamide-chitosan-poly(lactide-co-glycolide) (PLGA) nanoparticles which were 
decorated with ApoE 334. Increase uptake of rosmarinic acid in PLGA nanoparticles was 
found to halt the degenerative progress on damaged Aβ-neurons in Alzheimer’s model 
in rats, as compared to PLGA nanoparticles without ApoE decoration. This result shows 
that the addition of ApoE on the PLGA nanoparticles allow the interaction with LDL-
receptors at the BBB to promote the uptake into the brain 334.   
ApoE conjugated nanoparticles have been used to facilitate delivery of lipophilic 
drugs that have limited BBB permeability. For example, resveratrol a polyphenol 
compound that has been identified to have antioxidant, anti-inflammatory, anti-bacterial 
and neuroprotective effects. It has been shown to decrease pro-inflammatory cytokines 
in rodent and primate model, which confer neuroprotective effect for Parkinson’s, 
Huntington’s and Alzheimer’s diseases 335-342. Resveratrol is highly lipophilic and has 
poor aqueous solubility, undergoes rapid metabolism, chemical instability, low 
bioavailability and limited permeability across the BBB 343, 344. To overcome some of 
these challenges, in several studies, resveratrol has been encapsulated in solid lipid 
nanoparticles functionalised with ApoE with the aim that the particles are endocytosed 
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similar to lipoproteins into the endothelium via LDL-receptors 18, 345-347. In one study, a 
1.8-fold increase uptake of resveratrol by human brain endothelial cells, hCMEC/D3 was 
reported when formulated into solid lipid nanoparticles functionalised with ApoE, 
compared to nanoparticles without ApoE 333.  
Nanoparticles can also be targeted towards the LDL-receptors by decorating their 
surface with surfactants. Certain surfactants promote binding with ApoE in the blood 
plasma, which then facilitated the binding of the nanoparticles to the LDL-receptors. 
Various surfactants have been investigated and will be discussed in the next section.  
 
3.1.2 Surface coating of nanoparticles with surfactants to target LDL receptors at 
the BBB 
Nanoparticles formulated with polymers such as poly(lactide-co-glycolide 
(PLGA), poly(butyl cyanoacrylate) (PBCA) and poly(isohexyl cyanoacrylate) (PIHCA) 
surface decorated with Poloxamer 188, Polysorbate or Tween 20, 40, 60 and 80 have 
been shown to cross the BBB 348. These will be discussed in some detail in the subsequent 
sections. 
In one study, PBCA nanoparticles decorated with Tween 80 were used to deliver 
the anti-nociceptive drug dalargin, which has poor permeability across the BBB, into the 
mice. Successful delivery of the dalargin was confirmed with a functional anti-
nociceptive test in mice due to the effect of dalargin in the brain 349. However, the addition 
of surfactants such as Cremophor, polyxamine 908, Brij35, Poloxamers 184, 407 and 
338 did not result in any significant uptake of dalargin uptake into the brain 350. Therefore, 
it was concluded that only certain surfactants are able to bind to ApoE in the plasma to 
target the LDL-receptors. In certain formulations, the surface coating by the surfactants 
will affects the interaction with ApoE in the plasma. Moreover, the formation of protein 
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corona after the intravenous administration of nanoparticles may reduce or deactivate the 





3.1.2.1 Tween 80 coated nanoparticles 
Tween 80 is an amphipathic non-ionic surfactant with fatty acid esters of 
polyoxyethylene sorbiton monooleate (Figure 3.1). The hydrocarbon chain consists of 
an oleate moiety with double bond, which causes a kink in the structure 353. It is 
commonly used in cleaning and pharmaceutical products as a surface stabiliser due to its 
low cost, availability and biodegradability 354.  
 
Figure 3.1 Chemical structure of Tween 80. 
 
Drugs encapsulated in polymeric nanoparticles functionalised with Tween 80 
have been shown to have increased BBB permeability 192. Evidence suggests that after 
intravenous administration, plasma lipoproteins ApoB and ApoE binds with Tween 80 
moieties on the surface of nanoparticles (as discussed in the previous section). These 
protein-bound particles then mimic the endogenous transport of LDL to cross the BBB 
via receptor-mediated transcytosis 355-357. The BBB-targeting effects of nanoparticles 
coated with Tween 80 have been reported with varying degrees of success and are 
summarised in Table 3.1. PBCA nanoparticles with Tween 80 are widely studied to 
target the BBB. Various drugs such as dalargin, kyotorphine and methotrexate have been 




Encapsulation of resveratrol in glyceryl behenate-based solid lipid nanoparticles 
coated with Tween 80 as the surfactant can lead to an increase in concentration of 
resveratrol in the rat brain 27. Even at concentrations as low as 0.1% w/v of Tween 80, 
significant uptake of nanoparticles has been observed in vitro in MDCKII-MDR1 cells 
207. In addition to lipid-based nanoparticle, inorganic super iron oxide nanoparticles 
coated with Tween 80 have also been reported to be able to cross the BBB with the 
assistance of an external magnetic field 358. These studies show that Tween 80 plays an 









Dalargin  PBCA Positive analgesic effect in 
mice and observation of NP 
in Purkinje cells under EM 
206 
Dalargin (oral) PBCA Significant Dalargin-
induced analgesia in tail 
flick test 
359 
Kyotorphin PBCA Central analgesia by hot 
plate test in mice  
360 
Methotrexate PBCA Significant increase in drug 
concentration in brain 




antagonist MRZ 2/576 
PBCA Prolonged duration of 
anticonvulsive activity  
362 
Nerve growth factor PBCA Improved recognition and 






PBCA Increased permeability 
across HBMECs 
332 
Temozolomide PBCA Significant concentration of 
temozolomide found in the 
brain 
364 
Tacrine PBCA Significant increase in 
tacrine concentration in the 
brain 
215 
PBCA: Poly (butyl cyanoacrylate) NP: nanoparticles EM: electron microscope 




3.1.2.2 Poloxamer 188 coated nanoparticles 
Poloxamer 188 is a triblock copolymer sold under the trade name Pluronic F68® 
365. It is a non-ionic surfactant with poly (ethylene oxide):poly(propylene 
oxide):poly(ethylene oxide) at a weight ratio of 4:2:4 (Figure 3.2) 366. Poloxamer 188 is 
a biodegradable polymer that has been widely used to stabilise polymeric and lipid 
nanoparticles 367, 368. Poloxamer 188 has demonstrated neuroprotective and anti-
inflammatory activities 369, 370. The uptake of Poloxamer 188 coated nanoparticles into 
the brain has been shown to be similar to that for Tween 80 coated nanoparticles. ApoB 
or ApoE are adsorbed on the surface of the nanoparticles which can then bind to LDL-
receptors present on the cell surface at the BBB. The nanoparticles are then endocytosed 
into the cell via receptor-mediated transcytosis 371-373.  
 
Figure 3.2 Chemical structures of Poloxamer 188. 
 
A number of studies on nanoparticles coated with Poloxamer 188 for crossing the 
BBB are summarised in Table 3.2. The nanoparticles were either made from polymers, 
gelatin or nano-emulsions. Drugs such as loperamide, which is an opioid receptor agonist 
and a substrate to Pg-p is unable to cross the BBB but has potential as an anti-nociceptive 
agent. Loperamide was encapsulated in PLGA-PEG-PLGA nanoparticles and coated 
with Poloxamer 188 and Tween 80. A significant increase in anti-nociceptive effects 
(<20%) in mice was observed when loperamide was administered in Poloxamer 188 and 
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Tween 80 coated nanoparticles compared to uncoated nanoparticles 374. In another study, 
the oral administration of zolmitriptan, a selective serotonin receptor agonist 
encapsulated in PLGA nanoparticles coated with Poloxamer 188 had a 14-fold increase 





Table 3.2 BBB uptake studies with different drugs encapsulated in Poloxamer 188-coated 
nanoparticles. 
Drug Core polymer Results Reference 
Campthotecin SLN High concentration of 
campthotecin in the 
brain (brain AUC ratio) 
376 
Doxorubicin PBCA Increase in survival 
rate of rats with brain 
tumour 
377 
Loperamide PLGA Noticeable nociceptive 
effect 
378 
Doxorubicin PLGA Long term cancer 
remission in 40% of 
animals treated 
378 
Doxorubicin PLGA Increase uptake in U87 





PLGA Improved cognitive 
and neurological 
deficits in mice with 
traumatic brain injury 
350 
Cilengitide Gelatin based 
nanoparticle 
Improved median 
survival period for rats 
with glioblastoma 
379 
Risperidone Nanoemulsion Increase in brain-to-
plasma concentration 
ratios in rats 
380 
SLN: solid lipid nanoparticle AUC: area under curve PBCA: Poly (butylcyanoacrylate) 
PLGA: poly (lactide-co-glycolide) 
 
A significant number of studies have investigated the ability of nanoparticles 
prepared from synthetic polymers such as PBCA and coated with Tween 80 and 
Poloxamer 188 to improve delivery of drug molecules into the brain with varying degree 
of success. Despite the success, to date their use to transport CNS drugs have not been 
commercialised yet.  
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3.1.2.3 Pluronic F127 
The non-ionic triblock poloxamer, Pluronic F127 is commonly used to stabilise 
cubosome dispersions 263. It has an average molecular weight of 12 600 Da with 67 units 
of polyethylene oxide (PEO) and 100 units of polypropylene oxide (PPO) (Figure 3.3). 
Pluronic F127 is able to stabilise cubosomes by causing steric hindrance between 
individual cubosomes to avoid aggregation 381, 382. The hydrophobic parts of PEO 
moieties are thought to anchor to the surface of the lipid bilayer and hence influence 
membrane stability. However, a previous study has shown that a high amount of Pluronic 
F127 (3.96 mM) is required to cover the surface of cubosomes to produce a stable 
dispersion 383.  
In an ex-vivo model of U87 (human glioblastoma) cells, Pluronic F127 co-
formulated with angiopep iron oxide nanoparticles was found to significantly increase 
the delivery of rhodamine 123 (model drug) as observed under a fluorescence microscope 
384. In another study, positive uptake of rhodamine 123 by rat brain endothelial cells was 
again observed when it was formulated into Pluronic F127 micelles coated on TGPS- D-
α-tocopheryl polyethylene glycol succinate 385. However, both studies were conducted 
using cell culture model and more robust in vivo studies need to be conducted to evaluate 
the potential of nanoparticles co-formulated with Pluronic F127 in targeting the brain.  
Pluronic block copolymers have also been shown to inhibit P-gp and sensitise 
multidrug resistant (MDR) tumours efflux transporters, 386. This can increase the uptake 
of drug into the brain, as a result of the decrease in the efflux of the drug molecules 387, 
388. The mechanism of Pluronic F127 mediated inhibition has been proposed to be 
indirectly caused by ATP depletion, which is needed for Pg-p to function 385, 386, 389. This 
suggests that the uptake of Pluronic F127 coated nanoparticles does not go through the 
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LDL-receptors at the BBB. In this work, Pluronic F127 serves only as the control, and 
not specifically to target the LDL receptors.     
 
 
Figure 3.3 Chemical structures of Pluronic F127 
 
3.1.3 Selecting stabilisers for cubosomes that provide a dual role of colloidal 
stability and BBB targeting 
Cubosome particles are colloidally unstable and require a stabiliser to avoid 
particle aggregation 383. In this thesis, the stabilisers Tween 80 and Poloxamer 188 have 
been selected for investigation not only for their ability to provide colloidal stability to 
cubosome particles, but also for their potential to facilitate the binding of cubosomes to 
LDL-receptors at the BBB, as discussed in the preceding section. Pluronic F127, was 
selected as the control as it is the most commonly used stabiliser for cubosomes and 
regarded as the “gold standard” stabiliser 390. In this thesis, Pluronic F127 stabilised 
cubosomes are not expected to be able to cross the BBB. On the other hand, it is 
hypothesised that coating cubosomes with Poloxamer 188 and Tween 80 will lead to an 
increase in the uptake of cubosomes into the brain, as has been previously shown with 




3.2 Hypothesis and aims 
The overall aim of this chapter was to develop stable cubosome formulations with 
the stabilisers Tween 80 and Poloxamer 188 to target receptor-mediated endocytosis 
pathway at the BBB. The following hypotheses were tested: 
 
Hypothesis 1: That cubosomes could be stabilised using Tween 80 and Poloxamer 188. 
Hypothesis 2: That human brain endothelial cells were viable upon exposure to 
cubosomes. 
Hypothesis 3: That cubosomes stabilised with Tween 80 and Poloxamer 188 will lead to 
its uptake by human brain endothelial cells through LDL-receptor binding via receptor-
mediated endocytosis. 
 
In order to investigate the above hypotheses, the following specific aims were 
conducted: 
1) To prepare and characterise the physical properties of cubosomes stabilised with 
Pluronic F127, Tween 80 and Poloxamer 188. 
2) To investigate the toxicity of the stabilisers and cubosomes coated with different 
stabilisers in human brain endothelial cells, hCMEC/D3.  
3) To study the uptake of cubosomes coated with Tween 80 and Poloxamer 188 in 
vitro using hCMEC/D3 cell. 
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3.3 Results and discussion 
3.3.1 Physical characterisation of phytantriol cubosomes stabilised with 
Poloxamer 188 and Tween 80. 
Phytantriol lipid can self-assemble in excess water to form cubic phase at ambient 
temperature 246. However, the dispersion of cubic phase in excess water (cubosomes) is 
not stable and is prone to aggregation over time. The addition of stabilisers can stabilise 
the dispersion and increase the shelf life 390. The effect of adding poloxamer (Pluronic 
F127 and Poloxamer 188) and Tween 80 to phytantriol cubosomes were evaluated and 
the physical properties of the dispersions were characterised. A sufficient amount of 
stabiliser must coat the cubosomes surface in order to provide adequate steric repulsion 
383, 390. The cubosomes must retain its internal structure in excess water and to avoid 
premature release of the encapsulated drug molecules before crossing the BBB. 
Published bulk phase study of Tween 80 in phytantriol and water show that 
phytantriol/water mixtures can accommodate up to 20% w/w Tween 80 and still retain 
its cubic structure 393. Based on these reports, stabilisers with the concentrations ranging 
from 5% to 20% w/w (with respect to the lipid phytantriol) were investigated in this 
chapter. 
Cubosome dispersions were freshly prepared using the solvent precursor method, 
which involves the formulation of a precursor solution of lipid (phytantriol) and stabiliser 
by the addition of a co-solvent (propylene glycol). The resulting low viscosity precursor 
solution then can be dispersed into homogeneous dispersions with minimal energy input 
(vortex mixing) 313. This method has been shown to be more suitable for proteins and 
heat labile drugs compared to high energy homogenisation 394, thus allowing a wider 
range of drug molecules to be encapsulated inside the cubosomes.  
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3.3.1.1 Effect of poloxamers on the size and nanostructure of phytantriol 
dispersions 
The effect of varying the different concentrations of poloxamers on the size, 
polydispersity and the nanostructure of the dispersions can be observed in Table 3.3. 
Cubosomes stabilised with Pluronic F127 are usually below 200 nm 395. Increasing the 
concentration of Pluronic F127 from 5% to 20% w/w led to a decrease in particle size 
and more homogeneous particles (PDI <0.09). These results suggest that increasing the 
concentration of Pluronic F127 promotes better steric stabilisation in phytantriol 
dispersions. Pluronic F127 is thought to stabilise cubosomes by acting as a detergent in 
which the hydrophobic PPO moieties anchor to the lipid membrane, while the hydrophilic 
moieties protrude out and in contact with the aqueous phase. It is also proposed that the 
PPO and PEO residue can be incorporated into the lipid bilayer within various 
configurations. The possible configuration is determined by the length of PEO-PPO and 
the method of mixing the lipid with the poloxamers 396.  
It is most likely that the PPO moieties are adsorbed and partially inserted onto the 
surface of phytantriol lipid while the long PEO chains protrudes out into the aqueous 
phase providing steric stabilisation (Figure 3.4) 397. Increasing the amount of Pluronic 
F127 used from 5% to 20% w/w leads to higher adsorption of Pluronic F127 on the 
surface, thus reducing the interfacial tension between the phytantriol lipid and water. This 
then leads to the reduction in particle size of the cubosomes and therefore forming more 





Figure 3.4 The adsorption of poloxamer on the surface of phytantriol cubosomes. The 
PPO moiety (y) is adsorbed on the surface of cubosomes while PEO chains (x) protrude 
out to the aqueous phase to exert steric stabilisation. Adapted from 398 with permission.  
 
The suitable size of nanoparticles for intraveneneous administration was 
proposed to be in between 2 to 200 nm. While too small nanoparticles (<5 nm) can be 
subjected to renal excretion and clearance from tissues, larger particles might not be able 
to enter the cells through the desired pathway 399 
    In contrast, larger particles (~215 nm) were observed when 20% w/w of 
Poloxamer 188 was added as compared to 5% w/w (~180 nm), with more heterogeneous 
particles formed (PDI >0.3) at 20% w/w of Poloxamer 188. Poloxamer 188 has a high 
surface activity which aids in higher amount of insertion in the phytantriol lipid bilayer 
within cubosome structure 366, 400. This leads to an increase in cubosome size as the 
concentration of Poloxamer added, increases from 5% w/w to 20% w/w. Poloxamer 188 
has a shorter PEO-PPO-PEO chain compared to Pluronic F127 (Figure 3.2 and 3.3). It 
is likely that the PPO unit in Poloxamer 188 may adsorb differently onto the phytantriol 
bilayer as compared to Pluronic F127. Hence for the same concentration used, Poloxamer 
188 does not occupy the surface of the cubosomes as densely as Pluronic F127 396. 
However, these results contradict observations reported by Swarnakar et al. 401 where the 
authors found that an increase in the concentration of Poloxamer 188 led to smaller 
particle size and a more homogeneous dispersion. The conflicting observations can be 
explained by the method and lipid used in both studies. In this thesis, only a low energy 
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vortex mixer was used. Swarnakar et al. 401 employed high energy ultrasonication for 
particle formation. In addition, it also used GMO lipid instead of phytantriol. It is possible 
that this method of dispersion promotes better adsorption of Poloxamer 188 onto 
phytantriol bilayer, thus a greater reduction in the surface tension which promotes a 
reduction in particle size and increase in particle homogeneity. The choice of lipid also 
affects the final dispersion due to the effect of different lipid packing.  
 
Table 3.3 Effect of stabilisers on size, polydispersity index (PDI), internal structure and 
lattice parameter of cubosome particles. Data presented (size and PDI) are mean ± 
standard deviation of three independent experiments 
Stabilisers 
(% w/w to 
phytantriol) 








     5%  
     15%  
     20% 
 
267.0 ± 3.1 
177.5 ± 5.4 
176.2 ± 1.1 
 
0.22 ± 0.01 
0.18 ± 0.01 
0.09 ± 0.03 
 








     5%  
     15%  
     20% 
 
179.5 ± 0.3 
188.1 ± 1.2 
215.3 ± 4.5 
 
0.15 ± 0.01 
0.29 ± 0.02 









Tween 80  
     5%  
     15%  
     20% 
 
242.9 ± 35.0 
164.9 ± 1.8 
204.7 ± 1.1 
 
0.28 ± 0.00 
0.13 ± 0.01 










To confirm the internal structure of all the dispersions after the addition of 
stabilisers, SAXS was conducted and the data is summarised in Figure 3.5 and Table 
3.3. All dispersions stabilised with Pluronic F127 and Poloxamer 188 have the Pn3m 
cubic structure with lattice parameter between 66 to 69 Å, as indicated by the presence 
of three Bragg peaks with spacing ratios of √2: √3: √4. Even though Pluronic F127 has 
longer PEO and PPO units compared to Poloxamer 188 (76 PPO and 26 PEO), the 
interaction between both poloxamers and phytantriol bilayer produced cubosomes with 
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similar internal structure and lattice parameter. It is known that poloxamers with PEO 
units equal to or greater than 37 usually form Pn3m internal cubic structure in phytantriol 
based systems 398. The partitioning of the PEO chain from poloxamers into the phytantriol 
lipid bilayer increases the membrane surface curvature causing the formation of Pn3m 
structure 402.  
 
Figure 3.5 SAXS diffraction (intensity versus q plots) of cubosomes dispersions 
stabilised by (A) Pluronic F127 (F127), (B) Poloxamer 188 (P188) and (C) Tween 80 
(T80) at 5% to 20% w/w with respect to phytantriol. The plots showing Bragg peaks used 




In contrast, in GMO-based dispersions, increasing the amount of Pluronic F127 
(up to 1% w/w) leads to the change in the internal structure of cubosomes from Pn3m to 
Im3m cubic phase. This is because Pluronic F127 is capable of disrupting the internal 
crystalline structure of GMO cubosomes at higher concentrations 263, 367. From these 
results, it can be postulated that the mechanism of steric stabilisation provided by 
Pluronic F127 is influenced by the cubosome forming lipids, where in phytantriol, the 
concentration of Pluronic F127 studied (5 to 20% w/w) did not change the internal 








3.3.1.2 Effect of Tween 80 on the size and nanostructure of phytantriol dispersions   
Increasing Tween 80 concentration from 5% to 20% w/w in the dispersion leads 
to an increase in particle size. All formulation produced homogeneous dispersions (PDI 
<0.3) (Table 3.3). The internal structure formed was found to be Im3m cubic for all the 
concentrations, as evidenced by the presence of three Bragg peaks with relative positions 
in the ratio of √2: √4: √6 (Figure 3.5). A negative shift in the q value was observed when 
the amount of Tween 80 was increased. This is due to the overall expansion of the cubic 
phase consistent with the increased hydration as the lattice parameter is increased from 
102 to 120 Å. This is consistent with the finding that the increase in Tween 80 content 
leads to a shift in bulk phase behaviour from Pn3m cubic phase to Im3m cubic phase and 
then to lamellar phase 393. However, the decrease in particle size with increase in Tween 
80 concentration up to 15% w/w suggests an interaction between Tween 80 and the 
cubosomes bilayer leading to a reduction in the interfacial tension. 
 Upon addition of Tween 80, the hydrophobic PEG unit on the Tween 80 likely 
interacts with the phytantriol bilayer. The steric effect is likely be caused by the 
hydrophilic part of the Tween 80, which protrudes out of the phytantriol bilayer (Figure 
3.6). Increasing the Tween 80 content will increase the adsorption of Tween 80 molecule 
on the surface of the bilayer which will then increase the thickness of the bilayer and the 
pore size (lattice parameter). It is also observed that the increase in size of cubosomes 
after the addition of Tween 80 from 5% to 20% w/w suggests that Tween 80 interacts 





Figure 3.6 The chemical structure of Tween 80 with an illustration of its adsorption on 
the cubosomes surface. Hydrophobic moiety of Tween 80 (yellow) is inserted into the 
bilayer through hydrophobic interaction while the hydrophilic moiety (blue) exerts the 
steric hindrance on the surface of the cubosomes. (Adapted with permission 398). 
 
The suitable size of nanoparticles for intraveneous administration was proposed 
to be in between 2 to 200 nm. While too small nanoparticles (<5 nm) can be subjected to 
renal excretion and clearance from tissues, larger particles might not be able to enter the 
cells through the desired pathway 399. However, upon intraveneous administration into 
the body, the cubosomes and other nanoparticles are subjected to various protein and 
ionic interaction within the blood content and form protein corona. This might change 
the overall diameter of the particles and affect the interaction with the cells 403, 404. 
Regardless, this thesis did not investigate the effect of particle size on the uptake of 
cubosomes and only focus on formulation development, followed by uptake studies in 
vitro and in vivo. 
 
3.3.1.3 Effect of stabilisers on cubosomes surface charge  
From the studies conducted above, 15% w/w of stabiliser was selected for use in 
subsequent studies. At this concentration, cubosomes stabilised with Pluronic F127 and 
Poloxamer 188 formed Pn3m structure while Im3m structure is formed in Tween 80 
cubosomes. Even though Pluronic F127, Poloxamer 188, Tween 80 and phytantriol are 
non-ionic, these interactions lead to negative ζ-potential as shown in Table 3.4. The 
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differences in the charge between different formulation was shown to be significant 
(p<0.05). This has been previously reported and is likely due to the adsorption of 
hydroxyl ions from water at the phytantriol/water interface 405.   
 
Table 3.4 ζ-potential (mv) of phytantriol cubosomes stabilised with 15% w/w Pluronic 
F127, Poloxamer 188 and Tween 80. Data presented are mean ± standard deviation of at 
least three repeated measurements. 
Cubosomes ζ-potential (mv) 
Pluronic F127 -28.6 ± 0.3 
Poloxamer 188 -29.5 ± 0.4 
Tween 80 -31.8 ± 0.3 
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3.3.1.3 Visualisation of the internal nanostructure of cubosomes  
Direct structural evidence of cubosomes was obtained using cryo-TEM. This is 
an advanced microscopy technique for visualising the internal structure of nanoparticles 
406. Cryo-freezing is a crucial step in sample preparation and involves the formation of 
vitrified ice on the grids which contains the particles. Failure to form a thin layer of 
vitrified ice leads to the inability to observe the cubosomes particles under cryo-TEM. 
Due to the limitations of thick ice formation on grids, cubosomes stabilised with 
Poloxamer 188 could not be frozen for TEM imaging 
Cubosomes stabilised with 15% w/w Pluronic 127 formed heterogeneous sized 
particles (arrowhead) with a size distribution consistent with the results reported in Table 
3.3. In addition to cubosome particles, vesicles were also observed in the samples as 
illustrated in Figure 3.7. Vesicles as shown in Panel A (arrow) are commonly observed 
co-exist with cubosomes stabilised with Pluronic F127 407. Panel B shows particle with 
well-arranged cubic lattice periodicity, indicating successful cubosome formation when 
using 15% w/w Pluronic F127 as a stabiliser. Formation of cubosomes is also supported 





Figure 3.7 Cryo-TEM micrographs of cubosome dispersion stabilised with 15% w/w 
Pluronic F127. Panel A shows the cubosomes formation (arrow heads) with the 
presence of a vesicle (arrow). Panel B shows the surface structure of one single 
cubosome. Scale bar: 100 nm. 
 
Cryo-TEM was also used to investigate the effect of Tween 80 concentration on 
particle nanostructure. Cryo-TEM tomograms shown in Figure 3.8 show the 
nanostructure of particles stabilised 5% to 20% w/w. At 5% w/w Tween 80, a particle 
with a diameter of about 240 nm were observed (Panel A), while at the higher 
concentration of 20% w/w Tween 80, relatively more homogeneous dispersions (with 
about 200 nm particle size) were observed with the appearance of vesicles (Panel C). 
This observation correlates with the results from the particle size and polydispersity 
studies in Section 3.4.1.2 where when 5% and 20% of Tween 80 were used, higher PDI 
values were recorded (>0.2). Interestingly, the addition of 15% w/w Tween 80 resulted 
in uniformly-shaped and homogeneously dispersed cubosomes of about 170 nm in size. 
This shows that increasing the Tween 80 concentration does not necessarily produce 





Figure 3.8 Cryo-electron tomograms showing a field of cubosomes embedded in vitrified 
buffer suspension. Cubosomes were stabilised with (A) 5% w/w, (B) 15% w/w and (C) 
20% w/w Tween 80. The presence of a vesicular coat was seen in panel C and indicated 
by the arrowhead while the vesicles are indicated by the arrows. Panel a-c show the 
enlarged view of representative cubosomes from the tomogram with their Fast Fourier 
Transform (Panel a’-c’). Scale bar: 100 nm. (Adapted from 393 and reproduced with 
permission). 
 
Dispersions stabilised by Tween 80 were further investigated using cryo-electron 
tomography (cryo-ET) for a more in-depth analysis of the internal cubosome structure. 
The tomograms for each dispersion are shown in Figure 3.8. Panels a to c show the 
enlarged images of representative cubosomes from Panels A to C, and Panels a’ to c’ 
show their Fast Fourier Transform (FFT). The FFT pattern of the particles can provide 
information on the crystalline structures. From Figure 3.8, all the patterns reveal cubic 
packing and hexagonal symmetry, depending on the angle of rotation. Increasing the 
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concentration of Tween 80 from 5% w/w to 15% w/w resulted in more homogenous 
particles with the presence of vesicular coat and the absence of vesicles. A stronger FFT 
signal and clear symmetry is evident with 15% w/w Tween 80. At the highest 
concentration studied (20% w/w), the vesicular coats were also observed with the 
addition of a bilayer coating encapsulating the particles (Panel c). The presence of these 
vesicular coats is commonly reported in literature 245, 275. Tween 80 stabilised cubosomes 






3.3.1.4 The 3D reconstruction of Tween 80 cubosomes 
To observe the 3D structure of cubosomes stabilised with 15% w/w Tween 80, a 
single cubosome was randomly selected from the tomogram in Figure 3.9, Panel A 
(dotted box) and sliced in x, y and z planes (Panel B). A 3D surface projection of the 
whole particle is shown in Figure 3.9, Panel C. The internal cubosome nanostructure was 
captured at two different thickness, a ‘thick’ (Panel D) and a ‘thin’ slice (Panel E) through 
the vertical plane. The complex nanoporous structure and the 3D hierarchical 
organization of the lipid bilayer in a cubosome in its native state is evident in these slices. 
The surface of the slice in Panel D and E are magnified in Panels d and e, respectively 
and the surface is capped in light pink for clarity. Upon further magnification, a distinct 
bilayer arrangement with uniform water channels (dotted circle) is evident. The 
periodicity of the water channels shown in Figure 3.9 (Panel e’) was calculated at ~100 
Å. The reconstructed 3D images clearly show a tortuous structure with bicontinuous 
network comprising water channels as previously reported 408.  
The findings from physical characterisation and cryo-TEM imaging show that 
Tween 80 is as effective as Pluronic F127 in stabilising phytantriol cubosomes. The 
absence of vesicles and the formation of homogeneous particles suggest that 15% w/w is 
the optimum concentration of Tween 80 to stabilise phytantriol cubosomes 394. To 
standardise the formulation preparation from all the stabilisers, the concentration of 







Figure 3.9 A full view cryo-electron tomogram of cubosomes dispersions stabilised with 
15% w/w Tween 80 (A). A single cubosome (box) is sliced in x, y and z planes (B) and 
reconstructed as a 3D image. The surface projection (whole particle) of the reconstructed 
cubosome is shown in panel C. The reconstructed particles are further ‘sliced’ 
tangentially at two different thickness, thick (D) and thin (E) to reveal the internal 
structure of the particles at different depths, labelled d and e, respectively. The surface 
of the particles in Panel d and e are capped in light pink. Upon magnification of Panel e’, 
an internal structure comprised of distinct bilayer arrangement (yellow) with uniform 


























3.3.2 Toxicity of phytantriol towards hCMEC/D3 
To develop a suitable drug carrier to deliver drugs to the brain, it is crucial to 
consider its toxic effect on the cells of the BBB, in particular the endothelial cells. This 
is because an observed high drug uptake may not necessarily be due to the successful 
preparation and targeting of the drug carrier, but because of the BBB being compromised 
by local toxicity effects. Therefore, it is important to establish that any observed uptake 
is with a result of the formulation and not due to cellular toxicity from the components 
of the formulation, which in the case of cubosomes can be due to the lipid phytantriol or 
the stabilisers.   
A preliminary study was conducted to evaluate an appropriate concentration 
range of cubosomes for use in the in vitro uptake study. The concentration of cubosomes 
studied was reflected to the concentration of phytantriol in the cubosome formulation, 
and will be referred as phytantriol concentration. The viability of hCMEC/D3 cells after 
two hours of incubation with increasing doses of phytantriol (8 to 300 µM) was 
determined and is presented in Figure 3.10. At low concentrations of phytantriol (8 to 
50 µM), cell viability is over 90%. As the concentration of phytantriol increases from 50 
to 300 µM, cell viability declines from about 80% to 40%. From these toxicity results, 
the concentration of phytantriol used in subsequent in vitro studies was set at < 30 µM to 




Figure 3.10 Viability of hCMEC/D3 cells (total percentage of PI-negative cells) after 
incubation with increasing concentration of Pluronic F127 stabilised cubosomes, by 
using phytantriol concentration (M) in the cubosome formulation as reference. Data 
presented are mean  standard deviation of three independent experiments.   
 
3.3.3 Toxicity of stabilisers towards hCMEC/D3 cells 
With the toxicity effects of phytantriol lipid established, this study now focuses 
on the toxicity of stabilisers used in this thesis. In order to understand the in vitro toxicity 
effect of stabilisers, both stabilisers (0.75 µg to 1.88 µg) as a suspension (without 
phytantriol lipid) and in cubosome dispersions were studied.  
The effect of Pluronic F127, Poloxamer 188 and Tween 80 in a suspension or in 
cubosomes on the viability of hCMEC/D3 cells are presented in Figure 3.11 by 
comparing the cell viability after incubation with stabiliser in suspension. A similar effect 
on cell viability was observed in all groups studied, however the cellular toxicity was 
significantly higher (p<0.05) when the stabilisers were in a suspension form (dotted line, 
closed symbols). In cubosome dispersions, the hydrophobic part of the stabilisers is 
expected to be inserted in the lipid bilayer while the hydrophobic part is protruded out to 
exert steric stabilisation, as discussed previously. This observation suggests that the 
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toxicity of the stabilisers might be masked by their incorporation in the phytantriol lipid 
bilayer within the cubosome structure 409. The overall toxicity study suggests that 
cubosome dispersions stabilised with Pluronic F127, Poloxamer 188 and Tween 80 at 






Figure 3.11 Viability (%) of hCMEC/D3 cells after two hours incubation with cubosomes 
stabilised with Pluronic F127 (open circle), Poloxamer 188 (open square) and Tween 80 
(open triangle). The viability of Pluronic F127 (closed circle), Poloxamer 188 (closed 
square) and Tween 80 (closed triangle) in solution form (dotted line) without cubosomes 
were also tested in the same way. Data presented are mean ± standard deviation of three 





3.3.4 Uptake of cubosomes by hCMEC/D3 cells 
3.3.4.1 Uptake of cubosomes coated with Tween 80 and Poloxamer 188  
For uptake studies, cubosomes were fluorescently labelled with NBD (refer to 
Section 2.2.1.1 for preparation). The cellular uptake of cubosomes by hCMEC/D3 cells 
were analysed by quantifying NBD positive populations in hCMEC/D3 cells incubated 
with cubosomes or equal concentration of NBD only as a suspension (control). The 
analysis was conducted using flow cytometry. The general cell autofluorescence was 
taken into account and deducted from the total fluorescence measurement.  
Figure 3.12 summarises the uptake of cubosomes stabilised by the three different 
stabilisers. The uptake (%) of cubosome formulations by hCMEC/D3 cells were 
significantly lower (p<0.05) compared to the control group across all concentrations. It 
is possible that the processing stepps involved in the analysis of cellular uptake using 
flow cytometry may have led to the loss of positive NBD cells, causing the low level of 
detection observed. Therefore, fluorescence microscopy was used to visualise uptake of 
cubosomes by hCMEC/D3 cells. By using fluorescence microscopy, any evidence of 






Figure 3.12 Uptake of NBD labelled cubosomes stabilised with Pluronic F127, 
Poloxamer 188 or Tween 80 with NBD suspension (control) in hCMEC/D3 cells, after 
two hours of incubation at five different doses. The concentration of NBD in NBD 
suspension (control) corresponds to the concentration of NBD in cubosome dispersion. 
Data presented are mean ± standard deviation of three independent experiments. *P<0.05 
compared to control (NBD suspension). 
 
In the fluorescence microscopy studies, the concentration of phytantriol was kept 
constant at 38 µM, and the cubosomes were labelled with NBD. Figure 3.13 illustrates 
the presence of NBD in the cells, observed as green spots within the cells after two hours 
of incubation. The fluorescence signal from NBD was not strong and only low levels of 
cellular uptake were observed in cells incubated with Pluronic F127, Tween 80 and 
Poloxamer 188 stabilised cubosomes compared to the control (cells incubated in NBD 
suspension). This observation is in agreement with the uptake studies using the flow 
cytometer (Figure 3.12).  
Even though hCMEC/D3 cells have been shown to express LDL-receptors on 
their cell surface 305, 309 however, uptake by the LDL-receptor requires the binding with 
apolipoproteins. In the in vitro environment, the lack of apolipoproteins in the cell media 
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might be a reason for the poor cellular uptake observed in Tween 80 and Poloxamer 188 
cubosomes 305, 355, 410, 411. In order to optimise the interaction between Tween 80 and 
Poloxamer 188 cubosomes with LDL-receptors, the cubosomes can be pre-incubated 
with ApoE or the cell culture media can be conditioned with ApoE solution. 
Another limitation in the uptake might be due to the incubation period of 
cubosomes with hCMEC/D3 cells. Other studies with positive uptake utilising LDL*-
receptors were conducted with incubation for 24 hours or more. However, under static 
cell culture condition, a longer incubation time might force the cell to endocytose the 
particles due to the gravity effect. Cells that divide rapidly are prone to endocytose 
particles that were exposed on their cell membrane for a long period 305, 307, 412-416. In 




Figure 3.13 Micrographs showing uptake of NBD tagged cubosomes stabilised with 15 % w/w Pluronic F127 (F127), Poloxamer 188 (P188) and 
Tween 80 (T80), under fluorescence microscope. Cubosomes concentrations were selected at 38 µM of phytantriol. Cell membranes were stained 
with CellMask® (Texas red filter), nucleus was stained by Hoercht 33258 (DAPI-blue) for live cells and FITC channel was used to observe the 
green fluorescence from NBD. Positive uptake (NBD) was observed from the presence of green fluorescence spots (arrowhead). Scale bar: 10 µm.
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3.4 Conclusion 
Cubosomes stabilised with three different stabilisers with BBB-targeting 
potential were successfully formulated and their uptake by human brain endothelial cells, 
hCMEC/D3 was investigated.  
The cell toxicity of all cubosome formulations was observed to be concentration 
dependent and not affected by the type of stabilisers. However, to the contrary of the 
hypothesis that Tween 80 and Poloxamer 188 stabilised cubosomes will be endocytosed 
into the hCMEC/D3 cells, only a very low cellular uptake (<1%) was observed in the 
formulations studied. This is probably due to lack of ApoE in the media which is 
necessary to facilitate interaction with the LDL-receptor for subsequent endocytosis by 
endothelial cells.  
In the next chapter, cubosomes with a positive surface charge to target the 
adsorptive endocytosis pathway at the BBB will be formulated and their uptake by 








Cationic cubosomes to target adsorptive 
endocytosis at the BBB   
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4 Cationic cubosomes to target adsorptive endocytosis at the BBB. 
4.1 Introduction 
There are several uptake pathways at the BBB that can be utilised to deliver 
nanoparticles to the brain, including adsorptive endocytosis transport which will be 
explored in this chapter using cubosomes. As discussed in Section 1.2.2.5, adsorptive 
endocytosis provides a mechanism for positively charged endogenous and exogenous 
macromolecules and particles to enter endothelial cells through electrostatic interaction. 
In the following sections, the literature regarding the mechanism of adsorptive 
endocytosis for nanoparticle uptake into the brain, the use of charged lipids to surface 
coat nanoparticles to target this pathway and the current information on monolayer 
interactions between phytantriol and charged lipids will be reviewed.  
 
4.1.1 Adsorptive endocytosis transport at the BBB.  
The endothelial cell membrane has a highly negative surface charge that creates 
a repulsive effect on anionic molecules, while attracting cationic molecules, 
predominantly through electrostatic interactions. Designing nanoparticles with positively 
charged surfaces can induce uptake across the negatively charged cell membrane through 
electrostatic interactions 201, 418, 419. 
The negative charge present on endothelial cells, at the luminal, abluminal and 
the basement membrane is illustrated in Figure 4.1. The cell membrane is surrounded by 
a specific glycoprotein called glycocalyx, which is composed of heparan sulfate 
proteoglycans (HSPG) and sialo-glycoconjugates that exerts the negative charge on the 
endothelial cells 420-422. The two major forms of HSPG are syndecan and glypican where 
the luminal side has a larger proportion of glypican. Meanwhile, the abluminal side of 
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the cell membrane is made up of mixed proteoglycans, HSPG and chondroitin sulfate 
proteoglycans (CSPG). The basement membrane consists of HSPG and a different type 
of CPSG, which is the perlecan. The anionic charge presented on both luminal and 
abluminal surfaces is affected by the distribution of glypican, where the charge is more 
negative at the luminal side due to higher amount of glypican 423.  
Overall, the net negative charge decreases from the luminal to abluminal and 
finally basement membrane 423. This effect was observed and confirmed by examining 
the localisation of cationic colloidal gold at the BBB, with more intense staining being 
detected on the luminal surface of the endothelial cells 420.  
 
 
Figure 4.1 The endothelial cell and basement membrane components with different 
distribution of proteoglycans. The overall negative charge of the cell membrane and the 
basement membrane allows the uptake of cationic molecules through the electrostatic 
attraction followed by adsorptive endocytosis. HSPG: heparan sulfate proteoglycans; 





The overall anionic charge on the cell can therefore facilitate the shuttling of 
cationic molecules from the cell surface, all the way through the brain interstitium. For 
example, ebitaride, an adrenocorticotropic hormone analogue developed for treating 
Alzheimer’s disease, has a positive net charge at physiological pH and can cross the 
BBB using this adsorptive endocytosis pathway 424. However, not all positively 
charged molecules enter the brain through the same pathway. Positively charged 
drugs such as amantadine, enter the brain via the cationic amino acid transporter 425. 
Large peptides and proteins like histone and avidin with positively charged surface 
have a greater tendency to cross the BBB through the electrostatic pathway 423, 426. 
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4.1.2 Cationic nanoparticles for drug delivery to the brain.  
Developing nanoparticles with positive surface charge via the addition of 
positively charged molecules or ligands on their surface can improve drug delivery across 
the BBB. For example, in one study, the addition of a hexamethylediamine group on 
albumin and antibodies to modify their charge (positive charge) has led to an increase 
in the uptake to the brain (rats) within 10 minutes of subcutaneous administration, as 
compared to native albumin and antibodies 427.  
The addition of specific cationic ligands known as cell penetrating peptides 
(CPP), which are cationic peptides with a maximum of 30 residues in length, have been 
widely investigated for their capacity to increase uptake of liposomes and the delivery of 
small-molecule drugs, proteins, peptides and oligonucleotides 428-433.  
Docetaxel loaded in nanoparticles conjugated with angiopep-2 and activatable 
cell-penetrating peptide (ACP) has increased drug localisation at glioma site 434. Albumin 
nanoparticles carrying doxorubicin prepared with the addition of cationic albumin and 
mannose modified albumin showed dual targeting to glioblastoma from mannose binding 
to the glucose receptor and the electrostatic interactions from cationic albumin in bEnd.3 
cells, U87MG glioblastoma cells and spheroids 201. This shows that adding specific 
cationic moieties to the nanoparticle surface, can increase their delivery into the brain 
cells. However, since adsorptive endocytosis pathway is non-selective, and all cell 
membranes are negatively charged (not just the BBB), the uptake of positively charged 
nanoparticles will also occur at other non-target tissues.  
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4.1.3 Cationic cubosomes to target the BBB 
The addition of specific molecules to change the overall cubosomes charge to a 
net positive charge in order to target adsorptive endocytosis has been reported 435. This 
chapter will explore the potential of adding cationic lipids into phytantriol cubosome 
formulations to target the adsorptive endocytosis pathway at the BBB. It was 
hypothesised that cationic lipids with long hydrocarbon tails and hydrophilic heads will 
most likely be inserted in between the phytantriol lipid bilayer within the cubosome 
particle and change the ζ-potential and surface charge of the particle. Single and double 
chain cationic lipids were studied to evaluate the effect of chain number and length on 
the formation of cubosomes and on cellular interactions such as uptake and toxicity. 
Three different cationic lipids (single and double chain) with quaternary ammonium head 
groups were selected to prepare cationic cubosomes while an anionic lipid was selected 






Figure 4.2 Chemical structures of single chain cationic lipid, cetyltrimethylammonium 
bromide (CTAB), double chain cationic lipid, 1,2-Dioleoyl-3-trimethylammonium-
propane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) 
and anionic lipid 1,2-di-O-tetradecyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DMPG). 
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4.1.3.1 Cetyltrimethylammonium bromide 
Cetyltrimethylammonium bromide (CTAB) is a single-tailed monocationic 
surfactant with quaternary amine group (Figure 4.2). It has been used as a stabilising 
agent in nanoparticle preparations 436 due to its miscibility with other amphiphilic 
molecules. Moreover, the addition of CTAB with other surfactants has been shown to 
favour the formation of different nanostructures including lamellar, hexagonal and 
bicontinuous cubic phases 437-442. This suggests that CTAB can be incorporated into 
cubosome formulations. However, the addition of cationic lipids into nanoparticle 
formulations can also lead to cellular toxicity 443-445. Therefore, it is important to 
determine an optimum concentration of CTAB that imparts a positive charge to the 
cubosome surface but does not cause cell toxicity.  
 
4.1.3.2 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) 
DOTAP (Figure 4.2) is a double-tailed cationic lipid which has been commonly 
used as a cationic additive in nanoparticle formulation to improve cell uptake and gene 
transfection 446-449. It has double monounsaturated carbon chains and a monocationic 
head group. The presence of ester bond makes DOTAP biodegradable. This characteristic 
was reported to reduce the cell toxicity as compared to single-tailed cationic lipid like 
CTAB 450, 451. Interestingly, DOTAP has been shown to improve gene transfection in 
nude mice regardless of the type of nanoparticle used 452, 453. These results suggest that 
the interaction of the nanoparticle with cells was influenced by the positive charge 
exerted by DOTAP and not the type of nanoparticle.  
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4.1.3.3 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) 
DOTMA is another double chain cationic lipid commonly used to form lipid-
DNA complexes due to the electrostatic interactions between negatively charged DNA 
and positively charged DOTMA for gene transfection studies with a similar structure to 
DOTAP (Figure 4.2) 454, 455. DOTMA has a similar structure to DOTAP and the mixtures 
of DOTMA with neutral phospholipids has been shown to result in the spontaneous 
formation of multilamellar liposomes upon sonication 456, 457.  
DOTAP and DOTMA are selected in this thesis as double chain cationic lipids to 
formulate cationic cubosomes and compared with CTAB cubosomes for the uptake 
across BBB. Both DOTAP and DOTMA have quaternary ammonium group and 
unsaturated double chain hydrophobic domain. However, they have different linkages 
between the long alkyl chain and trimethyl ammonium headgroup, where two ether bonds 
are present in DOTMA while two ester bonds in DOTAP 458. In gene transfection studies, 
the differences in the linkage plays an important role where ether linkage from DOTMA 
promotes a higher efficacy in gene transfection 458-460. The influence of structural 
differences of these cationic lipids on their uptake by brain endothelial cells will be 
investigated in this thesis. 
 
4.1.3.4 1,2-di-O-tetradecyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DMPG) 
1,2-di-O-tetradecyl-sn-glycero-3-phospho-(1'-rac-glycerol) or 
dimyristoylphosphatidylglycerol (DMPG) is an anionic, double-tailed phospholipid with 
a negatively charged head group (Figure 4.2). DMPG has been added to liposomes to 
increase the biological activity of cis-Bis-neodecanoato-trans-R,R-1,2-
diaminocyclohexane platinum (II) (NDDP), a lipophilic cisplatin analogue anti-tumour 
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agent, to target liver cancer 461. While cationic lipids have been known to cause cell 
toxicity, anionic lipids are less toxic 462. It was hypothesised that the addition of this 
anionic lipid to the cubosomes will not lead to uptake via adsorptive endocytosis pathway 
and this will therefore act as a control for the in vitro studies. It was hypothesised that 
any cellular uptake of anionic cubosomess into cells might therefore occur through 




4.1.5 The interaction of phytantriol lipid bilayers with charged lipids 
The addition of charged lipids may influence the stability of the phytantriol lipid 
bilayer in cubosomes. In order to form stable cubosome dispersions, the added charged 
lipid needs to be miscible with phytantriol 464-466 and is expected to be inserted in between 
the phytantriol lipid bilayer, due to the nature of the hydrophilic head and hydrophobic 
tails from the charged lipids as illustrated in Figure 4.3. An optimum concentration of 
charged lipids needs to be added to avoid disruption of the bilayer and causing any 
structural change or affecting the stability of cubosomes. Possible interactions between 
charged lipids and the phytantriol bilayer was investigated in this thesis using a lipid 
monolayer model. These are representative models for studying liposomes as the bilayers 
are considered an approximate superimposition of two monolayers 467, 468. The monolayer 
studies are discussed in more detail below.  
 
 
Figure 4.3 Illustration on the insertion of amphiphilic charged lipids into phytantriol 
bilayer. 
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4.1.5.1 Langmuir monolayer study 
Pure and mixed lipid monolayers can be studied using a Langmuir-Blodgett 
trough to understand interactions and miscibility within lipid monolayers when charged 
lipids are introduced into the system. Theoretically, amphiphilic lipid molecules such as 
phytantriol are expected to accommodate and orientate at the water/air interface and form 
a stable film which is known as a Langmuir monolayer 469, 470. The miscibility between 
phytantriol and charged lipids and their impact on monolayer stability can be examined 
by Langmuir trough studies. It is important to know the miscibility of charged lipids with 
phytantriol before formulating them into cubosomes, as these two components have to 
be miscible in order to form a stable dispersion and allow the charged lipids to express 
the charge on cubosome surface 471.  
 
 
Figure 4.4 Illustration of Langmuir-Blodgett trough showing the lipid was added on the 
water surface and the barriers are moved (in the direction of the arrows) to slowly 
compress the monolayer.  
 
In order to examine this, molecular area and surface pressure isotherms are 
plotted to obtain information on the orientation, dimensional properties and molecular 
interactions between molecules in single and mixed components monolayers 471. To 
construct the isotherm of a single lipid component (e.g. phytantriol) or mixed 
components (e.g. phytantriol with charged lipids), the lipids (in solvent) are added on the 
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subphase (water), and the solvent is evaporated. The barriers then slowly compress the 
monolayer (Figure 4.4) and the pressure isotherm is plotted. Figure 4.5 shows the 
surface area of the monolayer slowly reducing upon compression which then cause an 
increase in the surface pressure. As the surface area of the monolayer decreases further, 
the monolayer changes from gaseous phase (G) and into the liquid phase. The 
intermolecular interactions between the molecules led to a more ordered orientation of 
the molecules on the interphase. The proximity and orientation of molecules determines 
the liquid expanded (LE) and liquid condensed (LC) states. Meanwhile, the plateau 
region of LC + LE indicates rearrangement of the molecules into a more ordered 
monolayer as the barriers are compressed. In the solid state (S), the amphiphilic 
molecules are closely packed, and the hydrophobic tails are arranged in parallel. Further 
compression leads to the collapse of the monolayer and is shown as a break in the 
isotherm, as illustrated by red dotted line in Figure 4.5. Monolayer packing and 
molecular orientation can be affected by the presence of unsaturated bonds, polar head 
groups, steric hindrance and hydrophilic interactions between the molecules 471. The 
structural effects of the selected lipid can be explained by the theory of critical packing 





Figure 4.5 Langmuir isotherm that exhibits the different phases adapted by lipids at a 
monolayer; G: gaseous, LE: liquid extended, LC: liquid condensed and S: solid with 
schematic drawings of molecular arrangements of the different phases of lipids at 
interphase. The red dotted line shows the collapse pressure (CP) of the monolayer when 
the monolayer finally collapsed (Adapted from 471).  
 
The miscibility of two lipids in a system can be investigated from the isotherm 
where the collapse pressure in mixed monolayer of two lipids being related to miscibility.  
The addition of a second lipid into the monolayer can cause a reduction in the collapse 
pressure, as the mixed monolayer is more compressible than a single lipid monolayer 322. 
A mixed monolayer with single collapse pressure is indicative that the two lipids are 
miscible 472, while two separate collapse points indicate there is lack of interaction 
between the lipids and that the two components are immiscible. In this case, each of the 
components will separate from the mixture and result in two collapse points 
corresponding to their respective individual collapse pressures 473.  
Deviations from the limiting molecular areas can be calculated from the isotherms 
to further evaluate the miscibility of mixed monolayers. A detailed analysis of the 
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isotherm and the calculation of the limiting molecular areas was presented in the method 
section (Section 2.2.4). The deviation is calculated from the differences in calculated 
(from the experiment) versus ideal molecular area. A negative deviation indicates a non-
ideal behaviour of the mixed monolayer where there are attractive forces between the 
lipids, indicating the lipids are miscible. Meanwhile, positive deviation in the calculated 
molecular areas in mixed monolayers shows an ideal behaviour and that the monolayers 
are immiscible. Repulsive forces usually occur due to interactions between the head 
groups of the two lipids and can lead to immiscibility 323, 474. If the lipids are immiscible, 
they will separate during the preparation and cubosomes with positively charged surface 







4.2 Hypothesis and aims 
The overarching aim of this chapter is to develop cationic cubosomes to target 
the adsorptive endocytosis pathway at the BBB, as a potential drug delivery pathway to 
the brain. Hence, the hypotheses for this chapter are: 
Hypothesis 1: That double chain cationic lipid will have a greater impact on the stability 
of phytantriol monolayer as compared to single chain cationic lipid. 
Hypothesis 2: That single and double chain cationic lipids can be added into cubosomes 
formulation to form positively charged cubosomes. 
Hypothesis 3: That the chain length from cationic lipids will affect the toxicity in vitro. 
Hypothesis 4: That the addition of cationic lipids will lead to increased cellular uptake in 
vitro through the adsorptive endocytosis pathway.  
 
To investigate the above hypotheses, the following experiments were conducted. The: 
1) investigation of the stability and miscibility of phytantriol monolayer after the 
addition of single and double chain charged lipids; 
2) investigation of the physicochemical properties of cubosomes after the addition 
of single and double chain charged lipids; 
3) evaluation of the cellular toxicity of cubosomes after the addition of single and 
double chain charged lipids in hCMEC/D3 cells, in comparison to the free 
solution of charged lipids; and the 
4) evaluation of cellular uptake of cubosomes after the addition of single and double 
chain charged lipids.  
 
Pluronic F127 was used as a stabiliser in all cubosome formulations at a 
concentration of 15% w/w (to phytantriol), based on the results in Chapter 3. Since this 
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chapter aimed to study the effect of cationic cubosomes on the interaction with 
hCMEC/D3 cells, cubosomes stabilised by Pluronic F127 were used because it is not 
expected to cross the BBB, and the effect of adding cationic lipids can be studied. 
4.3 Results and discussion 
4.3.1 Effect of adding single and double chain charged lipids on phytantriol 
monolayer formation. 
To predict the effect of adding a cationic lipid to cubosome formulations, the 
interactions between phytantriol and selected cationic lipids in a monolayer were studied 
using a Langmuir monolayer trough. 
Pure phytantriol had a typical phospholipid isotherm as shown in Figure 4.6. 
Referring to Figure 4.5 previously, the lipid oriented in an expanded state and showed a 
transition at about 65 Å2 from the liquid condensed to the solid state before the monolayer 
collapsed at 42.3 ± 3.6 mN/m. The collapse pressure for pure phytantriol was similar to 
the published value of 42.4 ± 1.4 mN/m 475. The addition of DOTAP, CTAB and DMPG 
at the selected concentration had no significant impact on the stability of phytantriol 
(p>0.05), as observed from the collapse pressures (Table 4.1). In contrast, the addition 
of DOTMA to phytantriol led to a significant reduction (p<0.05) in collapse pressure 




Figure 4.6 -A isotherm for pure phytantriol and mixed monolayer of phytantriol with 
CTAB, DOTAP, DOTMA and DMPG from Langmuir monolayer studies. The isotherms 
are the average of three independent experiments.  
 
Interestingly, as observed from the limiting molecular areas (Table 4.1), the 
addition of DOTMA to phytantriol lead to an experimental area of 52.5 Å2/molecule 
while phytantriol plus CTAB, DOTAP and DMPG resulted in areas of 58.4, 60.9 and 
58.7 Å2/molecule, respectively. DOTMA has a smaller head group as compared to 
DOTAP and DMPG and was expected to have less of an impact on phytantriol 
monolayer. However, it is possible that the packing properties of DOTMA were 
influenced by the small head group and hydrophobic interaction from the long double 
chain lipids, which led to a densely packed lipid monolayer, a lower molecular area and 
a less stable monolayer as observed from the reduction in collapse pressure after the 
addition of DOTMA 476. 
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Table 4.1 Experimental and calculated ideal limiting molecular area (Å2) of phytantriol, 
mixed monolayers of phytantriol and charged lipids at water-air-interface with the 
deviation from ideality. 
















61.6 ± 3.9 





42.3 ± 3.6 
46.1 ± 0.35 
DOTAP 60.9 ± 0.1 62.7 -2.8 42.3 ± 0.35 
DOTMA 52.5 ± 11.8 62.8 -16.4 30.9 ± 0.5 
DMPG 58.7 ± 1.2 61.5 -4.6 42.9 ± 1.9 
 
4.3.2 Miscibility of phytantriol mixed monolayers 
In order to formulate cubosome dispersion with charged lipids, the lipids must be 
miscible with phytantriol. Non-miscible components will have two collapse pressures 
where the lipids have no interaction and are immiscible, hence the components will 
separate from the monolayer and show two collapse pressures 472, 473. The miscibility of 
phytantriol monolayer with CTAB, DOTAP, DOTMA and DMPG can be observed from 
the presence of a single collapse pressure as illustrated in Figure 4.6.   
To further evaluate the miscibility of the mixed monolayer, the experimental 
limiting molecular area was calculated and compared to the ideal limiting molecular area. 
Table 4.1 above summarised the limiting molecular areas for the isotherms and the 
deviation from ideality. Negative deviation indicates miscibility of the components in the 
mixed monolayers while positive deviation shows that there was lack of interaction 
between the lipids, and the mixture has low miscibility 477, 478. At the studied 
concentration, the addition of all charged lipids resulted in a negative deviation from 
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ideality which indicates there was interaction between the lipid and lead to miscibility. 
These results corroborate with the value from the collapse pressure, which confirms the 
molecular interaction between the charged lipids with phytantriol monolayer leads to the 
miscibility in the monolayer. The addition of DOTMA again had the largest impact on 
the deviation from ideality. This further suggests the miscibility of DOTMA with 
phytantriol monolayer might be from the smaller head group as compared to DOTAP 
and DMPG.   
The Langmuir monolayer study can assist in predicting the bilayer stability in 
cubosome formation. However, the monolayer study only represents a layer of the lipid, 
while cubosomes are formed by multiple lipid bilayers 471. Nevertheless, the Langmuir 
monolayer studies showed that the addition of charged lipids at 1.4 mol% to phytantriol 
monolayer had a minimal impact on monolayer stability and that the lipids were miscible, 
although DOTMA might have a higher interaction with phytantriol lipid layer.  
 
4.3.3 Physicochemical properties of cubosomes with the addition of single and 
double chain cationic lipids.  
Cubosomes formulated with the addition of 1.4 mol% of cationic lipids were 
prepared and the effects on particle size and homogeneity evaluated (Table 4.2). The 
average size for all formulations was less than 200 nm and all the cubosome formulations 
were homogenous based on having a PDI value of less than 0.3. As expected, the addition 
of cationic lipids, CTAB, DOTAP and DOTMA led to highly positively charged particles 
with ζ-potential of 45.2 to 45.7 mV. The addition of the anionic lipid, DMPG increased 
the negative charge to -31.0 ± 0.2 mV, as compared to the control, which was Pluronic 
F127 stabilised cubosomes without any cationic lipids) from Section 3.4.1.3 (Table 3.5), 
which had a charge of −28.6 ± 0.3 mV.  
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Table 4.2 Particle size (Z-average) and polydispersity index (PDI) for cubosomes 
stabilised with 15% w/w Pluronic F127 ± lipids. Data presented are the mean ± standard 













Control 177.5 ± 5.4 0.18 ± 0.01 -28.6 ± 0.3 Pn3m 69 
CTAB 176.7 ± 2.4 0.242 ± 0.292 46.2 ± 0.2 Pn3m 71 
DOTAP 201.8 ± 1.1 0.174 ± 0.014 45.7 ± 0.8 Pn3m 71 
DOTMA 158.1 ± 3.6 0.090 ± 0.026 45.5 ± 2.9 Pn3m 74 
DMPG 193.5 ± 2.1 0.248 ± 0.002 -31.0 ± 0.2 Pn3m 74 
 
To confirm the internal structure of the charged cubosome dispersions, diffraction 
patterns were obtained and are summarised in Figure 4.7 and Table 4.2. When 1.4 mol% 
of CTAB, DOTAP, DOTMA or DMPG was added, the internal structure of cubosomes 
was recorded to be Pn3m cubic with lattice parameter between 70.5 to 74.1 Å. The 
increase in the lattice parameter (swelling) after the addition of charged lipids was 
consistent with previous studies 435, 479. The formation of Pn3m cubic phase was 
confirmed by the presence of three Bragg peaks with spacing ratio of √2: √3: √4 as 
observed in Figure 4.7. These results show that the addition of single and double chain 
charged lipids at studied concentration (1.4 mol%) is sufficient to induce a positive 
surface charge on particles, thereby facilitating adsorptive endocytosis, without 
disrupting the internal structure of the cubosomes.  
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Figure 4.7 SAXS diffraction (intensity versus q plots) of phytantriol cubosome 
dispersions stabilised by 15% w/w Pluronic F127 without any additives (F127) and with 
the addition of CTAB, DOTAP, DOTMA and DMPG at 1.4 mol %. The Bragg peaks at 
√2: √3: √4 confirm the formation of Pn3m cubic structure. 
 
Electron microscopy was carried out (Figure 4.8) to confirm the homogeneity 
and to visualise the nanostructure of cubosome particles. Under electron microscopy, a 
heterogeneous distribution of particles was observed in the CTAB, DOTAP and DOTMA 
cubosome formulations. The image from DMPG cubosomes is not available due to the 
failure in freezing the samples for cryo-TEM observation. Adding DOTAP and DOTMA 
produced a number of vesicles (arrow) with some of the cubosomes having vesicular 
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coats surrounding the cubosomes (arrowhead). The formation of vesicles is commonly 
reported for cubosomes stabilised with Pluronic F127 245, 382, 407. These vesicles are 
believed to be the precursors for cubosomes that eventually transform into cubosomes 
245, 480, 481.  
The presence of vesicles was not observed under SAXS analysis (Figure 4.7) 
because the signal for vesicles are usually weak as compared to the signals from 
cubosomes. Hence, in the dispersion that contains a mixture of cubosomes and vesicles, 
the scattering signals for the vesicles are being masked and did not appear as an 
individual peak 482, 483. However, direct observation under electron microscopy can 
illustrate the presence of vesicles in the dispersion. Vesicles formation in DOTAP and 
DOTMA cubosomes can be explained from their molecular structure. The presence of 
unsaturated double chain led to a decrease in the lipid curvature hence spontaneously 
transforming the phytantriol lipid bilayer into lamellar phase 238, 484, 485. DOTAP has a 
larger headgroup compared to DOTMA and this leads to further decrease in the 
curvature. The molecular structure of DOTAP leads to the presence of a larger number 




Figure 4.8 Cryo-TEM micrographs of cubosomes dispersions stabilised with phytantriol 
and added with CTAB (Panel A-B), DOTAP (Panel C-D) and DOTMA (Panel E-F). The 
arrows indicate the vesicles formation while the arrowhead showing the vesicular coats 





DOTAP and DOTMA cubosomes were further analysed by cryo-ET. The 
tomogram in Figure 4.9 (Panel A) illustrates the vesicles (Panel a”) observed in DOTAP 
cubosomes dispersion as having “onion” like layers under Fast Fourier Transform (FFT) 
analysis (Panel iii). These vesicles are most likely liposome like structures with the lipid 
bilayer forming the outer vesicle layer 395. The “budding” off structures surrounding 
cubosomes were also apparent under cryo-ET. This might indicate the process of 
cubosome formation in the dispersion 487-489. Meanwhile, FFT analysis of the DOTAP 
(Panel i and ii) and DOTMA (Panel iv and v) cubosomes show cubic packing and 
hexagonal symmetry depending on the axis of rotation. DOTMA cubosomes (Panel B) 
also showed cubosomes with vesicles surrounding the particles.  
Overall, even though the dispersion was observed to be heterogeneous, it can be 
concluded that adding 1.4 mol% of charged lipids to Pluronic F127 stabilised cubosomes 
did not change the internal structure of Pluronic F127 stabilised cubosomes but was able 
to change the surface charge. This observation allows the use of the formulation at 




Figure 4.9 Cryo-electron tomograms showing field of cubosomes embedded in vitrified buffer suspension. Cubosomes were added with 1.4 mol% 
(A) DOTAP and (B) DOTMA. Panel a’, a” and b’ show the enlarged view of representative cubosomes from the tomogram with their Fast Fourier 
Transform in (Panel i-v). Arrows indicate the “budding off” structure observed outside the cubosomes. Scale bar: 100 nm. 
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4.3.4 Toxicity of charged cubosomes in hCMEC/D3 cells. 
As cationic lipids are associated with cell toxicity, it is important to determine 
whether the addition of cationic lipids in cubosomes results in cellular uptake due to 
adsorptive-mediated endocytosis, and not from passive diffusion across the cell as a 
result of local cell toxicity 490, 491. Therefore, cubosome toxicity was studied with flow 
cytometery where cells were incubated with cationic cubosomes and their respective 
cationic lipids in a suspension (no cubosomes) at different concentrations (Figure 4.10). 
The suspensions were included in the study to investigate whether the toxicity of charged 
lipids was different in suspensions versus within cubosome formulations.   
Cell toxicity was evaluated after two hours of incubation with the formulations 
and the percentage of live cells was measured. There was no concentration dependent 
toxicity observed in all formulations studied with cell viability being approximately 98 
to 99% in cells treated with cubosomes containing charged lipids. The low toxicity 
recorded might be due to the low concentration of charged lipids added into cubosomes 
formulation (1.4 mol%) where in gene transfection study, the amount of charged lipids 
added are 2 to 3 times higher 492, 493.  
Interestingly, from Figure 4.10, it was observed that the cell viability 
significantly decreased to about 96 to 97% (p<0.05) when the charged lipids are in 
suspension form (dotted line, closed symbols) as compared to cubosome formulations 
(solid line, open symbols). Even though the difference between charged lipids in 
suspension and within cubosome formulation is less than 2%, it is possible that the 
toxicity of charged lipids was being masked by cubosome formation. This could suggest 
that the charged lipids were inserted in between the phytantriol lipid bilayer in cubosome 
particles. This insertion has been proposed for liposomes co-formulated with cationic 
lipids where the lipids were inserted in between the lipid bilayers 494-496 in which the 
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presence of hydrophobic chain within the molecule assists the insertion of charged lipids 
into the lipid bilayer 497.  
In addition, there was no impact on cell viability relating to the type of lipid added 
(single versus double chain cationic lipids). Overall, this viability study suggests that, at 
the concentration of charged lipids used in this thesis, toxicity is less than 5% therefore 
any change in cell uptake following cubosome modification will most likely be from the 
cellular interaction of cubosomes with the cell membrane, and not from the cellular 
toxicity. Moreover, this also showed that the addition of cationic lipids at studied 
concentration is not toxic to the cells.   
 
Figure 4.10 Viability (%) of hCMEC/D3 cells after two hours incubation with increasing 
concentration of cubosomes stabilised with 15% w/w Pluronic F127 and containing 1.4 
mol% of CTAB (CTAB-C), DOTAP (DOTAP-C), DOTMA (DOTMA-C) and DMPG 
(DMPG-C). Toxicity of all the charged lipids (in suspensions, dotted line) were studied 
at concentrations corresponding to those present in their respective cubosome dispersions 
and compared against toxicity from Pluronic F127 stabilised cubosomes containing 1.4 
mol% of charged lipids (solid line). Data presented are mean ± standard deviation of 
three independent experiments. The difference in viability is statistically significant 
(*p<0.05) for all formulations at all concentrations. 
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4.3.5  Uptake of cationic cubosomes by hCMEC/D3 cells 
The addition of cationic lipids into cubosome formulation was shown to produce 
positively charged cubosomes. To test the hypothesis that cellular uptake of cubosomes 
is influenced by the positive surface charge, DMPG (anionic lipid) cubosomes which are 
negatively charged were used as a negative control. Meanwhile, the uptake of Pluronic 
F127 stabilised cubosomes (no additive) was used as a control to evaluate the absence of 
charged lipids in the cubosomes on cell uptake. All cubosomes were fluorescently 
labelled with NBD (as in Chapter 3) for the detection by flow cytometry. Uptake of all 
formulations was compared to the uptake of Pluronic F127 stabilised cubosomes. 
There was a significant increase in the observed uptake of cationic cubosomes 
containing DOTAP and DOTMA (p<0.05) as compared to DMPG and Pluronic F127 
stabilised cubosomes (Figure 4.11). There was a trend of dose dependent uptake in 
DOTAP and DOTMA cubosomes. Cubosomes with single chain cationic lipid, CTAB 
had no significant increase in uptake at all concentrations. At the concentration of 38 M 
(of phytantriol), the uptake of DOTAP and DOTMA cubosomes were about 17 times 




Figure 4.11 Uptake (%) by hCMEC/D3 cells after two hour incubation with Pluronic F127 stabilised cubosomes without additive (control), CTAB 
cubosomes (CTAB), DOTAP cubosomes (DOTAP), DOTMA cubosomes (DOTMA) and DMPG cubosomes (DMPG).  All the cubosomes were 
stabilised with 15% w/w Pluronic F127 and fluorescently labelled with NBD fluorescence tag. Data presented are mean  standard deviation of 
three independent experiments. *P<0.05 compared to the uptake of control. 
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In order to visually observe the uptake of cationic cubosomes, the uptake studies 
were repeated with hCMEC/D3 cells and 38 µM (of phytantriol) of cubosomes, with 
analysis via fluorescence microscopy (Figure 4.12). The cubosomes were labelled with 
NBD and cell membrane with CellMask®. Increased NBD fluorescence was observed in 
cells cultured with DOTAP cubosomes, followed by DOTMA cubosomes. Lower uptake 
was observed in CTAB and DMPG cubosomes treated cells. However, it was uncertain 
that the fluorescence molecules were inside the cells or adhered on the surface of the cell 
membrane. While confocal microscopy technique can be a solution for this issue, NBD 
molecule is subjected to bleaching effect from the laser exposure from the confocal 
imaging. The bleaching effect on NBD can affect the intensity of the signal and might 
lead to insufficient fluorescence detection.   
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Figure 4.12 Micrograph showing uptake of NBD tagged cubosomes stabilised with 15% w/w Pluronic F127 +/- CTAB, DOTAP, DOTMA and 
DMPG at 1.4 mol%. Cells were incubated with 38 M of cubosomes for two hours. Cell membrane was stained by CellMask® (Txred), nucleus 
was stained by Hoercht 33258 (DAPI-blue) and NBD positive was observed under FITC channel. Positive uptake was observed from the presence 
of green fluorescence spots showed by the white arrows. Scale bar: 10 m. 
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The uptake of cationic cubosomes is likely to be through adsorptive endocytosis 
pathway, where uptake should be inhibited by lowering the temperature (energy 
dependent uptake) or pre-coating the cell membrane with positively charged molecule in 
order to prevent the electrostatic interaction between the cationic cubosomes and the 
anionic cell membrane.  
Cells were therefore incubated with cubosomes at 37 °C and 4 °C for two hours. 
Figure 4.13 shows that there was a reduction in uptake for cubosomes in all groups at 4 
°C. The reduction in uptake was about 2-fold for DOTAP and DOTMA cubosomes at 4 
°C. The inhibition at 4 °C is associated with the reduction in energy dependent 
endocytosis thus decreasing the uptake through non-specific adsorptive endocytosis 
pathway 498-501. However, at the same time, other transport pathways at the endothelial 
cells also utilise the ATP and the uptake will be inhibited at low temperature. For 
example, carrier mediated endocytosis such as glucose transporter at the BBB requires 
energy to function and transport glucose into the brain 118, 502. The uptake recorded at 4 
°C was not completely inhibited. There is a chance that the cubosomes were associated 
and adsorbed on the cell membrane (without internalisation) and detected by flow 
cytometer as positive uptake. Therefore, to further test whether uptake of charged 
cubosomes was from adsorptive endocytosis pathway, cells were pre-incubated with 
positively charged poly-L-lysine for 60 minutes to neutralise some of the positive charge 





Figure 4.13 Uptake (%) by hCMEC/D3 cells after two hours incubation with cubosomes 
(38 µM of phytantriol) stabilised with 15% w/w Pluronic F127 +/- CTAB, DOTAP, 
DOTMA and DMPG at two different temperatures (37 °C and 4 °C). Data presented are 
mean ± standard deviation of three independent experiments. *P<0.001 compared to 
incubation at 37 °C. 
 
Following pre-incubation with positively charged poly-L-lysine, cells were 
incubated with cubosomes for two hours before uptake was analysed by flow cytometry 
(Figure 4.14). Uptake was significantly reduced when the cells were pre-treated with 
poly-L-lysine (p<0.05 for DOTAP and DOTMA) with an approximate 3-fold reduction 
in uptake for cells treated with DOTAP and DOTMA cubosomes. The aim of pre-
incubation with positively charged poly-L-lysine was that through electrostatic 
interactions it would coat the negatively charged surface on the cell membrane. The 
coating would neutralise some of the negative charge on the cell membrane, hence 
reducing cubosomes uptake through adsorptive endocytosis pathway. This data supports 
the hypothesis that the uptake of cubosomes, modified through the addition of the double 





Figure 4.14 Uptake (%) by hCMEC/D3 cells after two hours incubation with cubosomes 
stabilised with 15% w/w Pluronic F127 without additives (control) and with the addition 
of charged lipids. The concentration selected for each cubosome dispersion was 38 µM 
of phytantriol. The uptake was compared to cells pre-incubated with 931 nM poly-L-
lysine. Data presented are mean ± standard deviation of three independents experiments. 









The significantly high cellular uptake of DOTAP and DOTMA cubosomes can 
be explained by the effect of; cubosomes charge, chain length and hydrophobicity of 
charged lipids. Firstly, the cationic charge exerted by the addition of the cationic lipids 
DOTAP and DOTMA likely promotes electrostatic interactions with the cell membrane 
as supported by the poly-L-lysine studies. This non-specific interaction promotes 
endocytosis of cubosomes into the cell through the adsorptive endocytosis pathway. This 
is in agreement with published studies reporting that adding cationic lipids into liposomal 
formulation increases gene transfection in the cells 503-505. Similarly, the use of cell 
penetrating peptide and cationic lipids were shown to promote the uptake into the cell 
through adsorptive endocytosis pathway 506, 507.  
Even though the charges for DOTAP, DOTMA and CTAB cubosomes are 
between 45 to 46 mV, the difference in surface charge might be too small to show any 
significant effect in the uptake. Meanwhile, for cubosomes modified with DMPG, there 
was a lack of uptake observed. The negative charge (-31 mV) on the surface of DMPG 
cubosomes suggests that there will be repulsion with the negatively charged cell 
membrane.  
However, among the cationic cubosomes, DOTAP and DOTMA cubosomes 
showed significantly higher uptake than the CTAB cubosomes (about 15 times higher). 
This suggests that chain length and the chemical structure of the cationic lipids might 
play a significant role in the uptake process. The presence of (1) hydrocarbon chains 
adjacent to the head group, (2) hydrocarbon chains connected to the backbone by the 
ether bonds and (3) two oleyl chains that acts as the hydrophobic anchor, were reported 
to increase the efficacy of gene transfection by DOTAP and DOTMA liposomes 458. In 
addition, the long and double hydrocarbon chains from DOTAP and DOTMA increase 
the hydrophobicity of the particles and contributes to higher uptake, due to the lipidic 
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nature of the cell membrane 508. This favour the partitioning of DOTAP and DOTMA 
cubosomes, from the presence of double chain hydrophobic tails compared to single 
chain in CTAB. Alternatively, CTAB as a highly water-soluble molecule might partition 
out of the cubosomes and interact with the cell membrane and neutralise the effect on the 
surface, which then reduce the cationic character of the cubosomes, which further impact 
the chance of uptake into the cell.  
In addition, the difference in the linkage bonds between DOTMA and DOTAP 
was proposed to affect the uptake efficiency into the cell 458. The two ester bonds in 
DOTAP exhibited a 10 times higher gene transfection in vitro compared to DOTMA with 
two ether bonds as the linkage 203, 460, 509. However, in this chapter, the differences in the 
uptake between DOTAP and DOTMA was not significant at any of the concentrations 
studied. Thus, the overall observation from this in vitro uptake study is the increase 
uptake of cationic cubosomes was affected by the chain length of the double chain 






In order to target the adsorptive endocytosis pathway, positively charged 
cubosomes were formulated by adding single or double chain cationic lipids into Pluronic 
F127 stabilised cubosomes. The addition of charged lipids should not interfere with the 
stability of the phytantriol lipid layer and the lipid mixture should be miscible. Langmuir 
monolayer studies have shown that the addition of CTAB, DOTAP and DMPG did not 
affect the stability of the phytantriol monolayer while DOTMA reduced the collapse 
pressure by 30% (p<0.05). The reduction in collapse pressure reflects the change in 
limiting area per molecule observed after adding DOTMA. The hydrophobic interaction 
between the long double chains from DOTMA with phytantriol lipid layer might lead to 
a formation of dense mixed monolayer, which makes the phytantriol monolayer less 
stable after DOTMA addition 476. CTAB, DOTAP, DOTMA and DMPG lipids were 
shown to be miscible with phytantriol, as observed from the negative deviation in the 
limiting molecular area and the single collapse pressure in each mixed monolayer. 
Cationic cubosomes were successfully formulated at a concentration of 1.4 mol% 
of CTAB, DOTAP and DOTMA with Pluronic F127 stabilised cubosomes. All the 
formulations formed cubosomes with Pn3m internal structure and a lattice parameter 
around 70 to 74 Å. The addition of charged lipids at this concentration did not change 
the internal structure of Pluronic F127 stabilised cubosomes. This might suggest that the 
charged lipids had a minimal impact on the stability of phytantriol bilayer in cubosomes 
formulation.  
Pluronic F127 stabilised cubosomes, modified through the addition of 1.4 mol% 
of charged lipids had low toxicity to hCMEC/D3 cells. It appears that by incorporating 
the cationic lipids into the cubosome formulation, the cytotoxicity effect of the cationic 
lipids is masked to some degree. The increased uptake of cubosomes containing DOTAP 
138 
 
and DOTMA was not associated with cellular toxicity and was likely due to adsorptive 
endocytosis uptake through electrostatic interaction between the cationic cubosomes and 
the anionic cell membrane. It was shown that the uptake was energy dependent and that 
it could be inhibited through partial neutralisation of the cell membrane (with cationic 
poly-L-lysine), supporting the hypothesis that uptake was via adsorptive endocytosis. 
The lack of increased uptake of cationic cubosomes containing the single chain lipid 
CTAB might be due to the presence of a different linker as compared to DOTAP and 
DOTMA and length of the hydrocarbon chain 468, 510. It can be concluded that the positive 
uptake observed in hCMEC/D3 cells, is influenced by the positive surface charge of 
cubosomes, the linker group and the chain length of the cationic lipids. In Chapter 5, 
further uptake studies will be conducted using an in vivo model to understand and 















5 In vivo brain uptake of cubosomes in a zebrafish model 
5.1 Introduction 
Cubosomes with BBB targeting moieties Tween 80 and Poloxamer 188 were 
prepared and characterised in Chapter 3 and Chapter 4 to target receptor-mediated 
endocytosis, while cationic lipids were incorporated into cubosomes to target adsorptive 
endocytosis. In Chapter 3, in vitro studies with hCMEC/D3 cells suggested that the 
addition of Tween 80 and Poloxamer 188 into cubosome formulations do not lead to 
significant uptake by human brain endothelial cells. In contrast, positively charged 
cubosomes formed through the addition of double chain cationic lipids (DOTAP and 
DOTMA) lead to significant cellular uptake via adsorptive endocytosis. Given in vitro 
studies do not represent the in vivo environment, due to the static nature of the cell culture 
and lack of plasma proteins, which in the case of Tween 80 is essential for receptor-
mediated endocytosis, an investigation using a suitable in vivo BBB model is needed.  
Various in vivo models have been used to predict the uptake of nanoparticles into 
the brain. The mouse model is the most commonly used BBB model due to similarities 
in the transporters, receptors and cell properties to the human BBB 511. Unfortunately, 
mouse models can be costly and labour intensive, therefore hindering high throughput 
screening in uptake studies. The zebrafish model was therefore chosen as a BBB model 
and is discussed in more detail below.    
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5.1.1  Zebrafish as an in vivo model in drug development 
Zebrafish (Danio rerio) originate from Southeast Asia and have been widely 
utilised in various fields of study, especially in molecular genetics and developmental 
biology 512, 513. Zebrafish have been reported to be 200 to 1000 times cheaper than 
mammalian models and the cost can be as low as 1% of that of rodents 514, 515.  
Zebrafish offer several advantages as an animal model over the mouse model. It 
has been reported that 70% of their genes are similar to those in human and they can 
therefore be a suitable in vivo model for certain genetic or developmental studies 516. The 
advantages of zebrafish model over the mouse model in drug development studies are 
summarised in Table 5.1. Zebrafish are a small size vertebrate and only occupy a small 
space for living. The husbandry of zebrafish is simple and a single medium size fish tank 
can accommodate about 50 to 60 adult zebrafish. The larvae and embryo only require as 
low as 50 µL of liquid to survive 517. In contrast, fewer than 10 mice can live together in 
a medium sized cage. Zebrafish have a fast reproduction rate with approximately 10 days 
breeding cycle and a fish produces from 50 to 300 eggs at a time, while a single mouse 
produces around 10 pups in a single breeding. Zebrafish will take about 24 hours after 
fertilisation to develop into larvae, while the gestation period for mice is about 21 days 
517, 518 
The large number of offspring and shorter gestation period significantly reduces 
maintenance cost and offers options for high throughput screening of high cost molecules 
518-521. Furthermore, since the larvae are about 3 to 8 mm length, this allows experiment 




Table 5.1 Key differences between the zebrafish model and mouse model 517, 526, 527. 
Zebrafish Mouse 
Vertebrate Mammal 
Small space to live (60 fish per medium 
tank) 
Large space needed (<10 mice per 
medium cage) 
Low cost  High cost 
Breeding cycle every 10 days, 50 to 300 
eggs at a time 
Breeds 3 times throughout life, < 10 
pups every pregnancy 
External fertilisation Placental viviparity 
Transparent larvae Not transparent 
No prostate, mammary glands or lungs Have similar organs to human 
 
Zebrafish eggs are fertilised externally and the embryos survive and grow outside 
the parent’s body. Meanwhile, the reproductive mode for mice is placental viviparity, 
where the pups grow inside the mother until birth. In zebrafish, manipulations can be 
conducted during the gestational period by treating the embryo and development can be 
observed through the transparent skin 517, 518. The transparent skin allows live imaging to 
be conducted without the need to sacrifice or dissect the animal 528. 
In zebrafish, organogenesis begins as early as 24 h.p.f (hours post fertilisation) 
with the organs being fully developed at about 5 d.p.f. (days post fertilisation) 524. 
Zebrafish also matures quickly but has a longer life span than mice and therefore can be 




Table 5.2 Stages of zebrafish life from fertilisation until death 529. 
Age Stage 
0 to 72 h.p.f Pre-hatching (embryo) 
72 to 120 h.p.f Post-hatching  
1 to 29 d.p.f Larvae 
Start swimming at 5 d.p.f 
30 to 89 d.p.f Juvenile 
90 d.p.f to 2 years Adult 
Sexually active after 90 to 120 d.p.f 
> 2 years Aged fish (to study aging) 
4 to 5 year old Death 
   
In the first few hours after fertilisation, the embryo can be injected with DNA or 
RNA to genetically modify the embryo, so it will develop into a specific adult transgenic 
line. In addition, disease models can be induced in the early hours of fertilisation and 
since the embryo is transparent, the changes in the organ development can be observed 
under a microscope 530, 531. A number of transgenic lines used for drug discovery studies 
have been developed, for example the Tg(fli1a:EGFP) fish which expresses green 
fluorescent protein in all endothelial cells 520, 532. Another transgenic line, 
Tg(flk:nsmcherry) is similar but the endothelial cells have red fluorescence instead.  
It must be acknowledged that zebrafish are an incomplete mammalian model as 
they do not have organs such as lungs, skin, prostate and mammary glands 517. 
Nonetheless, zebrafish are cost-effective and versatile model in various field. It is widely 
studied in toxicological studies that requires high throughput screening. The similarity of 
organs in zebrafish and human allow different toxicological studies to be conducted to 
screen a large number of toxic compounds. A detailed discussion on neurotoxic 
compounds and toxicological studies in zebrafish was conducted and reviewed 533 and 
will not be discussed here.  
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Zebrafish is a highly useful and ethical model that can bridge the gap between in 
vitro and higher animal studies as illustrated in Figure 5.1 below 523. Using this model 
allows adherence to the 3R principles (replacement, reduction and refinement) in ethical 
research. As a non-vertebrate model, zebrafish is an attractive alternative to the 
mammalian model as it is a less sentient species (replacement) 516. By only using larvae, 
we can avoid the use of adult zebrafish without sacrificing reliability (reduction). The 
study also reduces animal distress by minimising the procedures involved (refinement). 
In addition, the live-imaging technique allows non-invasive quantification step and lesser 
sample processing 534. 
 
 
Figure 5.1 Zebrafish model as a bridge between cell culture method (first-line screening) 






5.1.2 Zebrafish as a model for the BBB 
Zebrafish have been widely used and this model is used to study the uptake of 
cubosomes across the BBB as the central nervous system and brain development between 
zebrafish and mammals are similar 535.   
In order to use zebrafish as the BBB model for the uptake of cubosomes into the 
brain, the zebrafish brain needs to express similar receptors, transporters and 
neurotransmitter to that of the mammal brain 514. Table 5.3 outlines in detail the 
development of the CNS in zebrafish. After fertilisation, the brain starts to develop at 3 
d.p.f signified by the formation of transporters and TJs. ATP binding cassette (ABC) 
transporters are also found in the brain and they have been shown to behave in a similar 
fashion to those in the mammalian brain 536, 537. Claudin-5 and ZO-1 have also been 





Table 5.3 Zebrafish brain development at different stages of life. 
Age Development References 
6 h.p.f 
10 h.p.f 
Formation of neural plate 
End of gastrulation 
Formation of neural tube followed by spinal cord 
537, 540 
24 h.p.f Formation of olfactory nerve, primary neurons, 
forebrain, hindbrain and midbrain 
541, 542 
28 h.p.f Major vessels and angiogenesis are fully developed 517 
48 h.p.f Brain ventricles and optic nerve 543-545 
2 to 3 d.p.f Neurons secreting neurotransmitter and tight 
junctions formed 
533, 538, 539  
4 d.p.f Oligocytes, astrocytes, Schwann cells and glial cells 544, 546  
6 d.p.f Development of complex circulatory system 512  
8 d.p.f Efflux transporter fully functional 537, 547  
10 d.p.f BBB fully functional and formed 
Tight junction fully formed and function similarly to 
human 
Complete development of feet process of pericytes 
and astrocytes 
520, 538, 548  
 
 
Even though the BBB starts to develop at 3 d.p.f, it is only at 10 d.p.f that the 
BBB is fully developed and functional 538, 548, thus any nanoparticle uptake studies (into 
the brain) should be carried out after 10 d.p.f. However, some studies have started earlier 
at 5 to 6 d.p.f. In one of these studies, doxorubicin and paclitaxel encapsulated in 
exosomes were shown to enter the brain region of the zebrafish based on the observation 
of fluorescence signal inside the zebrafish brain 549. In another study, transferrin 
conjugated carbon dots were observed to be able to cross the BBB and enter the zebrafish 
brain after intravenous injection. The appearance of fluorescently-labelled carbon dots in 
the central canal suggests the potential use of transferrin conjugated nanoparticles to 
target the receptor-mediated pathway at the BBB 550. As these studies were carried out in 
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larvae below the age where the BBB is thought to be fully developed 538, 548, 551, there is 
an uncertainty to whether the positive uptake was due to the nanoparticle design or the 
BBB not being fully developed, hence leaky to nanoparticles.  
To date, larvae after 10 d.p.f have not been used to study nanoparticle transport 
across the BBB. This might be due to the fact that larvae develop pigmentation as they 
age. At 12 to 14 d.p.f, significant pigmentation appears on the skin reducing optical 
transparency, therefore preventing direct imaging of the brain. However, for brain uptake 
studied use of larvae younger than 10 d.p.f which do not have a fully developed BBB 
will most likely lead to unreliable results due to the leakiness at the BBB. Hence, this 
thesis uses larvae of 10 to 12 d.p.f to study the uptake and toxicity of cubosomes. Since 
the BBB has been reported to be fully developed at 10 d.p.f 520, 538, 548, it can be concluded 
that any cubosomes uptake reported in this thesis is likely due to endocytosis, and not 
from the BBB being leaky. To circumvent the interference in imaging cause by the 
pigmentation on the skin, the larvae are oriented laterally, where the midbrain area can 




5.1.3 Observing the uptake of cubosomes using confocal microscopy 
Real-time live imaging of the uptake of nanoparticles into the brain has been a 
challenge with animal models such as mice, due to their size and anatomy. Positron 
emission tomography, magnetic resonance imaging and computer tomography have been 
used to image the whole brain 552, 553. However, the resolution from these techniques is 
insufficient to provide detailed information on individual cells and nanoparticles. While 
fluorescence, confocal and two-photon microscopy can offer higher resolution 554, the 
depth of penetration is limited to a sample thickness of less than 1 mm 555. While this 
limits the option to image the whole brain of rodents, it can be used on zebrafish larvae 
because of their small size and thickness. 
Confocal microscopy is used in this thesis to view the uptake of cubosomes in the 
zebrafish brain, as it offers several significant advantages over fluorescence microscopy. 
Firstly, zebrafish larvae have a thickness of about 0.5 to 1.0 mm, so imaging with a 
fluorescence microscope can produce high background noises due to signals being 
collected above and below the plane of focus 556, 557. The depth of illumination is also 
limited thus reducing the image quality 558. Even though the area of interest can be 
focused to increase the contrast, non-specific background fluorescence reduces the 
quality of the image which may cause inaccurate interpretations of nanoparticle uptake 
559, 560. The pinhole in the confocal microscope focuses light onto the sample and removes 
background interference and out of focus glow (Figure 5.2). The captured images have 
a higher resolution with less artefacts caused by light scattering. In addition, confocal 
imaging allows optical sectioning of the sample along the z-axis. The images can be 
captured at different depths through the sample and collectively translated into a 3D 
structure. This provides information on the uptake of nanoparticles at different depths of 
the brain 561-565. However, samples imaged using both fluorescence and confocal imaging 
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can suffer from photo bleaching 566-569. It is important to minimise the exposure time and 
avoid excessive bleaching that can lead to data misinterpretation.  
 
 
Figure 5.2 Schematic diagram of a confocal microscopy showing the location of the 
pinhole; at the light source and the detector (circled in red). The detector pinhole allows 
the light source from the focal plane to be detected while blocking the light from above 
and below the plane. (Reproduced with permission from 570). 
 




5.2 Hypothesis and aims 
The overall objective of this chapter is to investigate the uptake and toxicity of 
surface modified cubosomes using zebrafish. The hypotheses tested were, that: 
Hypothesis 1: cubosomes stabilised with Tween 80 and Poloxamer 188 have increased 
uptake into the zebrafish midbrain due to the interaction with ApoE (see Section 3.1.2) 
Hypothesis 2: gold-labelled cubosomes can be used to investigate the localisation of 
cubosomes in the brain. 
Hypothesis 3: cubosomes containing double chain cationic lipids, DOTAP and DOTMA 
will have a higher uptake into the zebrafish midbrain compared to cubosomes with single 
chain cationic lipid based on cell uptake studies in Section 4.3.5.  
Hypothesis 4: the uptake of cubosomes into the midbrain is not driven by their toxicity 
at the BBB. 
 
To explore the hypotheses above, the following aims were investigated: 
1) The uptake of cubosomes stabilised with Tween 80 and Poloxamer 188 into the 
zebrafish brain. 
2) The distribution of gold-labelled cubosomes in the zebrafish brain at the ultrastructural 
level. 
3) The uptake of cubosomes surface decorated with single chain (CTAB) and double  
chain (DOTAP and DOTMA) cationic lipids into the zebrafish brain.  




5.3 Materials and methods 
5.3.1 Materials 
Octanethiol functionalized 3 nm gold nanoparticles was purchased from 
Nanoprobes (New York, USA). 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) was purchased from Avanti Polar Lipids. Inc 
(Alabama, USA). Milli-Q water (ion exchanged, distilled and purified by Millipore, 
Bedford, MA) was used in all experiments.  
 
5.3.2 Preparation and characterisation of modified cubosomes tagged with lipid 
dye and gold nanoparticles 
Tween 80, Poloxamer 188, Pluronic F127 and cationic cubosomes were prepared 
as described in Section 2.2.1.1 and 0.01% w/w of lissamine rhodamine PE (LR) or 89.3 
nM octanethiol functionalized 3 nm gold nanoparticles were added to the chloroform 
before the evaporation step. Particle size and polydispersity index were measured as 
described in Section 2.2.1.1 and SAXS analysis was conducted as outlined in Section 
2.2.1.2. 
 
5.3.3 Zebrafish husbandry and experimental procedure 
Adult zebrafish were kept in a flow-through system with UV-treated water and 
maintained at 24 to 30 °C, pH 7.0 to 8.0 and conductivity of 200 to 1000 µS1. Adult fish 
were mated by leaving a breeding pair in the dark, overnight. Zebrafish usually lay their 
eggs in the first two hours after the lights are switched on the next morning. The embryos 
were collected and kept in an E3 solution (0.17 mM KCl, 5 mM NaCl, 0.33 mM MgSO4, 
0.33 mM CaCl2, and 0.1% Methylene Blue) in a petri dish at 28 °C. Larvae were fed 
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with dry food ZM-000 (Zebrafish Management Ltd (ZM), UK) and rotifer (plankton) 
starting on 5 d.p.f. All experiments were carried out at 10 to 12 d.p.f.   
Zebrafish larvae were anaesthetised with 0.2 mg/mL tricaine (ethyl 3-
aminobenzoate methanesulfonate, Sigma-Aldrich) and mounted laterally on a depression 
slide with 10 mg/mL warmed agar solution (Sigma-Aldrich). Control solutions or 
modified cubosomes (labelled with LR or gold nanoparticles) were injected 
intravenously (5 nL) using a microinjection gauge into the common cardinal vein with 
the aid of a dissecting stereomicroscope (Leica, Switzerland).  
The zebrafish brain consists of three different regions; forebrain, midbrain and 
hindbrain 571. Since the studies were conducted on 10 to 12 d.p.f larvae, the midbrain 
region is selected to observe and quantify cubosomes uptake as it represents the largest 
region of the brain in the zebrafish. The location of the midbrain also facilitates clear 
imaging without interference from skin pigmentation that starts to develop from day 8 to 
9 d.p.f 572, 573.  
Three different transgenic zebrafish lines were used in order to study the toxicity 
of cubosomes towards the BBB and their uptake into the brain and neurons. The 
Tg(fli1a:EGFP) transgenic line was selected to study brain uptake as it expresses the 
green fluorescence protein in the endothelial cells. Figure 5.3 shows the expression of 
green fluorescence protein under fluorescence microscopy, where the lining of the blood 
vessels (endothelial cells) are green. The area of interest, the midbrain, where uptake of 




Figure 5.3 The transgenic zebrafish line, Tg(fli1a:EGFP) with blood vessels which 
fluoresce in green under fluorescence microscope. The dotted white line illustrates the 
midbrain region. Scale bar: 500 µm 532. 
 
The Tg(sox10:EGFP) transgenic line was chosen because the neurons in this line 
express the green fluorescence protein. In this line, the accumulation of LR-labelled 
cubosomes (which fluoresce in red) in the green fluorescing neurons can be observed. 
This was used to investigate whether cubosomes which enter the brain are taken up by 
neurons.  
Finally, to evaluate any toxic effects of cubosomes in the midbrain, zebrafish 
were exposed to acridine orange dye (which has a green fluorescence) which is used as 
the apoptotic cell marker. Therefore the Tg(flk:nsmcherry) zebrafish line which expresses 
the mcherry fluorescence protein (fluorescence in red) along the blood vessels was used 
131, 574.  
 
5.3.4 Live imaging of cubosome uptake using confocal microscope 
To observe the uptake of cubosomes in the midbrain of the zebrafish, 
Tg(fli1a:EGFP) and Tg(sox10:EGFP) larvae were anaesthetised with 0.2 mg/mL of 
tricaine and mounted laterally on a depression slide using 1.5 % warmed agar solution. 
The larvae were injected with 5 nL of cubosome formulations and observed under the 
confocal microscope.  
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Following the injection of cubosomes, the midbrain was observed, and confocal 
images were captured using a Nikon C2 Si confocal microscope (Nikon Corp., Japan). 
Only single time point imaging was undertaken to avoid bleaching effect on the 
fluorescence label (LR). After 120 min post injection, 20 stacks of z-series were collected 
(thickness: 2 µm each) without any image saturation. To avoid image saturation, an 
image acquisition software (Nikon Corp., Japan) was used (while setting up the 
acquisition parameters) to monitor the intensity values 575-577. To observe the green 
fluorescence, FITC filter (ex 488/em 509 nm) was used and for LR, Texas red filter (ex 
545/em 572 nm) was used. To analyse the uptake of LR-labelled cubosomes into the 
midbrain, each z-stack was analysed individually using ImageJ software (National 
Institutes of Health, NIH). The midbrain area was selected, and a threshold was applied 
to identify the fluorescent blood vessels in the brain. Thresholding is a method which 
divides the image into two classes of pixels so that the blood vessels or neurons (fluoresce 
in green) and LR which fluoresce in red can be differentiated. This differentiation allows 
the quantification of fluorescence intensity from LR which are located outside the blood 
vessel, which indicates the uptake of uptake into the brain.  
In Tg(fli1a:EGFP) larvae, the fluorescence was quantified using the “integrated 
density” measurement, where it measures the total sum of the pixel values for all 20 z-
stacks in the midbrain area 578-580. The fluorescence intensity in the brain of zebrafish that 
were administered with LR-labelled cubosomes was compared to that of zebrafish 
administered LR formulated as suspension (no cubosome control). The experiments were 
conducted on a total of at least 15 zebrafish larvae in each experimental group on separate 
days, and the images were analysed. The cubosome formulations were freshly prepared 
on the day of injection. 
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5.3.5 Toxicity analysis 
To determine whether the administration of cubosomes was causing any toxicity 
in the midbrain of the zebrafish larvae, acridine orange staining was carried out. 
Tg(flk1:mcherry) zebrafish larvae were anaesthetised with 0.2 mg/mL tricaine, mounted 
laterally and injected with 5 nL of cubosome dispersions, DMSO (80%) as positive 
control or saline as the negative control. Immediately following this, 5 nL of 1 mg/mL 
acridine orange solution was injected intravenously into the larvae and after a period of 
two hours, the midbrain area was imaged using a Nikon C2 Si confocal microscope 
(Nikon Corp., Japan). The images were qualitatively analysed using ImageJ software to 
detect the presence of fluorescent acridine orange.  
 
5.3.6 Uptake of gold-labelled cubosomes 
For uptake studies with gold-labelled cubosomes, only Tween 80 cubosomes was 
studied as this formulation showed uptake into the brain without any associated toxicity. 
Day 10 larvae were anaesthetised with 0.2 mg/mL tricaine and fixed in agar. The larvae 
were then injected intravenously with 5 nL of 15% w/w Tween 80 stabilised cubosomes 
labelled with gold nanoparticle, gold nanoparticle suspension or 15% Tween 80 
stabilised cubosomes. Two hours after injection, the agar was broken open using a scalpel 
and the larvae were transferred into a 5 mL tube for fixation. 
Microwave processing has been reported to improve the diffusion of fixative 
chemicals into larvae and improve ultrastructural observation under TEM 50, 581. A Pelco 
BioWave Pro Laboratory microwave oven fitted with a ColdSpot heating reduction 
system (Ted Pella Inc, Redding, California, USA) was used to maintain the temperature 
at 23 °C throughout the processing. The processing steps were adapted from 582 with 
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slight modification. The first two cycles involved fixing the larvae with 2.5% EM grade 
glutaraldehyde (Sigma-Aldrich, New Zealand) in 0.1 M cacodylate buffer (Sigma-
Aldrich, New Zealand) and microwave heating at 100 W under vacuum (2 psi) at a cycle 
of two min on-off-on. Then the larvae were then rinsed with 0.1 M cacodylate buffer for 
10 min followed by microwave heating at 250 W without vacuum for 40 sec. After that, 
the vacuum was switched on and larvae were fixed with 1% osmium tetroxide (Sigma-
Aldrich, New Zealand) buffered with 0.1 M cacodylate buffer and microwaved for two 
min on-off-on cycle at 100 W. This step was repeated twice without changing the 
solution. The larvae were then rinsed with double-distilled water in the fume hood for 10 
min and were microwaved for 40 sec at 250 W to remove the osmium solution. Next, 2% 
uranyl acetate (Sigma-Aldrich, New Zealand) in double-distilled water was added and 
again the larvae were microwaved for one min on-off-on cycle at 150 W for tertiary 
fixation. The samples were then rinsed for 10 min followed by microwave for 40 sec at 
250 W with double-distilled water. The samples were then enhanced using enbloc 
staining technique with 2% uranyl acetate in 50% ethanol (to enhance TEM images 
contrast) and then microwave heated at 150 W with vacuum in a two min on-off-on-off 
cycle. The larvae were then dehydrated by using increasing ethanol concentrations from 
50 to 100% and microwaved for 40 sec at 250 W without vacuum. The larvae were 
infiltrated with epoxy resin in four steps described below, with three min of microwave 
heating at 250 W and vacuum after each step: 
Step 1: 1 part resin : 2 parts 100% ethanol 
Step 2: 2 parts resin : 1 part 100% ethanol 
Step 3: 100% resin 





The resin block was remounted and ultra-thin sections (80 nm sections) were 
obtained using a Reichert-Jung Ultracut E ultramicrotome (C. Reichert AG, Vienna, 
Austria). The sections were fixed on Formvar carbon coated 100 mesh copper grids and 
viewed under TEM, Philips CM100 BioTWIN with LaB6 emitter (Philips/FEI 
Corporation, Eindhoven, Holland). Images of the brain ultrastructure at the midbrain 
region were captured using MegaView lll digital camera (Olympus Soft Imaging 
Solutions GmbH, Münster, Germany). 
 
5.3.8 Energy dispersive X-ray spectroscopy (EDS) 
The presence of gold particles in the midbrain was confirmed by X-ray analysis 
using a JOEL 2300F EDS (Joel Ltd, Tokyo, Japan). Grids with the brain section were 
mounted and area with dense gold nanoparticles was analysed and compared to the 
reference spectrum in order to confirm the presence of gold. 
 
5.3.9 Statistical analysis 
The results are expressed as the mean ± standard deviation (SD). One-way 
analysis of variance (ANOVA) with Tukey’s multiple comparison’s test using Prism 6 





5.4 Results and discussion 
5.4.1 Uptake of Tween 80 and Poloxamer 188 stabilised cubosomes in the 
zebrafish brain. 
Zebrafish larvae were injected intravenously with Tween 80 or Poloxamer 188 
stabilised cubosomes, fluorescently-labelled with lissamine rhodamine (LR) to 
investigate the potential of these two stabilisers to target cubosomes to the BBB. The 
uptake of cubosomes (formulation described in Chapter 3) in the midbrain was analysed 
by quantifying the fluorescence of LR presented as integrated density (g/cm), two hours 
post injection. Figure 5.4 summarises the uptake of different cubosome formulations and 
a LR suspension as the control. The presence of red fluorescent signal in the midbrain 
region outside the blood vessels, suggests that the LR-labelled cubosomes crossed the 
BBB and entered the brain parenchyma (Figure 5.5).  
 
Figure 5.4 Uptake of LR in the midbrain from LR-labelled cubosomes expressed as 
integrated density (g/cm) and compared against control (LR suspension). Data presented 
are the mean ± standard deviation of uptake of LR in 10 to 20 larvae per group. *P<0.05 




A two-fold increase in the fluorescence was detected in the midbrain of zebrafish 
injected with Tween 80 cubosomes (p<0.05) compared to thecontrol and other groups 
(Figure 5.4). Zebrafish injected with Poloxamer 188 or Pluronic F127 cubosomes 
showed no significant increase in the uptake as compared to control (LR suspension). 
Figure 5.5 further illustrates the uptake of cubosomes in the midbrain region. A strong 
fluorescence signal was observed in the midbrain region of larvae injected with Tween 





Figure 5.5 Representative confocal micrographs of Tg(fli1a:EGFP) larvae 120 min after 
injection with Pluronic F127 (F127), Tween 80 (T80) and Poloxamer 188 (P188) 
cubosomes fluorescently labelled with LR. The yellow dotted line outlines the eye region 
while the white dotted line indicates the midbrain region. LR fluorescence in the midbrain 
is highlighted within the white dotted areas and indicated by the arrows. The GFP panels 
show green fluorescence from the blood vessels in the midbrain while the LR panels 
show fluorescence from LR while the merge panels show the area of LR fluorescence 
outside the blood vessel (arrows). The uptake of LR is compared against the uptake of 
control (LR suspension). Scale bar: 50 µm. 
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To observe whether the cubosomes accumulated in the neurons, the above study 
was replicated in Tg(sox10:EGFP) larvae, where the neurons fluoresce in green (Figure 
5.6). No LR accumulation in the neurons was detected for any of the cubosome 
formulations studied. Even though the brain uptake of Tween 80 cubosomes was 
statistically significant in the previous study, lack of fluorescence was observed inside 
the neurons, suggests that their uptake into the brain is not specifically localised to 
neurons. Similarly, in zebrafish injected with Poloxamer 188 and Pluronic F127 
cubosomes, lack of LR fluorescence in the neurons was observed. PBCA nanoparticles 
surface coated with Tween 80 were used to deliver β-galactosidase into the brain and 
were found to be localised in the neurons. The uptake of this protein (540 kDa) was 
proposed to be via LDL-receptors present at the BBB and neurons 583. As Figure 5.6 
shows, poor signal associated with LR is detected in the neurons when Tween 80 
cubosomes are used. To overcome this problem, the microscope can be adjusted to induce 
higher fluorescence intensity by increasing the intensity of the laser on the larvae. 
However, this can cause bleaching of the fluorescence molecules, leadings to 





Figure 5.6 Confocal micrographs of the midbrain of (Tg(sox10:EGFP) zebrafish larvae, 
120 min after intravenous injection with Pluronic F127 (F127), Tween 80 (T80) and 
Poloxamer 188 (P188) cubosomes labelled with LR. The yellow dotted line outlines the 
eye region while the white dotted line indicates the midbrain region. The uptake of LR 
suspension was used as the control. The GFP panel indicates the location of neurons 
which fluoresce in green while the LR panel indicates the LR, which fluorescence in red. 
The merge panels combine the GFP and LR panels to show any overlap of green and red 




The uptake of cubosomes across the BBB is crucial to transport drug molecules 
into the brain parenchyma. Here, the addition of Tween 80 to cubosomes resulted in an 
increased uptake of the fluorescent molecule, LR into the brain, without any significant 
accumulation observed in the neurons. Previous literature suggests that coating 
nanoparticles with Tween 80 or Poloxamer 188 can lead to an increase in their uptake 
across BBB. Polymeric nanoparticles coated with Tween 80 have been shown to promote 
the uptake of encapsulated dalargin and doxorubicin into the brain 27, 585, 586. The uptake 
of Tween 80 and Poloxamer 188 coated nanoparticles were proposed to be facilitated by 
the adsorption of Tween 80 and Poloxamer 188 moieties to ApoE in the plasma 192. The 
complexes then interact with LDL-receptors (particularly LDL-receptor related protein 
1, LRP) on the endothelial cells at the BBB followed by endocytosis into the cells. Drugs 
encapsulated in the nanoparticles might be released inside the cells or transcytosed across 
the cell into the brain parenchyma (Figure 5.7). The surfactant coating of nanoparticles 
might reduce the clearance rate by reticuloendothelial system and prolong the circulation 
time in the blood, hence allowing sufficient interaction time between nanoparticles and 
LDL-receptors 350. 
 
Figure 5.7 Illustration on the proposed uptake mechanism of Tween 80/Poloxamer 188 




The presence of LR observed in the midbrain region does not necessarily indicate 
the presence of cubosomes in the brain. It is possible that the cubosomes are broken down 
after internalisation into the endothelial cells and only the LR molecule is exocytosed out 
and into brain parenchyma. However, as observed from the LR suspension (control), the 
presence of cubosomes is necessary for the increased uptake of LR. The quantification 
of the LR signal in the midbrain region indicates that Tween 80 cubosomes have the 
potential to cross the BBB or facilitate the uptake of other molecules into the brain. These 
studies are however unable to provide information on the fate and exact localisation of 
Tween 80 cubosomes within the brain.  
There was insignificant uptake of Poloxamer 188 cubosomes into the midbrain 
or neurons of the zebrafish. This is in disagreement with studies that show polymeric 
nanoparticles surface decorated with Poloxamer 188 can increase uptake of molecules 
into the brain through the same mechanism proposed for Tween 80 coated nanoparticles 
347, 350.  
In liposomal formulation, Poloxamer 188 was inserted the bilayer due to the 
interaction of the PEO moiety with both the hydrophobic tails and hydrophilic head of 
the lipids that form liposomes 587, rather than adsorption on the surface 400. At the 
interface, the insertion of Poloxamer 188 can force the lipid molecules to pack tightly 
causing membrane compression 400, 588. However, 80% of the Poloxamer 188 chain 
consists of PEO moieties which increase the hydrophilicity. There is a possibility that a 
large amount of Poloxamer 188 added in the cubosome formulation are not inserted in 
the phytantriol lipid layer, but instead form aggregates and micelles in the dispersion 589. 
Previously in Chapter 3 (Table 3.4), Poloxamer 188 cubosomes were found to have 
higher PDI value when compared to the other cubosome formulations, which might 
indicate the formation of micelles in the dispersion. Therefore, it is possible that the 
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amount of Poloxamer 188 added to the cubosomes was sufficient to exert steric 
stabilisation on the surface, but not enough to allow for interactions with ApoE, which 
then lead to lack of uptake through LDL receptors at the BBB 352, 371, 404, 590, 591. There is 
a possibility that in cubosomes, Poloxamer 188 molecules are packed within the 
phytantriol lipid bilayer, with only a low amount protruding out to interact with ApoE in 
the plasma. The distribution of Poloxamer 188 on the internal and external interface 
might affect the successful interaction with ApoE.  
In this chapter, the same amount of Poloxamer and Tween 80 were added into the 
cubosome formulations. The PPO-PEO chain length in Poloxamer 188 might exert a 
different effect on the phytantriol lipid as compared to polyoxyethylene sorbiton and 
alkyl chain in Tween 80 400, 592. To further investigate the potential of Poloxamer 188 as 
a cubosome stabiliser for BBB targeting, future studies should explore a wider 




5.4.2 Ultrastructural localisation of Tween 80 cubosomes 
In order to observe the fate of Tween 80 cubosomes in the brain at the 
ultrastructural level, Tween 80 cubosomes were labelled with gold nanoparticles and 
their localisation in the midbrain was observed under electron microscopy.  
 
5.4.2.1 Characterisation of gold-labelled cubosomes 
Gold functionalised with octanethiol (89.3 nM) was added to Tween 80 
cubosomes in order to label the cubosomes to allow detection by electron microscopy. 
Gold has a high atomic weight (197 amu) and can provide contrast upon interaction with 
electron waves under electron microscope 593. Hydrophobic octanethiol chain conjugated 
to gold particle (Figure 5.8) mimics the structure of phytantriol lipid. The hydrophobic 
tail allows its insertion between the lipid bilayers within the cubosome structure 594. The 
gold nanoparticles are expected to be fully inserted into the bilayer. The addition of gold 
nanoparticles with less than 5 nm diameter into the phospholipid bilayer did not disrupt 
the bilayer, however, if the gold particles were larger than 5 nm in diameter, they may 
not fit in the bilayer and can alter the structure 595. Since this study used 3 nm sized gold 
nanoparticles, it was expected that they would be inserted within the phytantriol bilayer 
without disrupting the internal structure 596. 
 





The addition of gold nanoparticles at the studied concentration led to an increase 
on the size (p<0.05) and polydispersity of the Tween 80 cubosomes as shown in Table 
5.4. The gold nanoparticle was proposed to be inserted into the lipid bilayer within the 
cubosomes which caused an increase in size. The internal structure of cubosomes is 
maintained as Im3m cubic structure, which is confirmed by the presence of Bragg peaks 
with peak position in a ratio of √2:√4:√6 (Table 5.4, Figure 5.9A).  
 
Table 5.4 Characterisation of Tween 80 cubosomes and gold-labelled Tween 80 
cubosomes.  
Formulation Average size (nm) PDI Internal structure 
Tween 80 164.9 ± 1.8 0.13 ± 0.10 Im3m 
Gold-labelled Tween 80 196.0 ± 2.5 0.25 ± 0.02 Im3m 
 
Tween 80 cubosomes labelled with gold nanoparticles were analysed by EM to 
determine whether the gold nanoparticles were successfully encapsulated within the 
cubosome structure (Figure 5.9B). Electron-dense nanoparticles are visible inside the 
cubosome structure indicating the successful addition of gold nanoparticles into Tween 




Figure 5.9 (A) SAXS diffractogram of Tween 80 stabilised cubosomes after the addition 
of gold nanoparticles indicating formation of Im3m cubosomes. The incorporation of 
gold nanoparticles into Tween 80 cubosomes is shown in (B) from cryo-TEM imaging. 





5.4.2.2 Fate of gold-labelled Tween 80 cubosomes  
The midbrain sections were examined 120 min after intravenous administration 
of cubosomes. All sections were imaged without any staining to allow for clear imaging 
of the gold nanoparticles and to prevent artefacts related to lead citrate and uranyl acetate 
staining 597-599. There is evidence of dense nanoparticles in the brain tissue of zebrafish 
larvae injected with Tween 80 cubosomes, suggesting the presence of gold nanoparticles 
in the brain parenchyma (Figure 5.10d and e). The data suggests that gold nanoparticles 
are able to leave the blood vessels, translocate across the endothelial cells and enter the 
brain parenchyma (Figure 5.10f). Interestingly, the gold suspension was unable to enter 
the brain, again suggesting the presence of cubosomes facilitates uptake of gold 
nanoparticles (Figure 5.10c). To confirm that the dense particles are not artefacts, the 
brain sections from untreated larvae (Figure 5.10a) and from larvae treated with Tween 
80 cubosomes (without gold label) (Figure 5.10b) were investigated. With no dense 
particles observed, therefore, the circular dense and black structures visible in the images 
(panel d, e and f) are proposed to be the gold nanoparticles and not from the cubosomes. 
It is unlikely to observe intact cubosomes under TEM due to the lipidic nature of 





Figure 5.10 Representative electron micrographs of zebrafish larvae midbrain. Larvae that were untreated (a) or injected with Tween 80 cubosomes 
(b) or a gold suspension (c) showed no evidence of gold particles in the brain. Electron micrographs from larvae injected with Tween 80 cubosomes 
labelled with gold nanoparticles showed the presence of dense black particles (white arrowheads) as in panel e and f and cells adjacent to the blood 
vessel (panel f). Scale bar: 2 µm
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In order to confirm that the dense particles are gold nanoparticles, the chemical 
composition was analysed by EDS. From the micrograph in Figure 5.11A, two particles 
from the brain section were analysed (Figure 5.11B and Figure 5.11C). The expected 
elemental peaks for gold are indicated by the arrows. Unfortunately, the specific peaks 
for gold were not clearly detected. The lack of signal might be due to the low acceleration 
voltage and the size of gold nanoparticles used in the study which is only 3 nm in diameter 
602. Previously, 15 kv was used to detect 10 nm gold particles using EDS 603. To get a 
stronger signal for smaller gold particles, a higher accelerating voltage must be applied. 
However, this is avoided in this study as it could lead to sample damage and contribute 
to inaccurate peaks detected 604. Using an EDS detector with a higher sensitivity would 





Figure 5.11 EDS spectra from two different spots in (A) were analysed and presented in 
(B) and (C). Arrows indicate the position of expected peaks for gold nanoparticles. Scale 
bar: 5 µm. 
 
Overall, the microscopic examination of gold-tagged Tween 80 cubosomes 
suggests that there was uptake of gold nanoparticles into the midbrain region of the 
zebrafish even though intact cubosomes were not observed. It is possible that as the 
sections were unstained, the phytantriol lipid from cubosomes did not provide enough 
contrast for it to be detected under TEM. Negative staining could provide sufficient 
contrast to observe phospholipids and lipid structure within the cells 601, 605, 606. However, 
it is likely that then the tissues in the brain (which also have a high lipid content) might 
obscure the cubosomes causing inability to distinguish their differences 607, 608. It is 
therefore still uncertain that if, after the uptake into the brain, the cubosomes maintain 
their initial structure or if they are subjected to intracellular degradation. As cholesterol 
and lipid taken up into the brain are subjected to cellular metabolism before being utilised 
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by the brain cells 609, it is possible that Tween 80 cubosomes are also being metabolised 
after uptake, leaving behind gold particles which can be observed as dense particles under 
TEM.  
  
5.4.3  Evaluation of cationic cubosomes uptake in the brain 
In Chapter 4, positively charged cubosomes were successfully formulated and 
characterised. From the in vitro uptake studies using hCMEC/D3 cells, the addition of 
double chain cationic lipids, DOTAP and DOTMA into cubosomes led to increased 
cellular uptake. In order to further investigate the potential of using cationic cubosomes 
to target the BBB, they were fluorescently labelled with LR and uptake into the zebrafish 
brain was investigated (Figure 5.12).  
 
 
Figure 5.12 Uptake of LR in the zebrafish midbrain from LR-labelled charged cubosomes 
in the midbrain, expressed as integrated density (g/cm) and compared against control 
(LR-labelled Pluronic F127 stabilised cubosomes without additives). Data presented are 




Interestingly, the addition of the single chain cationic lipid, CTAB into Pluronic 
F127 cubosomes results in the highest uptake into zebrafish midbrain, with about a three-
fold increase as compared to the control (LR-labelled Pluronic F127 cubosomes). No 
increase in LR uptake was observed for double chain cationic lipid, DOTAP and 
DOTMA cubosomes. Uptake of LR in all groups was imaged and presented in Figure 
5.13. The signal from LR is clearly observed in the brain of zebrafish treated with CTAB 
cubosomes, while lack of signal from LR was observed with LR-labelled DOTAP and 





Figure 5.13 Representative confocal micrographs of zebrafish larvae treated with CTAB, 
DOTAP, DOTMA and DMPG cubosomes fluorescently labelled with LR. The dotted 
yellow line outlines the eye region while the white dotted line outlines the midbrain 
region. The GFP panel show green fluorescence indicating the blood vessels, while the 
LR panels show the fluorescence from LR. The uptake of LR was observed to be within 
the midbrain region, as evident by the presence of red fluorescence outside the blood 
vessel (indicated by the arrows). The merge panels show the overlap of GFP and LR 
panels to illustrate the presence of LR outside the blood vessels. The uptake of 
cubosomes is compared against the uptake from control (LR-labelled Pluronic F127 
stabilised cubosomes). Scale bar: 50 µm. 
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Further investigation was conducted to observe whether cationic cubosomes 
localise in the neurons (Figure 5.14). No LR was observed in the neurons for any 
formulation groups studied. This suggests that the uptake of CTAB cubosomes which 
previously observed, does not localise in the neurons. The positive charge on the surface 
of cubosomes most likely retards the diffusion of cationic cubosomes further away from 
the blood vessels after successful internalisation. The extracellular space within the brain 
parenchyma has an anionic charge that hinder the free diffusion of cationic cubosomes 
610-612.  
While the in vitro studies in Chapter 4 show increased cellular uptake for 
DOTAP and DOTMA cubosomes, the in vivo studies suggest that only CTAB cubosomes 
were able to cross the BBB and enter the brain. This is an interesting observation which 
suggests that the difference in conditions of the cell cultures and in vivo models can 
significantly influence nanoparticle uptake 613, 614. The in vitro model lacks the ADME 
(absorption, distribution, metabolism and elimination) properties as compared to studies 
using live animal (in vivo) 615. In addition, the flow properties of in vitro and in vivo might 
lead to different cubosomes uptake 616. Cell culture is a static model where a simple 
concentration gradient and the gravity will cause full interaction between cubosomes and 
the hCMEC/D3 cells 617, 618.  
It is possible that the presence of double chain cationic lipids DOTMA and 
DOTAP on the surface of cubosomes leads to protein corona formation in plasma in vivo 
which then neutralises the surface charge and thereby reducing interactions with the 
negatively charged endothelial cell membrane at BBB 619, 620. Another possibility is that 
the double chain DOTAP and DOTMA increases the clearance rate of cubosomes from 
blood, which then reduces contact time between the endothelial cells and the cubosomes, 
thus limiting successful uptake 621, 622. In contrast, previous studies have shown that the 
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addition of DOTAP and DOTMA into polymeric nanoparticles can increase gene 
transfection. The type of nanoparticles used might play a role in the adsorptive 
endocytosis process in vivo, which suggests that not all positively charged nanoparticles 





Figure 5.14 Confocal micrographs of zebrafish midbrain with the neurons fluorescence 
in green (GFP). The yellow dotted line shows the eye while the white dotted line outlines 
the midbrain region. LR-labelled CTAB, DOTAP, DOTMA and DMPG cubosomes were 
injected and the midbrain was observed 120 min after injection. The presence of LR 
signal in the neurons was compared to the control (LR-labelled Pluronic F127 stabilised 
cubosomes without additives). Scale bar: 50 µm. 
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5.4.4  Toxicity of surface modified cubosomes in the brain 
The in vivo toxicity assay in the zebrafish brain was conducted to investigate 
whether any uptake of cubosomes into the brain could be a result of local toxicity. 
Acridine orange is a positively charged molecule that selectively binds to nucleic acids, 
and it enters cells that have compromised membrane permeability. Acridine orange will 
stain cells that are in late apoptosis or necrosis 626-628. To evaluate cell apoptosis post 
cubosomes administration, the midbrain region was observed 120 min after 
administering cubosome formulations and acridine orange (AO) solution. Figure 5.15 
illustrates the toxic effect of administering cubosomes stabilised with Pluronic F127, 
Poloxamer 188 and Tween 80 to the midbrain region. DMSO was injected into zebrafish 
larvae as a positive control. The presence of green fluorescence signal in the DMSO 
treated group comes from acridine orange molecules that have crossed from the damaged 
blood vessel and permeated into the apoptotic cells, as indicated by the arrows. The green 
fluorescence observed in panel AO for Tween 80 and Poloxamer 188 groups show 
fluorescence signal from acridine orange which was restricted inside the blood vessel and 
no signal was detected in the brain parenchyma (outside the blood vessel). In the “merge” 
panel, the overlap between the red fluorescence (mcherry panel) and acridine orange (AO 
panel) confirmed that acridine orange did not cross the blood vessel and enter the brain 
parenchyma, which suggests that there were no local toxicity effects by Tween 80 and 
Poloxamer 188 cubosomes in the midbrain region. These observations suggest that these 
cubosomes have low toxicity in the midbrain and it also suggests that the uptake of 




Figure 5.15 Representative confocal micrographs showing toxicity of cubosomes in the 
midbrain region using acridine orange (AO) assay. Apoptotic cells stained with AO were 
observed as green fluorescence under confocal microscope. Zebrafish treated with 
Pluronic F127 (F127), Tween 80 (T80) and Poloxamer 188 (P188) stabilised cubosomes 
were imaged 120 min after injection. Saline was injected to illustrate negative toxicity 
and DMSO as positive control to induce toxicity (arrows). Scale bar: 50 µm. 
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The same analysis was carried out following administration of the charged 
cubosomes (Figure 5.16). Larvae treated with CTAB cubosomes showed the most 
obvious sign of brain toxicity where the green fluorescence signal from AO can be clearly 
observed in the midbrain region. In larvae treated with DOTAP and DOTMA cubosomes, 
the green signal was limited to the blood vessel.  
These observations suggest that the addition of single chain cationic lipids at the 
studied concentrations can cause toxicity at the brain. The toxicity of single chain cationic 
lipid is higher than that of double chain cationic lipids in agreement with previous reports 
in the literature 451, 631-633. The lipid structure of charged lipids added affected the toxicity 
level of the formulated cationic cubosomes. It was reported that the single chain CTAB 
increases the toxicity from its aliphatic chain. The hydrophobic tail causes disruption of 
the cell membrane bilayer, which leads to an increase in membrane fluidity and causing 
the cell membrane to collapse 634-636. This reduces the integrity of the cell membrane and 
allows the acridine orange molecule to permeate the cell and observed as the toxicity.  
The uptake of CTAB cubosomes observed previously might therefore be due at 
least in part to cellular toxicity and damage at the BBB, which would allow the 
cubosomes to enter the brain 637, 638. However, since the toxicity studies were conducted 
within two hours of cubosomes administration, the toxicity can be from acute effect 462, 
639. Acute toxicity can be temporary and the leakiness associated with the toxicity can be 
resumed after a while. This toxicity can possibly assist in shuttling drug molecules into 
the brain for a short duration 612. Future investigation should be undertaken to understand 
the type of toxicity involved when using CTAB cubosomes. The toxicity effect can be 
evaluated from cell lysis, transient TJ opening, DNA damage or programmed cell death 
637. To quantify acute toxicity, mitochondrial activity assay can be conducted while for 
chronic toxicity, quantification of reactive oxygen species and DNA damage can be 
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carried out 640, 641. Also, further investigation needs to be conducted to determine whether 







Figure 5.16 Confocal images of the midbrain section (white dashed line) showing the 
toxicity of charged cubosomes in Tg(flk:nmscherry). The blood vessels fluoresce in red 
(mcherry). Yellow dashed line outlines the eye and white arrows point to the positive 
toxicity region in the zebrafish. The toxicity effects are compared against the control 





In conclusion, the studies outlined in this chapter illustrates the uptake and 
toxicity of cubosomes in the midbrain section of zebrafish larvae. The addition of Tween 
80 into the cubosome formulation can promote its uptake into the midbrain. This most 
likely via its interaction with LDL-receptors at the BBB 391, 642-646. Even though the 
uptake into the brain was observed under confocal and electron microscope, there was 
no neuronal accumulation of Tween 80 cubosomes. Moreover, at this point, it is unclear 
whether the Tween 80 cubosomes enter the midbrain as intact particles or whether there 
is degradation of the cubosome structure which then releases the fluorescence label or 
gold nanoparticles. Further studies can be conducted by incorporating CNS drug 
molecules into Tween 80 cubosomes and then evaluating its clinical effects or drug 
accumulation in the brain. 
Another important issue to consider is that the addition of Poloxamer 188 to 
cubosome formulations failed to promote its uptake into the brain. It is unclear whether 
the Poloxamer 188 concentration studied in this chapter is insufficient to coat the surface 
of the cubosomes for interaction with ApoE at the BBB or whether the plasma interaction 
with Poloxamer 188 cubosomes led to formation of a corona, which prevents interaction 
with LDL receptors. More studies need to be conducted to determine if the concentration 
of Poloxamer 188 influences uptake of cubosomes into the brain. 
The addition of double tailed charged lipids into cubosomes failed to cause any 
significant uptake into the brain. Only cubosomes modified with the single chain cationic 
lipid, CTAB was able to cross the BBB but without any neuronal accumulation. 
Unfortunately, the uptake of CTAB cubosomes was related to the increase in toxicity at 
the midbrain region. Local toxicity effects might cause the BBB to be leaky, which then 
allow the CTAB cubosomes to enter the brain. Future studies should be conducted to 
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determine if the concentration of CTAB can be optimised such that it exerts a positive 
surface charge with minimum brain toxicity. However, even with the limitations 
described in this study, Tween 80 cubosomes are found to be a promising drug carrier to 













General discussion and conclusions   
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6 General discussion and conclusions 
The BBB remains a challenge in treating CNS diseases. This biological interface 
between the blood and the brain restricts the uptake of therapeutic drugs into the brain 
and thus hinders drugs from reaching the desired therapeutic concentrations in the brain 
20. As such, this thesis looked into the possibility of using lipid-based nanoparticles called 
cubosomes, in which their surfaces were decorated with varied moieties, primarily to 
target the uptake across BBB. Cubosomes were selected as a drug carrier due to the 
structural benefits they have to offer. The unique tortuous structure of cubosomes allows 
the encapsulation of lipophilic, hydrophilic, and amphiphilic drug molecules. The high 
drug loading observed in these nanoparticles is largely due to the high surface area. 
Furthermore, encapsulation of drugs within the cubosome structure has been shown to 
shelter and protect the drug from chemical degradation 264, 487, 647, 648. In comparison to 
several other nanoparticles, cubosomes can be easily prepared from lipids and 
surfactants, which happen to be commercially available. 
In this thesis, cubosomes were formulated using the lipid phytantriol, together 
with several specific BBB-targeting molecules, and their potential uptake by brain 
endothelial cells in vitro and in vivo in a zebrafish model was investigated. The overall 
hypothesis of the thesis was that the addition of certain molecules, which are known to 
target the BBB, on the surface of cubosomes would alter the surface properties to enable 
cubosomes to be targeted to endothelial cells of BBB. Although several uptake pathways 
are available, which are used by endogenous molecules to maintain brain homeostasis 20, 
71, this thesis only investigated two pathways, which are: 1) receptor-mediated 
endocytosis (through LDL receptors) and 2) adsorptive endocytosis.  
In several prior studies, polymeric nanoparticles have been conjugated with BBB-
targeting moieties in order to cross the BBB 373, 649. Inclusion of specific surfactants and 
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ligands, particularly on the surface of polymeric nanoparticles appeared to promote 
internalisation into the cell through a specific pathway at the BBB. Encapsulation of 
loperamide, dopamine and doxorubicin in specific polymeric nanoparticles resulted in 
successful uptake into the brain, especially due to surface modification of the 
nanoparticles 371, 644, 650. As such, this thesis focused on adding Tween 80 and Poloxamer 
188 on the surface of cubosomes to target the receptor-mediated pathway at the BBB. 
The second part of this thesis aimed to target cubosomes to the BBB via adsorptive 
mediated pathway. In order to target this particular pathway, the surface of phytantriol 
cubosomes was also decorated with cationic lipids to ascertain that they too become 
positively charged. 
 
Characteristics of surface modified cubosomes 
In finding effective drug nanocarriers for successful delivery of drug molecules, 
several physicochemical characteristics of the drug carrier are often investigated during 
the optimisation 57, 586, 651, 652. Whilst the size and dispersity of the various cubosomes 
were investigated as part of formulation optimization, a study looking at the effect of 
cubosome size on its uptake by endothelial cells was not conducted. Only the influence 
of targeting ligands and surface characteristics on endothelial cell uptake were 
investigated. Chapter 3 outlines the use of Tween 80 and Polysorbate 188 in phytantriol 
cubosomes, which had been used as stabilisers and ligands to target the BBB. It was 
hypothesised that the addition of these stabilisers  would facilitate the uptake of 
cubosomes via LDL-receptors at the endothelial cells 392. This is due to the interaction 
between the stabiliser and ApoE in the plasma which leads to binding to LDL-receptors, 
thus the uptake into brain endothelial cells 649.  
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Previously, polymeric nanoparticles with their surfaces coated with these 
surfactants promoted uptake across BBB 192. However, this thesis describes for the first 
time the use of a complex lipid-based carrier, the cubosome to target the brain. The 
flexibility in controlling the internal structure of cubosomes by changes in additives, 
temperature and pressure provides the extra advantages in using this type of drug carrier 
over other lipid-based carriers such as liposomes or micelles 258, 262, 394. This thesis has 
produced cubosomes with the addition of Poloxamer 188 and Tween 80, which 
functioned as stabilisers. The internal structures of the resulting cubosomes were 
influenced by Tween 80 and Poloxamer 188, and led to the formation of Pn3m and Im3m 
cubic structures, respectively. This is most likely a result of their respective influence on 
lipid packing and curvature as has been previously reported for other lipid systems 395.  
Both the internal structure and the morphology of Tween 80 cubosomes were 
clearly observed under cryo-TEM. The images displayed the lattice structure inside the 
cubosomes, along with clear illustrations of aqueous channels within the structure. The 
tortuosity within the structure offers a large surface area to encapsulate the drug 
molecules 648. Furthermore, the arrangement of lipid bilayers enables the encapsulation 
of lipophilic drug molecules, while the aqueous pores accommodate hydrophilic 
molecules. Additionally, amphiphilic molecules are also inserted between the lipid 
bilayers and the aqueous channels 267. It is therefore anticipated that highly lipophilic or 
hydrophilic drugs that fail to cross the BBB can be encapsulated within cubosomes, and 
with coating of specific ligands on the surface, the cubosomes can transport the drug 
molecules across the BBB.  
Apart from adding BBB-targeting ligands on the cubosomes, the surface 
properties of the cubosomes was altered by inducing a cationic charge. Cationic 
cubosomes offer a potential to target the BBB via the adsorptive mediated pathway 425, 
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465, 653. In a prior study, nanoparticles, such as liposomes, were co-formulated with 
cationic molecules to deliver DNA in gene transfection 464. As such, positively-charged 
liposomes were bound to negatively charged DNA and simultaneously promoted uptake 
into cell via adsorptive endocytosis pathway 631. Chapter 4 presents the preparation and 
the characterisation of cubosomes by including single- (CTAB) and double-chain 
(DOTAP and DOTMA) cationic lipids with the objective of preparing positively charged 
cubosomes. Varied cationic lipids were used to determine the impacts of single and dual 
chain lengths on the stability of cubosome. Overall, the stability of phytantriol monolayer 
was differently affected by its interaction with cationic lipids. DOTMA with double ether 
linkage caused a greater impact on phytantriol stability, in comparison to that of DOTAP, 
most likely as a result of its ester linkage 458. In contrast, CTAB and DOTAP exhibited a 
similar effect on monolayer stability. Interestingly, despite of the variances in chain 
length and linkage, they all appeared to be miscible with the phytantriol bilayer. This 
suggests that at studied concentration, these lipids can be inserted into phytantriol bilayer 
within the cubosomes structure. 
The addition of cationic lipids into phytantriol cubosomes which were stabilised 
with Pluronic F127 did not significantly alter the internal cubic structure but did result in 
additional vesicles in the formulation.  Furthermore, while the amount of charged lipids 
used did not alter the internal structure, it had been sufficient to exert a positive charge 
on the nanoparticle surface. The observation of vesicles that co-exist with cubosomes is 
in agreement with those reported in the literature 262, 395. These vesicles are thought to 
function as the precursors of cubosomes, whereby they fuse and form a single cubosome. 
But it is also likely that they are vesicles formed from the cationic lipids. The amphiphilic 
structure of the cationic lipids can form micelles and vesicles in water. The excess 
cationic lipids in the formulation that were not inserted in the cubosomes, will assemble 
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into vesicles as observed. Overall, cationic cubosomes were successfully formulated and 
insignificant difference was detected between adding single- and adding double-chain 
cationic lipids to the final structure of cubosomes.  
The characterisation steps involved in formulating the cubosomes had been 
crucial in order to assure the type and the characteristics of the nanoparticles formed. 
Recently, Tween 80 was found to not only stabilise cubosomes, but also to have 
successfully crossed the BBB, thus displaying a positive clinical effect via in vivo from 
the restoration of cognitive function in Alzheimer’s model (in rats). Nevertheless, the 
study failed to verify if the studied particles were indeed cubosomes mainly due to lack 
of characterisation 654. Therefore, characterisation sheds light on the correlation between 
the attributes of cubosome and its uptake into the brain.  
 
Fate of cubosomes in the brain 
The inclusion of Tween 80 and Poloxamer 188 as stabilisers for cubosomes had 
been aimed to serve as BBB-targeting moieties at LDL receptors, as demonstrated by 
several prior studies 20. Tween 80 and Poloxamer 188 cubosomes demonstrated low 
levels of uptake in the in vitro hCMEC/D3 cells, a human endothelial model of the BBB. 
Although the hCMEC/D3 cells express LDL receptors on their cell membranes 305, 416, 
655, the cell culture media does not contain any ApoE for the interaction between Tween 
80 and Poloxamer 188. This in vitro model is inadequate for demonstrating the potential 
exerted by cubosomes to target BBB. Hence, the potential in using cubosomes to deliver 
drug was investigated in vivo in zebrafish.  
The advantages of using zebrafish have been discussed in detail in Chapter 5, 
and this model was used to screen the potential of cubosome formulations to target BBB. 
Interestingly, even though Poloxamer 188 coated nanoparticles have shown evidence of 
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brain uptake 365, 374, only Tween 80 cubosomes showed significant uptake into the brain. 
It is likely that the concentration of Poloxamer 188 applied in this thesis was insufficient 
to completely coat the surface of cubosomes which affected the ability of cubosomes to 
interact with ApoE molecules in the plasma 590.  
The fluorescent molecules found in the midbrain region of zebrafish larvae 
showed that Tween 80 cubosomes can indeed function as a promising drug carrier. This 
finding is further supported by the localisation of gold nanoparticles that came from the 
gold-tagged Tween 80 cubosomes in the midbrain region, upon observation under 
electron microscope. The encapsulation of lipophilic dye, such as dil and nile red, in 
nanoparticles, has been related to premature release after in vivo administration 656, 657. 
Nonetheless, in this thesis a combination of fluorescent molecule and gold nanoparticles 
conjugated with lipid tails were used. These molecules were expected to have been 
inserted within the phytantriol bilayers found within cubosomes and released only when 
the cubosome structure was broken apart. At this point, it is uncertain if Tween 80 
cubosomes had remained intact after entering the brain or if the cubosomes had broken 
apart to leave behind the fluorescent molecules and the gold particles, as observed. 
Moreover, due to the lipidic nature of cubosomes, it is possible that after the successful 
internalisation into the cells, the Tween 80 cubosomes degraded and released the 
fluorescent molecules or the gold particles 288, 658. Even if the cubosomes did not remain 
intact after the uptake into the brain, it still can serve as a potential drug carrier. The 
degradation of cubosomes would eventually release the drugs encapsulated within the 
cubosomes structure, once the cubosomes have successfully entered the brain and reach 
the brain parenchyma.  
On the other hand, the cationic cubosomes displayed varied uptake properties for 
in vitro versus in vivo studies. It had been fascinating to note that cubosomes with double-
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chain cationic lipids; DOTAP and DOTMA, exhibited increment in their uptake under in 
vitro studies, but not for in vivo. On the contrary, while CTAB cubosomes showed low 
uptake in in vitro studies, a significant increase in brain uptake had been recorded after 
administration was performed into the zebrafish larvae. Unfortunately, the uptake was 
linked with the local toxicity at the brain. This observation signifies that the cationic 
cubosomes might behave differently under in vitro versus in vivo approaches. This is 
because; the presence of various proteins and molecules in the plasma could have led to 
the formation of protein corona, which may possibly mask or neutralise the positive 
charges on the surface of cubosomes 147, 659, 660. This has the potential to inhibit the 
electrostatic interaction with the negatively charged cell membranes found at BBB, thus 
lead to failure in uptake.  
It is important to note that DOTAP and DOTMA cubosomes exerted lower levels 
of toxicity, in comparison to that of CTAB cubosomes. This observation is in parallel 
with prior studies, where single-chain cationic lipids have been reported to cause higher 
levels of toxicity, when compared to that of double-chain cationic lipids 631, 661. Even 
though a positive uptake had been noted for CTAB cubosomes, they may be unsuitable 
for formulating cationic cubosomes, primarily due to the toxicity effect. Hence, it is 
worthwhile to further probe into the possibility of applying higher concentrations of 
DOTAP and DOTMA to formulate cationic cubosomes in targeting BBB, as they 
showcase lower levels of toxicity in cells.  
Overall, the significance of conducting in vitro and in vivo studies that determines 
cubosome formulation suitability is conducted towards targeting BBB. The observations 
derived from in vitro studies may be inconclusive to exhibit the potential formulation of 
cubosomes for further studies, while the in vivo studies, on the other hand, may offer 




Despite of all the extensive studies conducted previously, only a number of 
nanoparticles have been successfully translated into the clinic, and in this case, liposomes 
appear to be the most commonly applied nanoparticles. To date, neither nanoparticle 
surface decorated with Tween 80 nor any cubosome formulation has managed to reach 
the market for targeting drugs to the BBB. Therefore, in order to translate these 
formulations into pharmaceutical products, more research work is required for 
investigating the implementation of cubosomes as effective CNS drug carrier. 
This thesis only studied the uptake of surface modified cubosomes within a 
specific brain region (midbrain). However, receptor-mediated endocytosis through LDL-
receptors and adsorptive endocytosis via electrostatic interaction on the cell membrane 
can also occur at the other organ of the body. LDL-receptors are highly expressed in the 
liver and used to transport cholesterol molecules into the cells 662, while the cell 
membranes are negatively charged and can attract cationic molecules on their surface. In 
the future, it will be crucial to study the biodistribution of surface modified cubosomes 
and investigate the organ accumulation of these cubosomes.  
Even though cubosomes can offer high drug loading capacity, the properties 
related to drug release from cubosomes need to be further explored. The presence of 
aqueous pores within the structure of cubosomes may allow encapsulation of hydrophilic 
drugs, but it is also important to determine if the drugs may possibly be released prior to 
reaching the target organ. It is important to take note that the water channels can lead to 
uncontrolled release of drugs into the blood system even before the cubosomes can reach 
the brain. These drugs can possibly cause peripheral side effects as they are released 
within the peripheral drug circulation. On the other hand, lipophilic or amphiphilic drugs 
may be more suitable for encapsulation within cubosomes. The tortuosity of phytantriol 
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lipid bilayer within the cubosomes structure can trap these drug molecules, thus hindering 
premature release of drug into the blood system. Upon entering the brain and being 
degraded, the drugs encapsulated within the cubosome structure are released in the brain 
parenchyma to treat CNS diseases.  
In addition, as this thesis employed fluorescent molecules and gold nanoparticles 
as labels for the cubosomes, future studies can replace these molecules with CNS drugs 
like phenytoin to determine their clinical effects in vivo. It is significant to investigate the 
biodistribution of encapsulated drug molecules within the system of the body to further 
comprehend the localisation of cubosomes upon administration. Accumulation of the 
drug molecules in liver and kidneys also suggest an insight about the fate of cubosomes 
663, 664. Another possible suggestion refers to conjugating the CNS drug molecules with 
fluorescent molecules in the attempt to observe the location of cubosomes, aside from 
measuring the clinical effect from the drugs. Furthermore, it is important to characterise 
the drug encapsulated in cubosomes, mainly due to the interference of these drug 
molecules with phytantriol packing in the lipid bilayer, aside from potential alteration in 
its internal structure that may lead to formation of a different structure 435. Moreover, the 
inclusion of buffer or salt solution into the lamellar phase seemed to modify the structure 
into cubic phase 479, 665, whereas the size and the structure of the additives (including 
drugs) may transform the internal structure.  
Towards scaling up the formulation for mass production, a more sophisticated 
method is required. Vortex mixer with low heat production has been proven to generate 
homogenous cubosome dispersions, but one drawback of this technique is the use of 
solvent, thus projecting adequacy for small-scale production. As such, high energy 
ultrasonication has been proposed as an alternative to produce cubosomes in a larger 
scale as this particular approach omits the use of solvent for manufacturing 395, 407. 
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Nevertheless, due to the excessive generation of heat, its suitability is questioned for 
delivering of drug molecules or protein, which possesses a certain level of heat tolerance 
or are heat labile 313. Therefore, further research works are sought to look into suitable 
CNS drug molecules that can be encapsulated in cubosomes through ultrasonication 
method.  
In the attempt to translate the formulations into clinical applications, the 
dispersion requires long term stability and sterility. As cubosome dispersion requires an 
aqueous state, adding preservatives can extend the shelf life, aside from inhibiting 
microbial growth. Hydrophilic preservatives can be included into the dispersed phase 
(water) to protect the formulation. Nonetheless, it is imminent to comprehend that the 
preservatives might influence the stability of cubosomes or modify its internal structure 
666. Non-ionic preservatives with low molecular weight, thus, may be a good alternative 
to address the disruption that may occur within the cubosome structure. 
Another option is to freeze dry and store the cubosomes in powder form so as to 
ease reconstitution when required 273, 667. However, this particular technique may cause 
changes to its internal structure, especially upon reconstitution. Hence, further 
characterisation and formulation development need to be carried out in order to generate 
a suitable cubosome formulation to expand its shelf life for clinical use without disrupting 
the structure and stability.  
In conclusion, the development of surface modified cubosomes was undertaken 
in this thesis with Tween 80, which successfully stabilised the cubosomes that possess 
the potential to target BBB with limited toxicity. Nevertheless, these cubosomes are still 
at its initial stage to assertively conclude that the addition of Poloxamer 188 and cationic 
lipids into cubosomes does not offer any advantage to target the brain. With that, further 
investigations are demanded in seeking the right concentration that can target the brain 
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with minimum toxicity. Nevertheless, the outcomes from Tween 80 cubosomes deserve 
future investigations in a larger animal model to show that this formulation can be used 





7 Appendix 1 
 
FACS buffer 
Sodium azide    0.9 g 
Foetal bovine serum (FBS)  20 g 
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